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PREFACE 
Health expenditures around the world have been growing both in developed and in 
developing countries over the past decades. India is not an exceptional in this rising 
trend of health expenditure. One key ingredient of every health system is physical 
goods that are directly used for diagnosis and treatment of patients or that are vital for 
other elements of the health system, such as laboratory equipment to conduct medical 
research. The other main ingredients are the delivery of health services and services 
related to public health. 
Globalization of health services is reflected in the emergence of new kinds of health 
care markets over the past decade and in the increased cross-border delivery of health 
services through movement of personnel and consumers and through cross-border 
electronic and other means. It is also reflected in the growing number of companies 
engaged in joint ventures and collaborative arrangements in the health services sector 
and in the increased cross-border exchange and dissemination of information, 
education, and training in this sector. There has been a significant growth in 
opportunities and in the forms of trade and foreign direct investment (FDI) in health 
services in recent years, both in developed and developing countries. 
The present study is divided into six chapters. The first chapter is an introduction to 
the study, which deals a brief history of India’s trade relations with the world in 
general and particularly its competitors in health products and services. India’s trade 
linkages in health products and services with its competitors over the time, objectives, 
scope and importance of the study, hypotheses, methodology adopted, data sources 
and limitations of the study are discussed in this chapter. 
Chapter two is divided into two parts. First part discusses the theoretical studies of 
concerning international trade in health products and services. The second part covers 
the reviews of empirical studies related to the area of study. The third sub-section 
finds a research gaps after reviewing the existing literature.  
Chapter three discusses India’s international trade in health products over the time 
period. It is suggested that after identifying health products, India should take 
advantage by focusing on these products while trading with its competitive countries. 
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Chapter four analyses empirical verification of India’s trade in health products with its 
twelve competitive countries in health products individually. In this chapter an 
attempt is made to analyse to the trade patterns among the competitors with the help 
of RCA analysis, at two-digit, four-digit and six-digit level over the period 2001 to 
2014, the trade intensity index (Grubel-Lloyd index) and Marginal Intra-industry 
trade index (Brulhart index) have been calculated to find out India’s export and 
import intensity with that of its competitive countries. 
Chapter five presents the trade in health services. It covers all four modes of GATS 
for trade in health services. An attempt is made to represent Medical Tourism Index. 
It also analyses the RCA of health related services for the year 2012, 2013 and 2014. 
Chapter six summarises and ended up with conclusion and some policy implications 
of the study. Agenda for future studies is also given in this chapter. 
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Abstract 
lobalization of Indian economy over the past two and half decades has affected a wide G
range of sectors, directly or indirectly. Spurred in part by technological advances and by 
political and economic compulsions, the process of globalization has led to the emergence of 
new forms of business opportunities, processes, and organizations in India. It is necessary to 
establish international rules and regulatory frameworks in areas which were previously the 
exclusive domain of domestic policies. The health sector is one such area which has been 
significantly affected by globalization.  
The health care sector is among the most rapidly growing sectors in the world economy. 
Globalization of health products and services is reflected in the emergence of new kinds of 
health care markets over the past decade and in the increased cross-border delivery of health 
services through movement of personnel and consumers and through cross-border electronic 
and other means. It is also reflected in the growing number of companies engaged in joint 
ventures and collaborative arrangements in the health products and services sector and in the 
increased cross-border exchange and dissemination of information, education, and training in 
this sector. There has been a significant growth in opportunities and in the forms of trade and 
Foreign Direct Investment (FDI) in health products and services in recent years, both in 
developed as well as developing countries.  
Although, health expenditure is increasing in most of the countries of the world over the past 
decades, but the per capita public expenditure on health has declined. Trade of health 
products and services is driven by many factors. These include: 1) the decline in per capita 
public sector expenditure on health, 2) the rise in private sector participation in health care in 
many countries, 3) the liberalisation of related sectors increased mobility of consumers, 4) 
due to declining travel costs and greater ease of travel, 5) technological advances enabling the 
cross-border delivery of many health services. 
The presence of world‐class hospitals and skilled medical professionals has strengthened 
India’s position as a preferred destination for medical tourism. The growth in this sector is 
underscored by the cost advantage that India provides to patients from developed countries. 
Notably, India attracts medical tourists from developing countries due to lack of medical 
facilities in these countries. Yoga, meditation, ayurveda, allopathy and other traditional 
methods of treatment are major services offered that attracts medical tourists from Europe 
and the Middle‐East to India. 
One key ingredient of every health system is physical goods that are directly used for 
diagnosis and treatment of patients or that are vital for other elements of the health system, 
such as laboratory equipment to conduct medical research. The other main ingredients are the 
delivery of health services, and services related to public health. In an increasingly inter-
connected world, an ever larger share of these products and services is traded internationally.  
The 12th Plan budget for the health sector has been enhanced by $55 billion, which accounts 
for 2.5 per cent of GDP (Gross Domestic Product). The government is encouraging the PPP 
model to improve availability of healthcare services. Incentives and tax holidays are being 
offered to hospitals and dispensaries providing health travel facilities. 
It has observed that there is very less work on India’s trade in health products, neither any 
empirical study is attempted. Therefore, this study analyzing empirically India’s trade in 
health products and services. This study constitute the first attempt to cover all the traded 
health products using the product classification of the Harmonized System (HS) as a basis 
and health services using GATS classification of WTO in India. 
Countries typically keep detailed records of goods that enter their domestic markets. In order 
to make national trade data comparable and in order to facilitate the exchange of goods across 
borders, the World Customs Organization has developed a classification for international 
trade in goods, the so called Harmonized System (HS) which is now being widely used across 
the world. The HS classification dissects all trade flows into clearly distinguishable groups 
and breaks them down into 97 chapters and almost 6000 subheadings.  
It thereby follows a certain economic logic, mainly from crude products to more complex 
products and by sector of economic activity. The HS is a classification that was developed to 
clearly identify products that enter a country at the border and to be able to accord the 
respective treatment. Having been developed from a trade perspective, it does not offer the 
refinement which, from a public health perspective, would be desirable. 
However, it offers enough detail to assemble a list of health products which covers a 
substantial share of all health products that enter the public health sphere and thus offers 
interesting opportunities for analysis. In this study, all internationally traded goods are taken 
into consideration that can contribute in one way or another to public health. 
Analysing in detail the HS classification, following goods are-  
 Chapter-29 (Organic chemicals),  
 Chapter-30 (Pharmaceutical Products),  
 Chapter-35 (Albuminoids, modified starches, glues, enzymes),  
 Chapter-38 (Miscellaneous chemical products),  
 Chapter-40 (Rubber and articles therof),  
 Chapter-70 (Glass and glassware),  
 Chapter-84 (Machinery, boilers, nuclear reactors, etc.), 
  Chapter-87 (Vehicles other than railway tramway), 
 Chapter-90 (Optical, photo, technical, medical, etc apparatus),   
 Chapter-94 (Furniture, lighting, signs, prefabricated buildings) 
On the basis of HS classification at 2-digit level and 207 subheadings (at 4 and 6-digit 
HS-2007) containing products which can be directly linked to a health purpose. 
• All these products come under six sub-groups as follows: 
• Dosified Medicines 
• Bulk Medicines 
• Inputs specific to the pharmaceutical industry 
• Chemical inputs of general purpose 
• Hospital and laboratory inputs  
• Medical technology equipment 
The present study has calculated the export revealed comparative advantage index. In the 
trade literature this index has been extensively used to analyze the comparative advantage 
of exports of a country trade, its changing pattern of export structure over the years. The 
RCA is an index for calculating the relative advantage or disadvantage of a certain class 
of goods or services as evidenced by trade flows. It is based on Ricardian Comparative 
Advantage concept. It most commonly refers to an index introduced by Bela Balassa in 
1965. Measures of RCA have been used to help assess a country’s export potential. The 
RCA measures relative export performance by country and industry/commodity. It 
defines a country’s share of world exports of a commodity divided by its share of total 
world exports. The index takes a values between 0 to +∞. A value less than unity 
(RCA<1) implies that the country has no comparative advantage in the product. If the 
index exceeds unity (RCA>1), the country is said to have a revealed comparative 
advantage in the product.  
Intra-Industry Trade Index (IIT) refers to the exchange of similar products belonging to 
the same industry. The term is usually applied to international trade where the same types 
of goods or services are both imported and exported. Balassa (1963) proposed the first 
measures of intra-industry trade that measured the degree of trade overlap-simultaneous 
import and export of good within an industry. The Balassa index has not found much 
favour, because an index, which measured trade that gave pure trade overlap a value of 
zero, was not intuitively appealing. In the present study Grubel-Lloyd (1975) index has 
been used for measuring the degree of India’s intra-industry trade in health products. In 
the literature many indices have been proposed to calculate the level of intra-industry 
trade, but the GL-index has been used because even today it is most widely used and most 
accepted index. Herb Grubel and Peter Lloyd (1975) provided the definitive empirical 
study on the importance of intra-industry trade and how to measure it. If GLi = 1, there is 
only intra-industry trade, no inter-industry trade. This means for example the Country in 
consideration Exports the same quantity of good i as much at it Imports. Conversely, 
if GLi = 0, there is no intra-industry trade, only inter-industry trade. This would mean that 
the Country in consideration only either Exports or only Imports good i.  
Early empirical investigation of IIT had been confined to “static” indicators such as the 
standard GL-index, which do not have adjustment process. However, a paper by 
Hamilton & Kniest (1991) pioneered the use of indicators based on marginal trade flows. 
It has revealed a new and potentially challenging dimension to the empirical analysis of 
IIT by suggesting a measure of marginal intra-industry trade (MIIT). Three methods have 
been proposed to date for the ‘dynamic’ analysis of IIT; viz., the Hamilton-Kniest index, 
the Greenaway et al. (1993) index, and the Brulhart (1994) index. Among the different 
versions of MIIT index, the most widely used index has been the one developed by 
Brulhart (1994). The Brulhart index of MIIT takes on values between 0 and 100. With 0 
representing the scenario where new trade flows over a period of time are entirely due to 
inter-industry trade. Value 100 indicates a situation where new trade flows over a period 
of time are purely because of intra-industry trade.  
For obtaining data on health products and services, we have to rely on secondary data 
source such as UN COMTRADE, ITC (International Trade Centre), WTA (World Trade 
Atlas), WTO (World Trade Organization), UNCTAD, WB-World Development 
Indicator, DGCI&S, Kolkata, etc. In the present study, Data is collected for the period of 
2001 to 2014 (14 years). The data has collected at HS 2-digit level, 4-digit level, and 6-
digit level for specific chapter.  
India not only imports health products, but also exports a number of health products to 
various parts of the world. As a responsible member of the global community, India must 
take all possible steps to export only those products which do not pose a risk to health 
safety, which are effective and high quality. The export of organic chemicals has a rising 
trend over the period except in the year 2008. The down fall has occurred due to global 
recession in that period caused external demand for organic chemicals has declined which 
lead to decreased in export. India’s import of organic chemicals from the world has 
increased from US$176.9 million in 2001 to US$1823.9 million in the year 2014. There 
was unfavorable trade between India and the world for organic chemicals throughout the 
time period. Trade deficit was low in the beginning but after that it has deepened. India’s 
export of pharmaceutical products (chapter-30) has persistently rising except a mild fall 
in 2014, with having increasing trend in BoT.  
India’s export of Chapter 35 to the world has increased in a step manner over the years 
and import of Chapter 35 from the world has increased continuously during the study 
period. India’s percentage share of export for Chapter 35 in the world has increased with 
some fluctuations over the time period. India’s percentage share of import for Chapter 35 
in the world shows increasing trend. It has increased from 0.3 per cent in 2001 to 1.1 per 
cent in 2014.  
India’s export of Chapter 70 (glass and glassware) to the world has increasing trend with 
a dip in 2008-09 due to global financial crisis in the same year. The highest volume of 
export has registered i.e., US$70.2 million in 2014 and lowest US$17.3 million in 2001. 
India’s import of Chapter 70 from the world has also increasing trend. It has increased 
from US$13.5 million in 2001 to 81.6 million in 2014. India’s percentage growth of 
export for glass & glassware to the world has fluctuation over the time period. It has 
recorded a negative percentage growth in the year 2009 and very quick recovery in the 
succeeding year. The highest growth has registered i.e., 49 per cent in the year 2011. 
India’s percentage growth of import for glass & glassware from the world gained 
momentum in the initial years and registered highest growth in 2005 i.e., 48 per cent. 
There was a continuous increasing trend of India’s export of Chapter 90 (Optical, photo, 
technical, medical etc. apparatus) to the world. It has increased from US$30.2 million in 
2001 and US$87.9 million in 2007 to US$233.5 million in 2014. India’s import of 
Chapter 90 from the world has persistently increased over the years. It has increased from 
US$ 114.2 million in 2001 to US$464.8 million in 2008 and US$705.1 million in 2014. 
India’s percentage share of export for Chapter 90 has become double from 2001 (i.e., 0.2 
per cent) to 2014 (i.e., 0.4). India’s percentage share of import for optical, photo, 
technical, medical etc. apparatus in the world has increased in a step like manner. It has 
increased from 0.6 per cent in 2001 to 1.3 per cent in 2014.  
United States of America hold leading destination position in export of pharmaceutical 
products by India to different countries in the world. Its share has increased persistently 
over the years. It has increased from mere 11.9 in 2001 per cent to 33 per cent in 2014. 
South Africa (3.9 per cent), UK (3.8 per cent), Nigeria (3.3 per cent), Russia (3.8 per 
cent) are other top destination countries for export of pharmaceutical products by India in 
2014. United States of America (20 per cent), Germany (13.9 per cent), China (7.7), 
Indonesia (7), Switzerland (7.8), France (6.5), Italy (6), Belgium (3.8), Brazil (3.6), and 
Denmark (3.4) are the leading exporters of pharmaceutical products to India in 2014.  
India has comparative advantage in chapter 29 and 30 throughout the years except 2005 
and 2009 for pharmaceutical products. It has comparative advantage in chapter 35 only in 
the year 2007, and in chapter 40 in 2002, 2003 and 2005. It also has comparative 
advantage for chapter 38 in some years. In all the health products, India’s comparative 
advantage has improved over the time period.   
Switzerland has highest degree of comparative advantage among all the competitive 
nations throughout the study period. India has comparative advantage in chapter 38 
(Miscellaneous chemical products) only for few years like 2001, 2005, 2006, 2007, 2008 
and 2013. RCA in 9018 (Electro medical apparatus) and 2942 (Organic Compounds) for 
India is highest among its all competitive countries. India, Denmark, Italy, France and 
Belgium have comparative advantage in 3503 (Gelatin and Gelatin derivatives) 
throughout the years (table A.4.23). France has highest degree of comparative advantage 
in 3503 among all competitive member countries. 
All the competitive countries except Ireland, Netherlands, Spain and India have 
comparative advantage in 8414 (Air, Vacuum pumps) during the study period. Denmark, 
Belgium and UK have Comparative advantage for some years. Germany has highest 
degree of comparative advantage among all nations. India does not have comparative 
advantage in 8414, so it is advisable for India to import 8414 (Air, Vacuum pumps) from 
those countries which have comparative advantage. Germany, USA, France, UK, Italy 
and France have comparative advantage in 8413 (Pumps for liquids) over the years.  
Germany has keeping leading position followed by France in comparative advantage. 
India does not comparative advantage in 8413, thus it is fruitful for India to import 8413 
(Pumps for liquids) from countries like Germany, France, USA, etc.   
All the competitive countries except USA and Spain have comparative advantage in 
300420 (Antibiotics nes, in dosage) over the time period. Switzerland has highest degree 
of comparative advantage among all the nations. India has significantly high comparative 
advantage in 300420 over the years. It is favorable for India to export 300420 (Antibiotics 
nes, in dosage) in the world market. India has highest comparative advantage in 300410 
(Pencililines, or other streptomycin, in dosage) throughout the years among all its 
competitive nations. India, Spain, Ireland, France, Belgium and Switzerland have 
comparative advantage in 300390 (Medicaments nes, formulated in bulk) over the time 
period 
There is high Intra-industry trade for India in chapters 29 (Organic chemicals), 35 
(Albuminoids, enzymes, etc.), 38 (Miscellaneous chemical products), 40 (Rubber and 
articles thereof), 70 (Glass and Glassware), and 84 (Machinery, nuclear reactors, boilers 
etc.). In chapter 70 (Glass and Glassware), India has intra-industry trade over the years. 
The value of GL index remains as high as above 0.80 during the study period. For chapter 
94 (Furniture, lighting, signs, prefabricated buildings), India has intra-industry trade over 
the years. The value of GL index remains quite high throughout the years. It maintains 
more than 0.90 over the time period except few years.   
There is increasing MIIT for chapters 29 (Organic chemicals), 30 (pharmaceutical 
products), 40 (Rubber and articles thereof), 84 (Machinery, nuclear reactors, boilers etc), 
38 (Miscellaneous chemical products); while declining for chapters 94 (Furniture, 
lighting, signs etc.), 90 (Optical, photo, medical apparatus), 87 (Vehicles other than 
railway and tramway) and 70 (Glass and Glassware) over the time period. In case of 
chapter 35 (Albuminoids, Modified starches, glues, enzymes), new trade flow is in favour 
of intra-industry trade. The value of MIIT was very high in few years like 98.81 per cent 
in 2003 and 99.61 in 2010. International trade in health products have grown in a very 
dynamic way, especially trade in dosified and bulk medicines. Our results further indicate 
that international trade in health products is strongly dominated by trade among a small 
number of developed countries.  
Until the emergence of World Trade Organization in 1995, there was no multilateral 
agreement to facilitate trade of services. Negotiations at the WTO led to the General 
Agreement on Trade in Services, a comprehensive agreement on the international trade in 
services. GATS explicitly provides for successive rounds of negotiation with a view to 
achieving a progressively higher degree of liberalization. Trade discussions in health 
services typically adopt a wide definition of what constitutes trade, involving the four 
modes of supply namely Mode 1: cross-border supply, Mode 2: consumption abroad, 
Mode 3: commercial presence, Mode 4: movement of health personnel. 
India, asides from an increase in revenues, the importance of telemedicine trade in 
improving the national health system and the country image were highlighted as key 
advantages. Several major private hospitals have adopted telemedicine services, and a 
number of hospitals have developed public-private partnerships (PPPs), among them 
Apollo, AIIMS, Narayana Hridayalaya, Aravind Hospitals and Sankara Nethralaya.  The 
early successes of telemedicine pioneers have led to increased acceptance and 
proliferation of telemedicine. Today there more than 120 telemedicine centres are 
available throughout India. We can use telemedicine exports as a way to innovate and to 
catalyze and redesign our health system.  
India has made great stride in the field of telemedicine and e-health. Most of the 
telemedicine activities are in project mode supported by Indian Space Research 
Organization, Department of Information Technology which are being implemented 
through state governments. Few corporate hospitals have recently developed their own 
telemedicine network. Around 400 telemedicine nodes are in place across the country. No 
systematic evaluation of the telemedicine projects have been undertaken till date so as to 
gather evidence on cost-benefit aspects of integrating telemedicine tool into current health 
delivery system. Ministry of Health, Government of India is currently initiating 
evaluation exercise so as to decide investment on e-health in the 11th five year plan. 
India has historically been a regional medical tourism hub for neighbouring countries 
such as Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan and the Middle-
East. Evidence of ancient hospitals offering healthcare facilities funded by local kings and 
monarchs can be found in foreign travellers’ accounts as well as scripts. Medical tourists 
seek treatment abroad for two main reasons: 1) vastly disparate costs or 2) access to 
timely treatment. Several countries around the world provide destinations for medical 
tourists, but most of the increasing traffic is concentrated in Southeast Asia and South 
America. Popular destination countries include India, Thailand, Singapore, Argentina, 
Brazil, Columbia, Costa Rica, and Panama among others. Patients who seek treatment in 
these countries can expect highly trained physicians, often educated in the United States 
or Great Britain, and hospitals accredited by the Joint Commission International (JIC), an 
arm of the Joint Commission, an American non-profit organization that accredits a variety 
of health related organizations. These hospitals are staffed with highly trained medical 
staff and utilize the latest medical technologies and equipment. 
Africa is the group which depicts that largest percentage of total FTAs visit to India for 
medical treatment i.e. 8 per cent followed by South Asia 7.4 per cent. There is significant 
increase of FTAs for medical treatment in 2012 i.e. 2.6 from 2.2 per cent in 2011. South 
Asia shows highest percentage increment from 2011 to 2012. More international 
accreditation is required for Indian hospitals. India holds 15th rank in MTI, which is above 
Thailand (20), China (22), and Russia (25), which proves India may be an attractive 
destination of medical tourism in the World. The cost of surgery in India is one-tenth as 
compare to USA and other developed nation.  
The overall trend is towards opening up various segments of the health services sector to 
foreign equity or other forms of participation. With mounting pressures on public 
resources and a squeeze on public sector expenditures on health care in many countries, 
commercial presence in health services is likely to become more important as a means of 
generating resources for investment and upgrading of health care infrastructure. Trade 
flows in this mode are mainly from developed to developing countries. However, a few 
corporate hospitals in developing countries such as India are looking towards regional 
markets for establishing hospital chains and in the areas of hospital operations and 
management.  Since January 2000, FDI is permitted up to 100 per cent under the 
automatic route in hospitals in India. Prior to January 2000, FDI in hospitals was 
permitted under the FIPB route, which meant that the FIPB would consider the 
investment proposals and take a decision and the Indian company with the RBI would 
make thereafter filings. Foreign Direct Investment into India is governed by the Foreign 
Exchange Management Act (FEMA), 1999, the rules and regulations made there under by 
the Reserve Bank of India and the Industrial Policy and Procedures issued by the Ministry 
of Commerce and Industry through the Department of Industrial Policy and Promotion, 
Secretariat for Industrial Assistance. India is currently an important destination for 
Foreign Direct Investment (FDI) which is one of the biggest emerging markets. India has 
received USD 1, 32,837 million as aggregate FDI from April 2000 to April, 2011 and 
specifically hospital and diagnostic centres have received FDI of USD 1030.05 million 
from April 2000 up to April 2011 constituting 0.78 per cent of the total FDI into India.   
India being an extremely large country with a huge population and an enormous potential 
to supply English speaking health professionals to many developed countries stands to 
gain a lot particularly when their demand rises worldwide. In recent years, health care 
institutions in prosperous countries have discovered India as a new source country for 
recruiting well-trained, English-speaking nurses and physicians. Today, Indian doctors 
have become a powerful influence in medicine across the world - from US, UK, Australia 
and Canada etc.  
The movement of doctors from India to developed countries, mainly the US and the UK, 
is not a new phenomenon. They have been movement to developed countries for better 
training and higher medical degree since 1960s. While a majority of doctors prefer to stay 
there, some of them have come back. Since most of the doctors in India come from 
middle and higher income families, they find their own way to migrate. Contrary to this, 
nurses in India belong to lower or lower-middle class background. Indian medical 
professionals occupy the highest positions in world renowned clinics like the Mayo Clinic 
and a number of other prestigious institutions in the US. States Kerala and Tamil Nadu 
have established their own manpower export corporation to help the low-skilled 
professionals to move abroad. India’s comparative advantage w.r.t. the world in health 
services i.e., travel, health related (4.2.1) has shown in favour of India in the years 2013 
and 2014. The degree of comparative advantage has increased over the years. 
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Chapter - 1 
 
INTRODUCTION 
1.1 Introduction 
Globalization of Indian economy over the past two and half decades has affected a 
wide range of sectors, directly or indirectly. Spurred in part by technological advances 
and by political and economic compulsions, the process of globalization has led to the 
emergence of new forms of business opportunities, processes, and organizations in 
India. It is necessary to establish international rules and regulatory frameworks in 
areas which were previously the exclusive domain of domestic policies. The health 
sector is one such area which has been significantly affected by globalization. The 
health care sector is among the most rapidly growing sectors in the world economy. 
Globalization of health products and services is reflected in the emergence of new 
kinds of health care markets over the past decade and in the increased cross-border 
delivery of health services through movement of personnel and consumers and 
through cross-border electronic and other means. It is also reflected in the growing 
number of companies engaged in joint ventures and collaborative arrangements in the 
health products and services sector and in the increased cross-border exchange and 
dissemination of information, education, and training in this sector. There has been a 
significant growth in opportunities and in the forms of trade and Foreign Direct 
Investment (FDI) in health products and services in recent years, both in developed as 
well as developing countries. Although, health expenditures around the world have 
been growing strongly both in developed and in developing countries over the past 
decades, but the per capita public expenditure on health has declined. Trade of health 
products and services is driven by many factors. These include: 1) the decline in per 
capita public sector expenditure on health,2) the rise in private sector participation in 
health care in many countries, 3) the liberalisation of related sectors increased 
mobility of consumers, 4) due to declining travel costs and greater ease of travel, 5) 
technological advances enabling the cross-border delivery of many health services.  
In addition to above the differences in costs, availability of services, quality of health 
care across countries, the emergence of investment opportunities in the health care 
sector with the liberalisation of investment regulations. The general increase in 
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demand for health products and services arising from rising income levels and aging 
population. These have also contributed to the globalization of health products and 
services. 
Although trade in health products and services is modest at present, given the rapidly 
growing global health care industry and the likely removal of some of the regulatory 
barriers to such trade at the regional and the national levels. Trade in health products 
and services are likely to gain more importance in the future. 
 
1.2 India’s Pharmaceutical Industry: Since Independence  
At the time of independence in 1947, India’s pharmaceutical market was dominated 
by Western MNCs that controlled between 80 and 90 per cent of the market 
primarily through importation. Approximately 99 per cent of all pharmaceutical 
products under patent in India at the time were held by foreign companies and 
domestic Indian drug prices were among the highest in the world. The Indian 
pharmaceutical market remained import-dependent through the 1960s until the 
government initiated policies stressing self-reliance through local production. At 
that time, 8 of India’s top 10 pharmaceutical firms, based on sales, were subsidiaries 
of MNCs. To facilitate an independent supply of pharmaceutical products in the 
domestic market, the government of India founded 5 state-owned pharmaceutical 
companies.  
Government policy culminated in various actions including: the abolition of product 
patents on food, chemicals, and drugs; the institution of process patents; the 
limitation of multinational equity share in India pharmaceutical companies, and the 
imposition of price controls on certain formulations and bulk drugs. Subsequently, 
most foreign pharmaceutical manufacturers abandoned the Indian market due to the 
absence of legal mechanisms to protect their patented products. Accordingly, the 
share of the domestic Indian market held by foreign drug manufacturers declined to 
less than 20 per cent in 2005. As the MNCs abandoned the Indian market, local 
firms rushed in to fill the void, and by 1990, India was self-sufficient in the 
production of formulations and nearly self-sufficient in the production of bulk drugs. 
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Regulatory Environment  
To end the dominance of foreign drug companies, the Indian government enacted a 
series of policies designed to foster self-sufficiency in the production of basic 
drugs. Because these measures lowered barriers to entry, thousands of medium and 
small Indian pharmaceutical companies entered the market challenging the MNCs 
for control. These actions laid the foundation for today’s highly competitive 
domestic industry that is capable of offering some of the lowest drug prices in the 
world. These policies ended India’s dependence on expensive foreign drugs, 
fostered the development of a competitive pharmaceutical industry, and guaranteed 
the Indian public access to inexpensive drugs. 
Nonetheless, the Indian pharmaceutical industry also became one of the country’s 
most heavily regulated. The industry currently faces restrictions on imports, high 
tariff rates, ration requirements, and equity ceilings for foreign participation. 
The Patent Act, 1970 
The Act’s stated objective was to foster the development of an indigenous Indian 
pharmaceutical industry and to guarantee that the Indian public had access to low-
cost drugs. The Act replaced intellectual property rights laws left over from the 
British colonial era and ended India’s recognition of Western-style “product” patent 
protection for pharmaceuticals, agricultural products, and atomic energy. Product-
specific patents were disregarded in favour of manufacturing “process” patents that 
allowed Indian companies’ to reverse engineer or copy foreign patented drugs 
without paying a licensing fee. This allowed the domestic industry build up 
considerable competencies and offer a large number of cheaper “copycat” generic 
versions legally in India at a fraction of the cost of the drug in the West, as long as 
they employed a production process that differed from that used by the patent 
owner. The Act protected process patents for 7 years instead of the usual 15 years 
needed to develop and test new drugs. 
 
Drug Price Control Order, 1970 (DPCO) 
The order was introduced when most of India’s drugs were under strict price 
controls. Since its introduction, the number of bulk drugs under price controls 
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gradually declined from 347 in 1987 to 163 in 1994 to 74 in 1995. In 2005, the 
government capped prices on 74 bulk drugs and 260 formulations that account for 
approximately 25 per cent of India’s retail pharmaceutical market. Trade margins for 
these drugs were capped at 8 per cent for retailers and 16 per cent for wholesalers. 
The National Pharmaceutical Pricing Authority (NPPA), founded in 1997, is 
responsible for monitoring prices using the DPCO to fix ceiling prices on drugs and 
ensure that no Indian company in a monopoly position takes advantages of its 
monopolistic position by profiteering. In June 2006, the National Pharmaceutical 
Policy 2006 (Part A) proposed to add price controls on 354 specific drugs listed as 
essential medicines. The new policy will cap margins on generic drugs at 15 per 
cent for wholesalers and 35 per cent for retailers. It will also enforce a 5 per cent 
price cut on more than 75 commonly-used medicines resulting from import duty 
reductions of 5 to 7.5 per cent on certain Active Pharmaceutical Ingredients (APIs). 
The NPPA controls ceiling prices for controlled bulk drugs in all intra-industry 
transactions as well as the retail ceiling prices for controlled formulations. 
 
Patents (Amendment) Act 2005 
To meet its TRIPs obligations, India amended its patent law on March 22, 2005, 
abolishing its “process” patents law and reintroduced Western style “product” 
patents for pharmaceuticals, food, and chemicals. This action effectively ended 36 
years of protection for Indian pharmaceutical companies and stipulated that Indian 
companies selling copycat drugs must pay foreign patent holders a “reasonable” 
royalty for copies sold in the Indian market. The amendment made reverse 
engineering or copying of patented drugs illegal after January 1, 1995. The Act 
allowed for only two types of generic drugs in the Indian market: off-patent generic 
drugs and generic versions of drugs patented before 1995. At present, nearly 97 
percent of all drugs manufactured in India are off patent and therefore will not be 
affected by this Act. It also introduced a provision establishing compulsory 
licenses for exports to least developed countries with insufficient pharmaceutical 
manufacturing capacities. 
The Amendment grants new patent holders a 20-year monopoly starting on the date 
the patent was filed and, without a compulsory license, no generic copies can be sold 
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during the duration of the patent. The WTO also required India to establish a 
“mailbox” where patent applications could be filed between January 1, 1995 and 
2005. The Act encouraged significant numbers of foreign pharmaceutical companies 
to participate in the Indian market and, in 2005; foreign drug producers filed 
approximately 8,926 patent applications to cover their patented drugs sold as generics 
in the Indian market. Roche (Switzerland) became the first foreign company to win a 
patent under India’s new product patent regime and that patent, granted in March 
2006 for a drug to treatment of hepatitis C (Pegasys), will be valid for 20 years from 
May 15, 1997. Pfizer (US) has submitted the largest number of patent applications 
(373) followed by Johnson & Johnson (262) and Procter & Gamble (187).  
During 2010–13 periods, pharmaceutical segment accounted for more than 70 per 
cent of M&A (Merger and Acquisition) deals. In 2012, M&A value in healthcare 
stood at $2.7 billion, an increase of more than 30 per cent compared to those in 2011. 
The healthcare sector in India is attracting a number of PE (private equity) investors. 
Diagnostic centres, multi‐speciality hospitals, and chain of single‐speciality hospitals 
attracted the majority of PE investments in 2012. 
 
1.3 India’s Trade in Healthcare  
One key ingredient of every health system is physical goods that are directly used for 
diagnosis and treatment of patients or that are vital for other elements of the health 
system, such as laboratory equipment to conduct medical research. The other main 
ingredients are the delivery of health services, and services related to public health. In 
an increasingly inter-connected world, an ever larger share of these products and 
services is traded internationally.  
Healthcare in India is among the major sectors, in terms of revenue and employment, 
and the sector is expanding rapidly. During the 1990s, Indian healthcare grew at a 
compound annual rate of 16 per cent. Today the total value of the sector is more than 
$34 billion. This translates to $34 per capita, or roughly 6 per cent of GDP. The 
private sector accounts for more than 80 per cent of total healthcare spending in India. 
One driver of growth in the healthcare sector is India’s booming population, currently 
1.2 billion and increasing at about 2 per cent annual rate. By 2030, India is expected 
to surpass China as the world’s most populous nation. By 2050, the population is 
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projected to reach 1.6 billion. This population increase is due in part to a decline in 
infant mortality, the result of better healthcare facilities and the government’s 
emphasis on eradicating diseases such as hepatitis and polio among infants. In 
addition, life expectancy is rapidly approaching the levels of the western world. By 
2025, an estimated 189 million Indians will be at least 60 years of age, thanks to 
greater affluence and better hygiene. The growing elderly population will place an 
enormous burden on India’s healthcare infrastructure. The Indian economy, estimated 
at roughly $1 trillion, is growing in tandem with the population. Goldman Sachs 
predicts that the Indian economy will expand by at least 5 per cent annually for the 
next 45 years, and that it will be the only emerging economy to maintain such a robust 
pace of growth. India’s thriving economy is driving urbanization and creating an 
expanding middle class, with more disposable income to spend on healthcare. More 
women are entering the workforce as well, further boosting the purchasing power of 
Indian households. Many of these women are highly educated: the ratio of women to 
men who have a college degree or higher level of education is 40:60. Thanks to rising 
income, today more than 50 million Indians can afford to buy Western medicines, a 
market only 20 per cent smaller than that of the UK. If the economy continues to 
grow faster than the economies of the developed world, and the literacy rate keeps 
rising, much of western and southern India will be middle class. Another factor 
driving the growth of India’s healthcare sector is a rise in both infectious and chronic 
degenerative diseases. While ailments such as poliomyelitis, leprosy, and neonatal 
tetanus almost eliminated, some communicable diseases once thought to be under 
control, such as dengue fever, viral hepatitis, tuberculosis, malaria, and pneumonia, 
have returned in force or have developed a stubborn resistance to drugs. 
This troubling trend can be attributed in part to substandard housing, inadequate 
water, sewage and waste management systems, a crumbling public health 
infrastructure, and increased air travel. In addition to battling infectious diseases, 
India is grappling with the emergence of diseases such as AIDS as well as food- and 
water-borne illnesses. And as Indians live more affluent lives and adopt unhealthy 
western diets that are high in fat and sugar, the country is experiencing arise in 
lifestyle diseases such as hypertension, cancer, and diabetes, which is reaching 
epidemic proportions. Over the next 5-10 years, lifestyle diseases are expected to 
grow at a faster rate than infectious diseases in India, and to result in an increase in 
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cost per treatment. Wellness programs targeted at the workplace, where many 
sedentary jobs are contributing to an erosion of employees’ health, could help to 
reduce the rising incidence of lifestyle diseases. 
Poor health infrastructure in the colonial period continued to shape the health policy 
in India even after independence. The Indian states allowed little space for the health 
and wellbeing. The political economy of the healthcare reform in India has been 
characterised by widespread privatization and the dominant role of the private and 
informal sector in providing healthcare, even to the very poor. As, the private sector 
accounts for 80 per cent of healthcare delivery in India, an estimated 60 per cent of 
hospitals, 75 per cent of dispensaries and 80 per cent of all qualified doctors are in the 
private sector. The health sector was never on the priority list of the states or the 
central government since independence. 
In India, there has been a shift from communicable to lifestyle diseases due to 
increasing urbanization and problems related to modern day living conditions; 
currently about 50 to 60 per cent of spending is on inpatient beds for lifestyle 
diseases. This has increased the demand for specialized healthcare, particularly in tier 
II and tier III cities. As a result of these developments, health insurance is gaining 
momentum. The gross healthcare insurance premium was expanding at a CAGR of 39 
per cent over 2006–10. Indian health insurance industry expanded at a CAGR of 33 
per cent during the 2006–12; this fast pace of growth is expected to continue in the 
coming years. The share of population having medical insurance is likely to rise to 20 
per cent by 2015 from 2 per cent in 2006. An increasing number of companies would 
offer health insurance to their employees; other private sector companies are also 
likely to join. 
The presence of world‐class hospitals and skilled medical professionals has 
strengthened India’s position as a preferred destination for medical tourism. The 
growth in this sector is underscored by the cost advantage that India provides to 
patients from developed countries. Notably, India attracts medical tourists from 
developing countries due to lack of medical facilities in these countries. Yoga, 
meditation, ayurveda, allopathy and other traditional methods of treatment are major 
services offered that attracts medical tourists from Europe and the Middle‐East to 
India. The traditional healthcare market (Ayurveda, etc.) in India has much potential 
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was valued about $1.4 billion in 2010 and is expected to grow further in future. This 
sector has broadened its offerings and now includes services on diet and nutrition, 
yoga, herbal medicine and spa. Many big hospitals are also setting up wellness centres 
with traditional healthcare remedies. There is a growing interest from many private 
equity firms in the traditional healthcare sector. 
The 12th Plan budget for the health sector has been enhanced by $55 billion, which 
accounts for 2.5 per cent of GDP (Gross Domestic Product). The government is 
encouraging the PPP model to improve availability of healthcare services. Incentives 
and tax holidays are being offered to hospitals and dispensaries providing health 
travel facilities. 
Since the economic reforms, the manufacturing base has been adversely affected by 
liberalized imports of medical technology, ranging from low to high technology 
equipment and devices. In the 1990s there was a steep increase in the variety and 
quantum of import of medical equipment into the country. According to industry 
estimates currently almost 90 per cent of devices and disposables are being imported 
at international prices. For instance, the market for Indian syringes and needles was 
growing in the 1990s due to certain government incentives for brand promotion 
abroad, but these incentives were taken back in 2001, leading to adverse impact on 
local manufacture. The Indian syringes and needles manufacturing industry has since 
been facing competition from cheap Chinese and Korean imports; as a result most of 
the manufacturers have started trading in cheap imported needles and syringes, 
repackaging and selling them under any name. The import of syringes (with needles) 
increased by almost 125 per cent between 2004 and 2005 and by 70 per cent between 
2006 and 2007. 
In the 14 year period from 1990 to 2004 there has been an increase in imports by 25 
times. The items imported range from: Small consumables such as surgical gloves, 
syringes, needles, cannulae and catheters; A wide range of implantable and other 
cardiac, orthopaedic, dental and auditory devices; stethoscopes, thermometers and 
blood transfusion apparatus; assisted respiration apparatus; Dental chairs and drills, 
eye and ear, nose and throat precision instruments and lasers, etc., imaging 
equipment; auto-analyzers, anesthetic equipment, ECGs and electroencephalograms, 
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linear accelerators used in cancer therapy, haemodialysis machines, endoscopes, 
laparoscopes, baby incubators and other equipment. 
There is also import and sale of used, refurbished equipment, especially of Computed 
Tomography (CT)-scanners and Magnetic Resonance Imaging (MRI) equipment, 
even by the manufacturers themselves. Use of such equipment carries concerns of 
obsolescence, non-availability of spares, accessories and upgrades, after-sales support 
and warranty problems, all of which have implications for safety, proper calibration 
and reliability. Strong mobile technology infrastructure and launch of 4G is expected 
to drive mobile health initiatives in the country. 
 
1.4 Statement of the Problem 
India’s trade in health products and services is very low as compare to many 
countries.Currently, India’s healthcare sector is growing at less than 20 per cent per 
annum.The overall Indian healthcare market today is worth US$ 100 billion only, 
which has much potential to be double or triple in few years. 
There is a significant scope for enhancing healthcare services considering that 
healthcare spending as a percentage of Gross Domestic Product (GDP) is rising. 
There is a possibility of that the pattern and destination of trade in health products 
might change overtime. Therefore, there is a scope to study in depth India’s position 
of trade in health products and services. Therefore, the statement of problem may be 
summaries as follows- 
 What is the pattern and trends of India’s trade in health products and services 
during the study period? 
 Do India has same advantage as other developed countries have in health 
products and services?  
 What is the impact of India’s trade in health products on its competitive 
nations? 
 Is India has potential in all four modes of GATS in trade in health services in 
the world?  
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1.5 Objectives of the Study 
On the basis of statement of problem, objectives of the present study are as follows:  
• To examine the trends and pattern of international trade in health products and 
services in India after 2001.  
• A cross country analysis of health products and services.  
• To examine the comparative advantage of trade in health products in India. 
• To find out the trade-intensity of health products in India during the study 
period. 
• To examine the scope of trade in health services in India. 
 
1.6 Hypotheses 
On the basis of above objectives following hypotheses and alternative hypotheses are 
formulated.  
• There is no change in pattern of India’s trade of health products and services 
since 2001. 
• There is no change in the intra-industry trade of India in health products with 
respect to World. 
• There is no change in the comparative advantage of India’s health products with 
respect to the World at HS-2 digit, HS-4 digit level and HS-6 digit level for 
Chapter-30 (i.e. Pharmaceutical Products). 
 
1.7 Research Methodology 
Countries typically keep detailed records of goods that enter their domestic markets. 
In order to make national trade data comparable and in order to facilitate the exchange 
of goods across borders, the World Customs Organization has developed a 
classification for international trade in goods known as Harmonized System (HS) 
which is now being widely used across the world.  
The HS classification dissects all trade flows into clearly distinguishable groups and 
breaks them down into 97 chapters and almost 6000 subheadings. It thereby follows a 
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certain economic logic, mainly from crude products to more complex products and by 
sector of economic activity. 
The HS is a classification that was developed to clearly identify products that enter a 
country at the border and to be able to accord the respective treatment. Having been 
developed from a trade perspective, it does not offer the refinement which, from a 
public health perspective, would be desirable. 
However, we believe that it offers enough detail to assemble a list of health products 
which covers a substantial share of all health products that enter the public health 
sphere and thus offers interesting opportunities for analysis. In this study, we are 
interested in all internationally traded goods that can contribute in one way or another 
to public health. 
Analysing in detail the HS classification, we are able to identify-  
 Chapter-29 (Organic chemicals),  
 Chapter-30 (Pharmaceutical products),  
 Chapter-35 (Albuminoids, modified starches, glues, enzymes),  
 Chapter-38 (Miscellaneous chemical products),  
 Chapter-40 (Rubber and articles thereof),  
 Chapter-70 (Glass and glassware),  
 Chapter-84 (Machinery, boilers, nuclear reactors, etc.), 
  Chapter-87 (Vehicles other than railway tramway), 
 Chapter-90 (Optical, photo, technical, medical, etc. apparatus),   
 Chapter-94 (Furniture, lighting, signs, prefabricated buildings) 
On the basis of HS classification at 2-digit level and 207 subheadings (at 4 and 6-digit 
HS-2007) containing products which can be directly linked to a health purpose.  
All these products come under six sub-groups as follows: 
• Dosified Medicines 
• Bulk Medicines 
• Inputs specific to the pharmaceutical industry 
• Chemical inputs of general purpose 
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• Hospital and laboratory inputs 
• Medical technology equipment 
 
Revealed Comparative Advantage (RCA) 
The present study has calculated the export Revealed Comparative Advantage (RCA) 
index. In the trade literature this index has been extensively used to analyze the 
comparative advantage of exports of a country, its changing pattern of export 
structure over the years.   
The RCA is an index for calculating the relative advantage or disadvantage of a 
certain class of goods or services as evidenced by trade flows. It is based on Ricardian 
Comparative Advantage concept. It most commonly refers to an index introduced by 
Bela Balassa in 1965. 
The RCA indicates whether a country is in the process of extending the products in 
which it has a trade potential, as an opposed to situation in which the number of 
products that can be competitively exported is static. It can also provide useful 
information about potential trade prospects with new partners. 
Measures of RCA have been used to help assess a country’s export potential. The 
RCA measures relative export performance by country and industry/commodity. It 
defines a country’s share of world exports of a commodity divided by its share of total 
world exports.  
The RCA index of country i for product j is calculated as follows: 
RCAij= (xij/Xit)/(xwj/Xwt) 
Where; 
RCA is the revealed comparative advantage of ith country for jth product. 
xij is the value of country i’s exports of product j 
Xit is the value of country i’s total exports   
xwj is the value of world’s exports of product j 
Xwt is the value of world’s total exports 
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The index takes a values between 0 to +∞. A value less than unity (RCA<1) implies 
that the country has no comparative advantage in the product. If the index exceeds 
unity (RCA>1), the country is said to have a revealed comparative advantage in the 
product. 
 
Intra-Industry Trade Index (IIT) 
It refers to the exchange of similar products belonging to the same industry. The term 
is usually applied to international trade where the same types of goods or services are 
both imported and exported. Balassa (1963) proposed the first measures of intra-
industry trade that measured the degree of trade overlap-simultaneous import and 
export of good within an industry.  
The Balassa index has not found much favour, because an index, which measured 
trade that gave pure trade overlap a value of zero, was not intuitively appealing. In the 
present study Grubel-Lloyd (1975) index has been used for measuring the degree of 
India’s intra-industry trade in health products.  
In the literature many indices have been proposed to calculate the level of intra-
industry trade, but the GL-index has been used because even today it is most widely 
used and most accepted index. Herb Grubel and Peter Lloyd (1975) provided the 
definitive empirical study on the importance of intra-industry trade and how to 
measure it. This measure, now known as the Grubel-Lloyd index, is calculated as 
shown below:   
 
Where; 
GLi denotes the Grubel Lloyd index of the ith industry   
Xi denotes the export of ith industry,  
Mi the import of ithindustry 
If GLi = 1, there is only intra-industry trade, no inter-industry trade. This means for 
example the Country in consideration Exports the same quantity of good i as much at 
it Imports. Conversely, if GLi = 0, there is no intra-industry trade, only inter-industry 
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trade. This would mean that the Country in consideration only either Exports or only 
Imports good i. 
GL-index should, however be interpreted cautiously. The Intra-industry trade rise 
with aggregation {i.e. it (GL-index) is lower when calculated at more disaggregate 
product or industry levels}, so comparison require calculations at similar levels of 
aggregation.  
Marginal Intra-industry Trade Index (MIIT) 
Early empirical investigation of IIT had been confined to “static” indicators such as 
the standard GL-index, which do not have adjustment process. However, a paper by 
Hamilton & Kniest (1991) pioneered the use of indicators based on marginal trade 
flows. It has revealed a new and potentially challenging dimension to the empirical 
analysis of IIT by suggesting a measure of marginal intra-industry trade (MIIT).    
Three methods have been proposed to date for the ‘dynamic’ analysis of IIT; viz.,  
 the Hamilton-Kniest index, 
 the Greenaway et al. (1993) index, and 
 the Brulhart (1994) index 
Among the different versions of MIIT index, the most widely used index has been the 
one developed by Brulhart (1994). 
In this study the Brulhart index for measurement of MIIT has been used- 
MIIT=1-(|ΔXi-ΔMi|/ (|ΔXi|+ |ΔMi|))*100 
Where; 
ΔXi  refers to change in quantity of exports from country i in a particular product 
category from period t1 to t2. 
ΔMi refers to change in quantity of imports  to that country in the same product from 
period t1 to t2. 
The Brulhart index of MIIT takes on values between 0 and 100. With 0 representing 
the scenario where new trade flows over a period of time are entirely due to inter-
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industry trade. Value 100 indicates a situation where new trade flows over a period of 
time are purely because of intra-industry trade.  
1.8 Data Sources 
For obtaining data on health products and services, we have to rely on secondary data 
source such as; UN COMTRADE, ITC (International Trade Centre), WTA (World 
Trade Atlas), WTO (World Trade Organization), UNCTAD, WB-World 
Development Indicator, DGCI&S, Kolkata, etc. 
In the present study, Data is collected for the period of 2001 to 2014 (14 years).We 
have collected data at HS 2-digit level, 4-digit level, and 6-digit level for specific 
chapter.  
1.9 Limitations of the Study 
The HS subheadings might appear insufficient as they offer little details, making it 
difficult to detect the specific amount of certain medicines that are traded. One might 
be interested to know which specific medicines, including the name and dosage, 
containing insulin were imported. Several countries apply more specific goods 
classifications beyond the six-digit codes. However, as these codes are not yet 
harmonized at the international level, it is not possible to use them for comparative 
statistical analysis. 
Data on health products at disaggregated level is not available, prior to 2001. 
Therefore, the study does not cover period 1991 to 2000.RCA at 4-digit has calculated 
only for selected top five products.RCA at 6-digit is calculated only for chapter 30 
(Pharmaceutical products) in which, top five products have been selected. Tariffs still 
represent major impediments to free trade, but this study does not cover the role of 
tariffs for the trade in health products.   
One of the main constraints to understanding the nature of trade in health services and 
to analyse the trends in this area is lack of reliable, comprehensive, and internationally 
comparable data. Most of the data available is anecdotal in nature. While services 
have always been difficult to quantify in terms of volumes and values due to their 
non-storable and intangible nature, this problem is all the more severe in the case of 
social sectors such as health. 
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Chapter – 2 
 
REVIEW OF LITERATURE 
In this chapter, the important studies have been reviewed related to the topic. Both 
theoretical literatures as well as empirical works have been reviewed. It includes 
studies relating to trade in health products and services, intra-industry trade, revealed 
comparative advantage etc. This chapter has divided into three major sections. Section 
2.1 has analysed theoretical literature based on the topic, which has two sub- sections. 
Sub-section 2.1. (i) deals review on health products and 2.1. (ii) covers the review on 
health services. In section 2.2, the focus is on the empirical studies related with 
indices of trade. 
After reviewing theoretical and empirical studies the research gaps have been 
identified in the last section 2.3. 
2.1. Theoretical Studies 
The importance of trade for economic development has long been recognized by 
economists such as Adam Smith, David Ricardo, J.S. Mill, Alfred Marshal, A. Lewis 
among others. The classical economists believed that foreign trade has promoted 
economic growth in two ways. On the one hand, foreign trade has improved the 
optimal distribution of resources and productivity consequentially and then stimulated 
the economic growth; on the other hand, one country could gain raw materials and 
equipments which it could not produce. Those provided the material basis for 
economic development. The most famous theories were exports of surplus of Adam 
Smith, comparative advantage of David Ricardo, the interests of the trade 
development of John Mueller and “trade is the engine of economic growth” of D.H. 
Robert Morrison. All these theories interpreted the relationship to some extent but 
ignored that the international environment is complex and rule less.  
The new-trade theory economist, Haierpoman Paul Krugman believed that there were 
two ways for international trade to promote economic growth. One was the effects of 
economies of scale brought by trade, and the other was that international trade could 
promote economic growth through improving the optimal allocation of resources 
between materials production sector and knowledge production sector.  
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2.1.(i): Reviews on Health Products 
Bettcher, D. W., D. Yach, and G. E. Emmanuel (2000) observed that globalization 
of trade, marketing and investment has important implications for public health, both 
negative and positive. The article considers the implications of the single package of 
World Trade Organization (WTO) agreements for public health research and policy, 
focusing on three themes: commodities, intellectual property rights, and health 
services. The main aims of the analysis are as follows: to identify how trade issues are 
associated with the trans-nationalization of health risks and possible benefits; to 
identify key areas of research; and to suggest policy relevant advice and interventions 
on trade and health issues. The next wave of international trade law will need to take 
more account of global public health issues. However, to become more engaged in 
global trade debates, the public health community must gain an understanding of the 
health effects of global trade agreements. It must also ensure that its own facts are 
correct, so that public health is not blindly used for political ends, such as justifying 
unwarranted economic protectionism. ‘‘Healthy trade’’ policies, based on firm 
empirical evidence and designed to improve health status, are an important step 
towards reaching a more sustainable form of trade liberalization.  
Wakdikar, S. (2004) stated that India has the knowledge and skill to develop its 
Research and Development (R&D) capabilities. It is the second largest exporter of 
medicinal plants. Instead of exporting such a large amount of valuable resource with 
very low returns it can think about developing its own R&D capabilities and produce 
finished goods in the form of modern medicines and health care products derived 
from plant origin and based on the knowledge of alternative system of medicine. 
Standardisation of products is most essential to compete in the world market that 
India has to lay stress on. The finger printing and marker compound analyses are 
nowadays gaining momentum for standardisation of traditional medicinal 
formulations. 
Oclay, M. and R. Laing (2005) examined tariffs levied on medicines. The paper 
provides data on the tariff rates levied and revenue generated by over 150 countries 
around the world on different categories of pharmaceutical products. These categories 
include active pharmaceutical ingredients, finished products and vaccines for human 
medicines. Data for selected sub-categories of pharmaceutical products is also 
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provided. The analysis has shown that many countries (41 per cent for active 
pharmaceutical ingredients and 39 per cent for finished products) for which data are 
available do not levy duties on pharmaceutical products. Fifty-nine percent of 
countries for which data are available levy tariffs on pharmaceutical active 
ingredients. Sixty-one percent of countries levy tariffs on finished pharmaceutical 
products. A total of 35 per cent of countries still levy import duties on vaccine 
imports. Ninety percent of countries apply less than 10 per cent tariff rates on 
medicines.  
Bate, R., R. Tren and J. Urbach (2005) conducted a study which examines the role 
that tariffs, domestic taxes, and regulatory requirements pose on access to essential 
drugs, vaccines and devices for the diseases that afflict the developing world. While 
aid has increased in recent years and the price of many drugs has fallen, access to 
medicines, vaccines and devices has not increased greatly. There are numerous 
reasons for this, notably the paucity of medical professionals in the poorest countries.  
Greene, W. (2007) presents an overview of India’s pharmaceutical industry and its 
evolution from almost non-existent to one of the world’s leading suppliers of generic 
drugs. The Indian pharmaceutical industry was allowed to take off when India met its 
WTO TRIPs obligations and amended its patent laws with the passage and 
implementation of the Patents (Amendments) Act 2005. When India re-instituted 
“product” patents, it effectively ended 36 years of protection for Indian companies 
and terminated legal reverse engineering or copying of patented foreign 
pharmaceuticals drugs. To meet the short fall in revenues, many of India’s leading 
pharmaceutical companies turned to foreign acquisitions and exports, especially to the 
United States. Indian companies benefit from a greater acceptance of generic drugs 
among the U.S. public, tremendous pressure on healthcare providers to reduce costs, 
and impending expiration of patents on drugs with annual sales of $50 billion. India’s 
major pharmaceutical companies are positioning themselves to offer generic versions 
of these drugs and some have predicted that they will capture at least 30 percent of the 
U.S. generic replacement market. However, Indian companies face severe price 
compression in the U.S. for their generic drug market and stiff competition from 
domestic U.S. generic manufactures and suppliers from other low-cost countries. 
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Labonte, R., K. S. Mohindra and R. Lencucha (2011) examined that there is an 
emerging evidence base that global trade is linked with the rise of chronic disease in 
many low and middle-income countries (LMICs). This linkage is associated, in part, 
with the global diffusion of unhealthy lifestyles and health damaging products posing 
a particular challenge to countries still facing high burdens of communicable disease. 
They developed a generic framework which depicts the determinants and pathways 
connecting global trade with chronic disease. Then, they applied this framework to 
three key risk factors for chronic disease: unhealthy diets, alcohol, and tobacco. This 
led to specific ‘product pathways’, which can be further refined and used by health 
policy-makers to engage with their country’s trade policy-makers around health 
impacts of ongoing trade treaty negotiations, and by researchers to continue refining 
an evidence base on how global trade is affecting patterns of chronic disease. The 
findings summarized in the article imply the need for a more concerted approach to 
regulate trade-related risk factors and thus more engagement between health and trade 
policy sectors within and between nations. They recommended, an explicit 
recognition of the role of trade policies in the spread of non-communicable disease 
risk factors should be a minimum outcome of the September 2011 Summit, with a 
commitment to ensure that future trade treaties do not increase such risks.  
Cameron, A. et el. (2011) found that medicine availability and prices in both public 
and private sectors are key indicators of access to treatment. Surveys of medicine 
prices and availability have shown that poor medicine availability, particularly in the 
public sector, is a key barrier to access to medicines. Public sector availability of 
generic medicines is less than 60 per cent across WHO regions, ranging from 32 per 
cent in the Eastern Mediterranean Region to 58 per cent in the European Region. 
Private sector availability of generic medicines is higher than in the public sector in 
all regions. Due to low availability of medicines in the public sector, patients are often 
forced to purchase medicines in the private sector. For originator brand products, 
private sector prices were at least 10 times higher than international reference prices 
in all WHO regions. When originator brands are prescribed and dispensed for 
products that are also available in generic form, patients are paying four times more, 
on average, to purchase the brand. High medicine prices increase the cost of 
treatment. Additional problems of affordability face people living with chronic 
diseases due to the lifelong nature of treatment and the frequent need for combination 
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therapy. They suggest that countries should intensify efforts to measure and regularly 
monitor medicine prices and availability, and adopt policy measures to address the 
issues identified. Low public sector availability can be addressed through improved 
procurement efficiency, and adequate, equitable and sustainable financing. The most 
appropriate actions to follow depend on a country’s individual survey results and their 
underlying determinants, as well as local factors including existing pharmaceutical 
policies and market situations.  
Bate, R. (2011) observed that the trade in inferior quality medicines kills innocent 
patients. Price is the most obvious market signal of quality, and cheaper drugs have 
been shown to on average be inferior in quality. But the price signal from the original 
dataset analysed previously was weak. The paper disaggregates the sample into two 
groups, counterfeit products and substandard products. The disaggregated data show 
two statistically significant and opposing results, which account for the weak price 
signal overall.  Counterfeit products are sold at a negligible discount (0.6 per cent) to 
legitimate products they copy and substandard products are sold at a noticeable 
discount (19.3 per cent) to the generic drugs they copy.  These results are entirely 
explicable and a brief theoretical justification was given for them. Only larger studies 
will be able to determine whether the finding of this paper is strongly replicated and 
hence have relevance for policy makers.  
According to International Trade Centre (ITC) paper (2011) aims to determine to 
what extent this concern is justified by examining the size of possible fiscal revenue 
losses if tariffs on anti-malarial commodities were eliminated. To this end, the 
nomenclatures of 32 malaria endemic countries are examined in order to identify the 
relevant tariff lines under which medicines, mosquito nets, diagnostic tests, 
insecticides and spray pumps are (most likely) imported. These are subsequently 
matched with ITC tariff and trade data in order to estimate the theoretical customs 
revenue generated by anti-malarial commodities and as such the potential revenue 
losses if import duties on these products were reduced to zero. The results show that 
the contribution by the relevant tariff lines to total custom revenue is relatively small. 
As a share of total fiscal revenue, it is in most cases negligible.  
Creese, A. (2011) examined that domestic taxes can comprise a substantial proportion 
of the price people pay for medicines, and high prices are generally considered to be a 
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principal barrier to access to needed care. The paper brings together information on 
domestic taxes as they affect medicines in countries at different income levels and 
asks questions about the health effects of these taxes. It then presents some evidence 
of the likely effects of a change in tax policy and how access to medicines would be 
affected. The paper highlighted the role of taxes in influencing consumption levels of 
medicines and other commodities affecting health is explored, and in which access to 
medicines plays a fundamental role. Medicine taxes can be an important source of 
revenue. Yet governments have many options in the design of their fiscal policies, and 
these can often be better aligned with public health objectives, for greater consistency 
in national growth and development strategies. Many countries at all income levels 
currently raise taxes on some medicines, though some countries tax-exempt them all 
and others treat all medicines as any other goods and services. Yet other countries 
have tax concessions on some medicines. Medicine tax can be an important 
component of the price patients pay for a medicine and in countries without well-
developed health insurance systems this entails payment at the time of need.  
Helble, M. (2012) analysed the trade flows and tariff policies of health products. He 
not only focuses on medicines, but on a large set of products that enter the public 
health space and can be identified in the common trade classification. The first 
contribution is thus to construct three groups of health products based on the 2007 
Harmonized System classification of international trade. Using these commodity 
groups, he analysed trade flows between 167 countries for the years 1996 to 2009. He 
found that trade in health products has developed very dynamically, with trade in 
dosified medicine displaying the strongest growth with an annual growth rate of 
almost 12 per cent. The results further indicate that the market of health products is 
dominated by a small number of developed countries. Looking at tariffs on health 
products for developed and developing countries as well as LDCs and transition 
economies found that the overall level of tariffs is low, but far from being zero, 
especially in the last three country groups.  The tariffs on health products in 
preferential trade agreements between developing countries, the results show that the 
tariff level is low, but in some individual cases still substantive.  
Kallummal, M. and K. Bugalya (2012) observed that India’s pharmaceutical sector 
has pre-dominantly been a producer of generic products and has the potential to 
enhance its global presence. On an annual basis, exports and imports of 
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pharmaceutical products increased from 1996 to 2010. In order to undertake a detailed 
analysis of import trends and assess the extent of India's dependence for imports on 
China, the period 1996 to 2010 was divided into three phases - Phase 1 comprised 
1996-2000, Phase 2 comprised 2001-2005 and Phase 3 comprised 2006 - 2010. The 
analysis highlights that India has become overwhelmingly dependent for its imports 
on China. Further, the analysis suggests that China has used a strategic policy for 
establishing and deepening its presence in India's import market. This is also reflected 
in the fact that 8-10 pharmaceutical products from China face anti-dumping duty in 
India. 
2.1. (ii):Reviews on Health Services 
Vega, J.A.A. (1998) conducted a study on International trade in health services: A 
development perspective. The paper discusses the trade in health services with special 
case of Mexico-United States border area. The provision of health is different in 
Mexico and in the United States. In both cases, there are shortcomings that, to some 
extent, are being covered by the private sector. Interestingly, and due to proximity, 
some of the gaps within the American health systems are being covered by the 
Mexican private health sector, in this way opening opportunities for trade. Neither 
Mexico nor the United States has realized the full potential of developing 
international trade in health services between the two countries. The Mexican 
Government has not been aware of it. The United States Government is beginning to 
realize its importance, mainly as a way to reduce its health expenditure. The only 
sector to realize its potential has been the United States private health insurance.  
Zarrilli, S. (1998) observed that Brazil is facing several problems in the area of health 
care. The public health system has not sufficient resources to meet the needs of the 
population; therefore it is offering a service which in most cases is not adequate from 
either a quantitative or a qualitative point of view. Deterioration of the public system 
and improvement of the economic conditions of a (limited) number of the population 
have led to the development of a parallel private health system. Coexistence of the 
two systems is not easy. However, it is clear that there is no alternative to it, since 
those who can afford to join a private health scheme/insurance will continue to do so, 
because they do not trust the public health system. The Government decided to start 
opening the Brazilian health market to foreign investments in order to cut costs and 
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improve quality; for the time being, however, the opening is limited to health 
insurances. There could be an interest in exploring the option of further opening of the 
Brazilian market to foreign firms and capital. The presence of foreign-owned 
hospitals might alleviate the problem of bed shortage and increase competition in the 
market, resulting in a decrease in prices and an improvement in quality. 
According to Houyuan, X. (1998) public hospitals are the main suppliers of medical 
services in China. The main responsibility for eliminating or reducing the restrictions 
at home and abroad, in order to increase medical service exports from China, is 
naturally left to the central and regional governments. Because of the 
underdevelopment of China's medical service sector in technology, equipment, 
management and marking, national hospitals are unable to cope with competition 
from foreign medical service suppliers on equal conditions. The inflow of too great a 
number of mature foreign competitors will have irrevocable detrimental effects on 
domestic enterprises. Therefore, the practicable mode for medical service imports to 
China will be the establishment of joint ventures. The existence of wholly-owned 
foreign hospitals in China at present is not a suitable measure, bearing in mind the 
current free medical service policy and relatively low personal income in China. 
Because China is rich in qualified medical professional with extensive clinical 
experience, including doctors in modern medicine and traditional Chinese medicine, 
and nurses, negotiations should focus on freer conditions for the export of Chinese 
medical professionals. Computer networks need to be set up inside hospitals, among 
domestic hospitals, and even between Chinese hospitals and foreign medical and 
health-care organizations. Through the establishment use of open computerized 
medical databases and rapid transmission of medical data through the networks, even 
an inland hospital can at least be kept abreast of new developments in the field of 
medical sciences, thus facilitating the daily diagnosis process and improving its 
research capacity. Cooperation among national hospitals and between national 
hospitals and foreign hospitals should be expanded by way of establishment of joint 
ventures, which can help accelerate the renewal process of outdated equipment and 
techniques. With the orientation of medical service exports, the hospitals should make 
more effort and require higher service quality standards of them than are needed in the 
domestic market. The additional measures should include training their own teams of 
professionals, who can provide medical services to foreign consumers, up to 
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international standards, introducing state-of-the-art medical equipment and 
techniques, and moving towards meeting the requirements of international service 
standards.  
Gupta, I., B. Goldar and A. Mitra (1998) found that opening up the various areas of 
health services will be beneficial for the country as a whole. Trade in health services 
would affect curative care in India only in the short run. In the long run, the whole 
system of health care is likely to be influenced by the opening up of this sector.  This 
opening up is unlikely to affect the availability of health care within the country, and 
may in fact improve the quality and even the quantity of curative care available. 
Priorities in this area identified are three: outflow of health personnel, inflow of 
patients and inflow of foreign capital. This does not mean that these are the only three 
areas of current trade. However, these are areas where India is currently engaged in 
trade in health services, and where it should hope to gain the most. Overall restrictions 
on short-term movements of medical personnel should be reviewed and relaxed so as 
to facilitate the easy exchange of health personnel across countries. One of the major 
deterrents towards greater exchange of health personnel in India has been the fact that 
Indian medical degrees and diplomas are not recognized by many developed 
countries. A system of mutual recognition for qualification requirements and technical 
standards need to be worked out globally, so that no arbitrary rejection of deserving 
candidates takes place. India should have a more open mind towards foreign 
investment in the health sector. However, this should be accompanied by a system of 
regulations relating to the health sector as a whole, which would prevent unfair 
practices by both domestic and foreign establishments. India has a very strong and 
unique system of alternative medicines. This is an area which should be given more 
attention, especially in the context of foreign patients coming into India for treatment. 
India should recognize its competitive advantage in exports of health services 
between countries and the various trading blocs of the region. It should take the lead 
in making bi- and multilateral agreements and commitments which would promote a 
freer environment in trade in health services.  
Gonzale, A., L. Brenzel and J. Sancho (2001) conducted a study and submitted the 
report on Health tourism and related services: Caribbean development and 
international trade. The study focuses on the prospects for developing trade in health 
tourism services and identifying trade negotiation objectives and strategy. The 
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specific areas of health tourism that are under examination are convalescent care and 
rehabilitation; health and wellness programmes, such as use of spas, etc; drug and 
alcohol dependency programmes; the use of local health services by tourists; cosmetic 
surgery; and telemedicine. Based on supply and demand factors, the study advocates 
the development of a strategic plan with all stakeholders involved. Each individual 
country will have to decide who would lead the development strategy and be 
accountable for the development objectives being achieved. Each country in moving 
forward will need to complete a stakeholder analysis of or at least evaluate the various 
interests, resources and potential problems associated with trade in health tourism to 
determine the most appropriate role for each player in the formulation and 
implementation of the development strategy.  
Adlung, R. and A. Carzaniga (2001) observed that the potential for trade in health 
services has expanded rapidly in recent decades. More efficient communication 
systems have helped to reduce distance-related barriers to trade; rising incomes and 
enhanced information have increased the mobility of patients; and internal cost 
pressures have led various governments to consider possibilities for increased private 
participation. As yet, however, health services have played only a modest role in the 
General Agreement on Trade in Services (GATS). It is possible that Members of the 
World Trade Organization have been discouraged from undertaking access 
commitments by the novelty of the Agreement, coordination problems between 
relevant agencies, widespread inexperience in concepts of services trade, a 
traditionally strong degree of government involvement in the health sector, and 
concerns about basic quality and social objectives. However, more than five years 
have passed since GATS entered into force, allowing hesitant administrations to 
familiarize themselves with its main elements and its operation in practice. The paper 
is intended to contribute to this process. It provides an overview of the basic structure 
of GATS and of the patterns of current commitments in health services and of 
limitations frequently used in this context. The concluding section discusses 
possibilities of pursuing basic policy objectives in a more open environment and 
indicates issues that may have to be dealt with in current negotiations on services.  
According to Chanda, R. (2001) trade in health services is globally widespread. A 
wide variety of developing and developed countries are engaged in this trade, as 
exporters and as importers. The nature of trade flows in this sector is dictated by 
25 
 
sectoral needs and specificities in the exporting and importing countries and by a host 
of regulatory and infrastructural constraints. Comparative advantage in trade in health 
services is based on costs, natural endowments, and availability of human, financial, 
and physical capital, presence of niche areas within the sector, and the supporting 
policy environment and infrastructure. Trade in health services takes many forms, 
including movement of health professionals, movement of consumers, foreign direct 
investment in health services, and electronic delivery. Each mode of trade has 
associated with it positive as well as negative implications. The main positive 
implications of trade in health services include upgrading of infrastructure, increased 
exposure for health service providers, foreign exchange earnings and remittances, 
greater availability of quality health services and thus reduced pressure on public 
resources and domestic capacity. Overall, the study makes clear that trade in health 
services raises a variety of difficult questions. The answers to these questions cannot 
be generalized. They depend very much on country-specific circumstances and the 
policy environment. However, one of the main points highlighted by the study is that 
it is possible to enhance the gains from trade in health services and to mitigate the 
associated negative consequences through well-conceived policies and initiatives at 
the national, regional, and multilateral levels. 
Chanda, R. (2002) found that health services can be traded, using the mode-wise 
characterization of trade defined in the General Agreement on Trade in Services. The 
trade modes include cross border delivery of health services via physical and 
electronic means, and cross-border movement of consumers, professionals, and 
capital. An examination of the positive and negative implications of trade in health 
services for equity, efficiency, quality, and access to health care indicates that health 
services trade has brought mixed benefits and that there is a clear role for policy 
measures to mitigate the adverse consequences and facilitate the gains. Some policy 
measures and priority areas for action are outlined, including steps to address the 
‘‘brain drain’’; increasing investment in the health sector and prioritizing this 
investment better; and promoting linkages between private and public health care 
services to ensure equity. Data collection, measures, and studies on health services 
trade all need to be improved, to assess better the magnitude and potential 
implications of this trade. In this context, the potential costs and benefits of trade in 
health services are shaped by the underlying structural conditions and existing 
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regulatory, policy, and infrastructure in the health sector. Thus, appropriate policies 
and safeguard measures are required to take advantage of globalization in health 
services.  
Mathur, A. (2003) analysed Information Technology (IT) is poised to revolutionise 
healthcare trade through new thresholds in human connectivity. This paper focuses on 
the expanding role of IT in three distinct but related categories: (a) design and 
development of healthcare products and services, (b) delivery systems, and, (c) 
healthcare administration. Through information power that IT enables, capacities of 
decision-makers are continually transformed in how they link with each other, in the 
here and now. This not only promotes conventional trade in services and e-commerce 
and facilitates worldwide convergence in several aspects of healthcare management 
and organisation. However, this process also raises fears and anxieties because the 
pervasive nature of IT and its uneven diffusion increase some vulnerability where 
policy safeguards would be needed. The process of IT diffusion occurs at many 
different points of impact in the international economy. Thus, policy choices have to 
cater to a wide range of national and regional needs and circumstances concerning 
rights to health, rights to trade and rights to development. National policies and 
international regimes need to strike a harmonious balance between these sets of rights. 
The persistence of unresolved conflicts of rights and conflicts of interests point to the 
need for new international arrangements to be mandated and resourced. The extent to 
which this can be achieved is uncertain. This uncertainty is traceable to the ways 
responsibility for healthcare, authority to design healthcare products and systems, and 
the power to organise healthcare delivery remain separate or come together. The 
restructuring of private investments to integrate IT with life sciences in public-private 
partnerships is a sign of the growing significance of IT in healthcare. It is also a 
reminder of how powerfully IT could be harnessed in pursuit of millennium 
development goals.  
Smith, R. D. (2004) emphasised that globalization is a key challenge facing health 
policy-makers. A significant aspect of this is direct trade in health services, a result of 
the rise of transnational corporations, challenges in health care financing, porous 
borders and improved technology creating the scope for increased ‘foreign direct 
investment’ (FDI) in health care. This has gathered momentum with the General 
Agreement on Trade in Services (GATS), which aims to further liberalize trade in 
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services, and within which FDI has been noted as perhaps the most critical area for 
trade negotiation. Given the rapid development of this area, there are little empirical 
data. The paper therefore seeks to provide the first comprehensive and systematic 
review of evidence concerning FDI and health services. This process included 
electronic bibliographic database searches, website searches and correspondence with 
experts in the area of trade in health services, from which 76 papers, books and 
reports were reviewed. Perhaps due to the rapid developments in this area, most of the 
literature is speculative, polarized between those arguing for the benefits of 
liberalization and those arguing against. However, there seem to be three issues which 
emerge as of most importance: (i) the extent to which a national health system is 
commercialized per se is of more significance than whether investment in it is foreign 
or domestic; (ii) the national regulatory environment and its ‘strength’ will 
significantly determine the economic and health impact of FDI, the effectiveness of 
safeguard measures, and the stability of GATS commitments; and (iii) any 
negotiations will depend upon parties having a common understanding of what is 
being negotiated, and the interpretation of key definitions is thus critical. Each of 
these issues is explored in some depth, with the overall conclusion that countries 
should take a step back and first think through the risks and benefits of 
commercialization of their health sector, rather than being side-tracked in to 
considering the level of foreign investment.  
Baxi (2004) stated that the Confederation of Indian Industry (CII) in India has the 
potential to attract 1 million tourists per annum, and this could contribute up to $5 
billion to the economy. India offers a unique basket of services to an individual that is 
difficult to match by other countries. 
Mukherjee and Mookerji (2004) mentioned that after Singapore and Thailand, India 
may be the next multimillion dollar Asian medical industry. The Apollo Hospitals 
Group, Wockhardt, Escorts, Fortis, Hinduja and Breach Candy are some of the names 
in healthcare that have come forward to tie up with tourism industry players like 
Hyatt, Kuoni, Indian Airlines and the Bangladeshi carrier GMC which offers 
discount-laced customized packages to international medical tourist to India.  
Rao (2005) describes that a substantial number of foreigners are coming to India to 
avail themselves of quality medical treatment at a cost much lower than that of other 
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countries of the world, particularly in the field of cardiology, cardiac surgery, joint 
replacement, ophthalmology, pathology and Indian systems of medicine etc.  
Mohanty and Madhav (2006) are of the opinion that the Indian health care industry 
began to recently emerge as a prime destination for medical tourists by upgrading its 
technology, gaining greater familiarity with western medical practices and improving 
its image in terms of quality and cost.  
Datt (2006) also provides a picture of medical tourism in India. The current drive to 
improve facilities and the huge makeover is striking. Hospital floors are squeaky 
clean and interiors compete with those of five star hotels. Many hospitals also have 
prayer rooms, translators, visa extension and currency exchange services. Some 
hospitals are also tying up with travel agents and insurance agencies in lucrative deals.  
Jain (2006) states that most patients from countries like the USA and UK travel to 
developing countries such as India for treatment because India offers some of the 
cheapest pricing options of treatment, offers a good holiday, and there are no waiting 
lists or queues to stand in.   
Sujatha and Kumar (2006) claim that globalization has really opened many vistas 
for India to emerge as a centre of excellence in medical tourism. Irrespective of the 
country from which the medical tourists originate, they feel at home in India. Indian 
doctors are well-versed in English and when this is combined with Indian hospitality, 
Indians are second to none in the care industry.  
Chacko (2006) highlights certain issues that need attention in medical tourism such as 
the upgrading of basic amenities and hospital infrastructures, coordination between 
the health care and tourism sectors, creation of a resource pool of highly skilled and 
cordial staff, manpower standardization of services and accreditation of hospitals as 
well as a more positive impact on the domestic healthcare services. The number of 
medical tourists is increasing, which means demand for private healthcare services 
will increase.  
Arnold, P. J. and T. C. Reeves (2006) examined the implications of the General 
Agreement on Trade in Services (GATS), the World Trade Organization's agreement 
governing trade in health-related services, for health policy and healthcare reform in 
the United States. The paper describes the nature and scope of US obligations under 
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the GATS, the ways in which the trade agreement intersects with domestic health 
policy, and the institutional factors that mediate trade-offs between health and trade 
policy. The analysis suggests that the GATS provisions on market access, national 
treatment and domestic regulation, which are designed to eliminate 'regulatory 
barriers' to global trade in health services, limit the range of options that state and 
federal regulators and legislative bodies can employ to regulate the health sector and 
implement healthcare reforms. As such, the paper identifies the broader social and 
ethical implications of free trade policy.  
Bate, R. et. el. (2006) conducted a study on Tariffs, corruption and other impediments 
to medicinal access in developing countries. Their paper examines the impact of 
tariffs, taxes and other markups on imported medicines and medical products 
provided to lesser developed countries by pharmaceutical companies, not-for-profit 
groups, for-profit corporations, multilateral and bilateral aid and health agencies. It 
discusses how these regulatory barriers affect access to medication. Although, efforts 
to reform the current system of government revenue generation through tariffs 
collection may meet resistance in many developing countries, especially those 
featuring systemic corruption and those with domestic production, governments 
which take steps to eliminate tariffs could in fact expedite health care delivery and 
consequently improve the well-being of their people.  
Arunandchai, A. and C. Fink (2007) conducted a study on trade in health services in 
the ASEAN region. The paper has discussed on trade policy measures that could 
further harness the benefits from trade in health services and address potential pitfalls 
that deeper integration may bring about. Economic research on the effects of 
liberalizing trade in health services is still in its infancy.  
Mickick, M. (2007) conducted a study on the Health-related services in multilateral 
and preferential trade arrangements in Asia and the Pacific. In his paper he tries to 
contribute the debate by reporting on the status of liberalization achieved in the health 
services sector by members of ESCAP through their regional and multilateral trade 
liberalization commitments. The health services sector is one area where preferential 
agreements so far have not secured any deeper liberalization compared to multilateral 
and unilateral liberalization efforts. The role of policy makers, in consultation with all 
stakeholders is to find policy solutions in trying to maximize net benefits from the 
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opening of health sectors. This can be achieved through autonomous policies (such as 
domestic regulation ensuring quality control, transparency of information, 
introduction of universal coverage by the health service, adoption of more flexible 
labour markets, etc.), as well as further commitments through GATS or further 
bilateral/regional liberalization.  
Chanda, R. (2008) outlined the opportunity segments as well as constraints in India-
EU relations in the health services sector based on primary as well as secondary 
evidence. The corroboration of the discussions with sector specialists and experts 
based on secondary sources clearly show that it will be difficult to realize any major 
breakthroughs in the India-EU negotiations in this sector. The lack of an internal 
mandate to form a single market in health services is itself a reflection of the 
difficulties in negotiating greater market access to the EU in this area. Therefore, the 
most pragmatic approach is to launch joint programs with selected countries in the EU 
on a pilot basis in all possible segments of opportunity and to scale these initiatives 
depending on the outcome. A cooperation-based approach would be more applicable 
in this sector. Also, stakeholder buy-in will be essential and thus a limited and gradual 
approach is appropriate. Meanwhile, a variety of internal measures and regulatory 
reforms need to be adopted in India if these opportunities are to be scalable and 
sustainable in the long run. 
Mortensen, J. (2008) conducted a study on International trade in health services 
assessing the trade and the trade-offs. International trade in health services has gained 
momentum – both in terms of increased trade and level of media, political and 
academic attention – over the past decade. International organisations, non-
governmental organisations (NGOs) and academics have all contributed to a literature 
on the subject covering a wide range of perspectives and conclusions. As trade in 
services is broadly defined the literature covers aspects of all sides of the ‘triangle’ of 
economic globalisation: trade, investment and migration. The aim of this study is to 
provide an overview of the commercial opportunities from trade in health services for 
developing countries and the trade-offs these are argued to be associated with. The 
literature often falls into one of two ‘traps’. It either regards trade as a threat to public 
health that must be combated or it makes buoyant claims regarding the current and 
potential commercial opportunities from trade. Neither ‘trap’ is supported by 
empirical evidence. 
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Kategekwa, J. (2008) stated that an increasingly important phenomenon in 
globalization is the movement of health service suppliers to provide services. While a 
lot of this movement takes place within and among developed countries, the trend 
between developing to developed countries is more concerning. In the context of the 
World Trade Organization (WTO) negotiations, developing countries, including the 
Least Developed Countries (LDCs) are ambitiously negotiating for enhanced market 
access in developed countries for the provision of services through the presence of 
natural persons (mode 4), including in the health sector. While the type of movement 
envisaged under the WTO is only a fraction of the channels through which health 
service suppliers’ move, it is an important one.  
Davis, L. and F. Erixon (2008) found that health care services have so far resisted 
emerging forces of globalization. But the combination of fiscally unviable national 
health services with modern technological and medical innovations, are opening the 
door to the desirability and feasibility of trade in health. Continuing opposition to 
liberalizing trade in health care, means this potential for the health sector is under-
explored. This paper assesses the current status of health and trade policies and 
analyses opposition to liberalizing trade in health care. It conceptualises and contrasts 
two international policy dialogues. One, typified by UN bodies such as the WHO, is 
sceptical if not hostile to increased trade in health care, particularly north-south 
integration. Its policy errs on the side of protectionism and favours an industrial-
policy approach. The other, operating under WTO discourse, has more of a free-trade 
bent. And yet in policy practice, few countries in the WTO trade in health care and 
trade agreements typically contain little to promote liberalization.  Examples in this 
study from those few (mainly developing) countries that have shown initiative 
towards trade in health care, contradict this negative and apathetic approach. 
Countries as diverse as Brazil, China, Cuba, India and South Africa are already 
significant exporters of health care. Trade does hold some very tangible benefits for 
this sector, for north and south alike, and does not necessarily entail undermining 
government regulatory power. Further analysis of different health care systems’ trade-
compatibility is necessary, if the wealth of nations is to be applied to the health of 
nations.  
Vega, J.A.A (2009) found that the provision of health is different in Mexico and in 
the United States. In both cases, there are shortcomings that, to some extent, are being 
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covered by the private sector. Interestingly, and due to proximity, some of the gaps 
within the American health systems are being covered by the Mexican private health 
sector, in this way opening opportunities for trade. If international trade in health 
services is to be developed, more in-depth studies need to be conducted in order to 
identify more precisely the type and extent of the demand for Mexican medical 
services. There is a need to monitor the behaviour of this demand, its trends and 
shifts, in order to devise specific trade schemes. There is a great need for sufficient 
evidence in order to convince local governments of the importance of this sector and 
the potential benefits of promoting international trade.  
Smith, R. D., R. Chanda and V. Tangcharoensathien (2009) observed that the 
supervision of a domestic health system in the context of the trade environment in the 
21st century needs a sophisticated understanding of how trade in health services 
affects, and will affect a country’s health system and policy. However, establishment 
of systematic comparative data for amounts of trade in health services is difficult to 
achieve, and most trade negotiations occur in isolation from health professionals. 
These difficulties compromise the ability of a health system to not just minimise the 
risks presented by trade in health services, but also to maximise the opportunities. 
Considering these issues by presenting the latest trends and developments in the 
worldwide delivery of health-care services, using the classification provided by the 
World Trade Organization for the General Agreement on Trade in Services. This 
classification covers four modes of service delivery: cross-border supply of services; 
consumption of services abroad; foreign direct investment, typically to establish a 
new hospital, clinic, or diagnostic facility; and the movement of health professionals. 
Outside GATS, the main opportunities presented by increasing trade in health services 
include efficiency, specialisation and quality gains, public-sector cost savings, 
expansion of service provision, export revenues and remittances, transfer of 
technology and skills, and increased patient choice. Potential risks include distributive 
consequences for domestic patients through various means, and an internal and 
external brain drain of health professionals. The likely effect of trade liberalisation 
depends on the context of the country involved. For one country, mode 4 might 
present the opportunity to increase its health workforce through import, for another to 
secure foreign income and training through export, and for another present the risk of 
domestic brain drain, causing loss of human capital and education expenditure. 
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Similarly, mode 2 can enable one country to increase earnings through exports to 
foreign patients, while enabling another to import such services and thus relieve 
pressure on the domestic public system, and in another causing a two-tier system, 
with domestic patients being provided lower quality care than that for foreign patients 
and possibly resulting in higher overall health-care costs. 
Cattaneo, O. (2009) summarizes the existing knowledge and relevant abstracts and 
case-studies on the design of health and/or trade reforms and policies. The study aims 
to contribute to the understanding of the potential benefits and risks and ways to 
maximize the former and minimize the latter of trade in the health sector. It is 
designed for non-trade (health) experts to understand how trade can help to improve 
health systems and access to health services, and for trade specialists to understand 
the specific characteristics of the health sector.  
Calì, M. And M. Stern (2009) stated that the provision of health services is among 
the most regulated services sectors in developing (as well as developed) countries. 
Although regulatory frameworks and their enforcement do vary across countries, 
regulation generally poses serious barriers to trade in health services. Little is known 
on the effects of increased trade in health services on domestic health systems. The 
study addresses these issues through case studies in India and South Africa, both of 
whom are significant players in trade in health services. These countries are amongst 
the most important exporters and importers of health services. They also face big 
challenges in providing adequate health services to their entire domestic population. 
The two case studies are complementary. The Indian case study focuses on trade in 
health services via commercial presence and exports of health services via temporary 
movement of persons.  
Herman, L. (2009) has made a contribution by conducting a study on Assessing 
international trade in healthcare services. The study examines the extent to which 
global trade in healthcare is already a reality. Stories of “health tourism” have been 
increasing in recent years. But very little was previously known about the extent to 
which health services are traded internationally. He maps trends in the trade of health 
services, providing a fully comprehensive picture. He finds health professionals and 
healthcare firms moving in high numbers between countries. Cross-border services 
and patient travel however remain low. The economic significance of the healthcare 
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sector means this unexploited potential for greater trade could reduce costs for 
patients and governments.  
Pachanee, C. (2009) found that Mode 2 trade in health services in Thailand has 
occurred and was initiated by the private sector itself. It has occurred outside the 
multilateral and regional trade agreements. Thailand is recognised as a leading 
exporter of medical services to foreign patients due to its high capacity and good 
marketing strategies. Although the increase in demand of health services among 
foreign patients generates income for the country, negative implications also occur 
and take part in elevating existing problems in the Thai health systems such as 
inequitable distribution of health workforce and widening of the two-tiered health 
services. However, the implications have not been systematically measured and 
monitored.  As the magnitude of impacts from Mode 2 international trade in health 
services is still not clear and has not been systematically measure, good systems or 
methods for measuring the impacts should be developed. In addition, Thailand could 
learn from experience of other countries that promote Mode 2 trade in health services 
on how impacts on the health systems are prevented, measured and addressed. 
Mashayekhi, M. and E. Tuerk (2010) observed that the inter-linkages between 
primary health care (PHC) related services and rules covering international services 
trade. The issue is important from the perspective of policymakers seeking to 
minimize the risks of health services trade when seeking to deliver high quality and 
affordable PHC services at the national level. The paper examines whether 
international trade agreements contain any PHC-specific provisions; touches on costs 
and benefits related to trade in PHC related health services; stresses the need for 
regulation to complement liberalization; and highlights cooperation as a central 
element of international trade rules covering PHC-related health services. From a 
trade perspective, a PHC-related approach to services would be an important step 
towards putting development at the core of international trade negotiations and trade 
policies.  
Banik, A. et. el. (2010) examined the opinions of patients, hospitals owners and 
doctors involved in this service trade in India, Bangladesh and Nepal. It focuses on 
the liberalization of health services and assesses the challenges and opportunities 
posed by the liberalization of trade on the provisions of health services and options for 
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national policy makers. It further makes an effort to examine the barriers in health 
service trade in the two relatively small countries of South Asia. An effort is made to 
explore possible regional cooperation in health service trade among the above three 
countries of the SAARC region. The study opines that there exists a gender bias 
among the foreign patients coming to India for medical treatment. An overwhelming 
majority of the patients is male and more than half are in the age group of 40-59.The 
largest number of patients coming to India is for cardiac and cancer treatment. 
Orthopaedic and kidney-related treatment also forms a significant percentage. A vast 
majority of patients reported that they came to India because of its inexpensive and 
high quality doctors. Majority of the patients got their diagnosis done in their home 
country. Apparently, the local doctors advised them to go abroad for better treatment 
in view of insufficient facilities and expertise in the home country. In many cases, 
travel to India for treatment came after many months of diagnosis. It turns out that 
visa is a major obstacle to trade in medical services. Neither language nor central 
bank permission for remittance nor information regarding medical facilities in India is 
perceived to be a major   obstacle, but non-availability of Indian rail ticket in the 
patient’s home country is. 
Fahmida, K. and M. G. Ahamad (2011) examine the potentials and challenges of 
liberalizing health services in five South Asian countries under proposed SATIS. 
These countries are: Bangladesh, India, Nepal, Pakistan and Sri Lanka. In doing so 
the study presents an overview of the health sector and trade in the South Asian 
region and examines the regulatory framework of countries which govern the health 
sector. The study then identifies potential health sub-sectors under each mode of the 
General Agreement of Trade in Services (GATS) which can be considered for trade in 
the region and associated challenges. A number of policy recommendations as to how 
go forward in improving health services in the region are also made in this study.  
Geoffard, P.Y. and T. Verdier (2011) reviewed International trade in medical 
services. This paper develops a theoretical analysis of international trade in health 
services, considering explicitly the interaction between the market for health care 
services and the market for health care professionals in a "general" equilibrium 
model. The paper investigates one aspect of international trade in medical services: 
patients who travel abroad to consume health care. They consider trade in medical 
services when travel costs may substantially differ across patients according to their 
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health conditions. This feature induces a selection bias in patients’ movement, which 
has important consequences on the patterns of international trade. For intermediate 
travel costs, only patients who would not have been treated in their origin country 
travel for treatment. The positive demand shock may increase equilibrium medical 
wages and health care prices. At the margin, patients in a better condition than those 
who stay at home to get treated abroad, worsening the case-mix of patients treated in 
the origin country. This has conflicting effects on medical care prices, but 
unambiguously puts a downward pressure on medical wages.  
Saxena, K. B. (2011) conducted a study on trade in health services implications for 
people's health. The paper deals a theoretical framework of trade in health services. 
The neo-liberal transformation of global economy has brought in a new trade regime 
replacing GATT 1947 with incorporation of services and intellectual property in the 
products to be exchanged and WTO as its powerful regulator. Health being one of the 
services has become tradable for the first time. India has chosen to engage in health 
trade substantially to drive economic benefits from medical tourism, export of 
pharmaceuticals and manpower, and to carry out contract clinical trials. This has 
resulted in a paradigm shift in the role of state in the provisioning of health services 
with very adverse implications for the access of poor to the health care services and 
quality of public health system. India should therefore firmly oppose further 
liberalization of health sector in any future negotiations in the WTO.  
Kiriyama, N. (2011) studied on Trade and Innovation in the Pharmaceuticals 
industry. The study examines how various linkages between trade and innovation 
work in the pharmaceuticals sector, focusing on the role of globalisation in the current 
innovation challenges of the pharmaceutical industry. He found that emerging 
economies are increasingly important markets for pharmaceutical companies and 
more active participants in the R&D process. This study also contributes to upgrading 
the R&D capability of emerging economies and shows a high rate of growth in 
pharmaceuticals trade in the 1990s and the 2000s. Moreover, tariff elimination 
focusing on the pharmaceuticals sector has been agreed and implemented under the 
auspices of the World Trade Organization (WTO) by major players, whereas tariff 
harmonisation was achieved for the chemicals sector at large. In particular, this study 
focuses on how globalisation plays its part in the current innovation challenges of the 
pharmaceutical industry.  
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Tolliver, K. (2011) mentioned consumers from the developed world are now turning 
to emerging markets to seek and secure health services. Trends in cross-border trade 
in health services continue to rise. A global marketplace in health services liberalizes 
the accessibility of health care in both the developed and developing world. In 
recognition of both the economic and social gains associated with increased trade in 
health services, appropriate steps need to be taken to increase the viability and scale 
of prolonged international trade in the health sector.  
Mishra. R and K. Shailesh (2012)found that there are different opinions as to 
whether medical tourism is still a promising industry or had been considered firmly 
established. The industry is being followed and promoted by several trustworthy 
organizations, including the Medical Tourism Association (MTA), the Deloitte Center 
for Health Solutions, and the Joint Commission International. India’s medical tourism 
is dominated by the private sector from the corporate houses.  
According to the Babu, K. M. and T. Srinivas (2012) globalization of health 
services is reflected in the emergence of new kinds of healthcare organizations over 
the past decade and in the increased cross-border delivery of health services through 
movement of personnel and consumers and through cross border electronic and other 
means. It is also reflected in the growing number of companies engaged in joint 
ventures and collaborative arrangements in the health services sector and in the 
increased cross-border exchange and dissemination of information, education, and 
training in this sector. There are numerous constraints to trade in health services. 
Some are justified on public policy grounds while others are motivated by purely 
protectionist objectives and political economy reasons. Many of these barriers 
simultaneously cut across the different modes of supply. There are three broad 
categories of barriers to trade in health services. These include: (a) restrictions on 
entry and terms of practice by foreign health service providers; (b) restrictions on 
foreign direct investment in the health sector and in related sectors; and (c) domestic 
infrastructural, regulatory, and capacity constraints. 
AfDB (2013) conducted a study on the growth of international trade in health 
services: export prospects in North Africa stated that international trade in health 
services has been expanding rapidly since the late 1990s. Its share in the world market 
for tourism services rose from 1.2 per cent in 1997 to 1.5 per cent in 2010. The 
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international competiveness of the health sector provides opportunities to consolidate 
the tourism sector and/or diversify the range of tourism services towards wellbeing 
services. There are other major constraints on the international travel of patients that 
stem mainly from the specificity of health sector transaction costs. 
Bhat (2015) has observed that international trade in healthcare services has expanded 
under the GATS. Increasingly it has acquired new dimensions with application of 
advanced information and communication technology, flow of foreign investment, 
cross‐border mobility, rising income levels and demographics dynamics. India is one 
of the main participants in this process. The government’s expenditure on healthcare 
is highly inadequate. It is also a low priority area. India is a participant in the GATS 
agreement. It has made binding commitments to minimize trade barriers. Trade 
liberalization is facilitated through four modes. Mode 1 represents cross border 
supply, mode 2 (consumption abroad), mode 3 (commercial presence) and mode 4 
(presence of natural persons). In mode 3, the commitments to attract capital and skill 
are liberal. But it is more restrictive in mode 4. Modes 1 and 2 are subject to 
limitations.  
2.2: Empirical Studies 
Balassa (1975), in an analysis of the product composition of trade between each pair 
of the original EEC member over the periods 1958-63 and 1963-70, found that trade 
was increasingly an exchange of similar goods. Grubal and Lloyed (1975) 
subsequently estimated that 71 per cent of the increase in trade between the EEC 
countries from 1959 to 1967 was the result of intra-industry trade. 
Balassa (1977) has undertaken an analysis of the pattern of comparative advantage of 
industrial countries for the period 1953 to 1971. Based on the standard deviation of 
the RCA indices for different countries an association is also seen to hold between 
size and diversification of exports. Balassa’s results show that while the extent of 
export diversification tends to increase with the degree of technological development 
a reversal takes place at higher levels. 
Yeats (1997) studied the possible distortions in trade patterns on account of 
discriminatory trade barriers that are characteristic of the RTAs. He uses the index of 
revealed comparative advantage in conjunction with the changes in the regional 
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orientation of exports to identify any apparent inefficiencies in trade patterns for the 
MERCUSOR group of countries. 
Lim, K.T. (1997) attempted to illuminate the characteristics of North Korean 
economy by examining her foreign trade. He categorizes goods into “Ricardo”, 
Hechscher-Ohlin” (H-O) and “Product Cycle” (PC) goods. Based on the RCA index 
of these three categories, he elucidates the level of development achieved by North 
Korea. A progress from Ricardo to Heckscher-Ohlin and then to PC goods, is an 
appropriate indicator of the development of the country. Results suggest that while 
North-Korea’s comparative advantage had moved up from Ricardo goods, it would be 
difficult for the country to move into the area of Product Cycle goods, since the 
economic structure of the country was not being upgraded to produce goods requiring 
advanced technology.  
Richardson and Zhang (1999) have used the Balassa index of RCA for the U.S to 
analyze the patterns of variation across time, sectors and regions. They find the 
patterns to differ across different parts of the world, over time as also for different 
levels of aggregation of the export data. Differentials are accounted for by factors like 
geographical proximity of trading partners and per capita income with the extent of 
influence of these factors varying over time and across sectors/sub sectors. 
Bender and Li (2002) examined the structural performance and shift of exports and 
revealed comparative advantage of the East Asian and Latin American regions over 
the period 1981-1997. It examined, if there is a relation between changes in export 
pattern among different regions and shifts in comparative advantage between regions. 
The Vollrath (1991) index that accounts for double counting in world trade has been 
used for analysis. 
Ferto and Hubbard (2002) assess the competitiveness of Hungarian agriculture vis-
à-vis EU using four indices of revealed comparative advantage. The four indices are -
original Balassa index, relative trade advantage, relative export advantage, logarithm 
of the relative export advantage (original Balassa index) and relative competitiveness 
(difference of the log values of relative export and import advantage). A 
categorization of indices as cardinal (identifies the extent to which a country has 
comparative advantage/disadvantage), ordinal (provides a ranking of products by 
degree of comparative advantage), and dichotomous (a binary type demarcation of 
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products based on comparative advantage/disadvantage) has been undertaken in their 
study. The results show that the indices were less cardinal in identifying whether 
Hungary has a comparative advantage in a particular product group, but were useful 
as a binary measure of comparative advantage. Leu’s paper examines the systematic 
shift of comparative advantage in East Asian economies by computing and comparing 
revealed comparative advantage indices for ten selected East Asian economies in the 
U.S market. The results show that conventional wisdom of shifting comparative 
advantage in accordance with the level of development continues to hold true.  
Li, K.W. and S. Bender (2003) argues that instead of complimenting or substituting 
exports, the change in comparative advantage of the country leads to gain as well as 
loss for the country. They studied RCA of manufacture exports over the period 1981- 
1999 eight country groups incorporating 40 economies and put forth the view that a 
pattern of relative comparative advantage existed. 
Widren, M. (2005) focused on the comparative advantage of a sample of Asian, 
American and Europian countries between 1996 and 2002. His study examined the 
basis of RCA for the sample countries using the harmonized system (HS) 
classification at the 4 digit level. In his view, the factor content of comparative 
advantage had some similarity in the Asian countries. While the RCA for US was 
based on highly skilled labour that of the EU had moved towards use of human as 
well as physical capital.  
Batra, A. and Z. Khan (2005) assessed the RCA index at the 2 and 6 digit level of 
HS classification. They compared India’s comparative advantage with that of China 
and also studied the RCA for each of the country individually. The study constructed 
the RCA index of India and China for the years 2000 and 2003, thereby enabling it to 
focus on the changes in the structure of comparative advantage in the latter period. 
The authors also examined comparative advantage of the two countries according to 
factor intensity using the Standard International Trade Classification (SITC). This was 
done with the aim of assessing whether India’ s comparative advantage is in labour 
and resource-intensive items or in technology and science based manufactures. The 
study does not find any structural change in the comparative advantage of the two 
countries, except for some sectors within manufacturing. India and China enjoyed a 
competitive relationship in chemicals and minerals and metal manufactures while a 
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complementary relation was observed in labour and resource intensive items such as 
textile yarn and apparel.  
Chaddha, S.J. and L.G. Burange (2008) attempts to assess India’s revealed 
comparative advantage in merchandise trade by evaluating the structure of 
comparative advantage in India and the change in it over a ten year period from 1996 
to 2005. It is found through the results that India enjoys comparative advantage in the 
exports of labour intensive items like textiles and scale intensive items such as 
chemicals and iron and steel. 
2.3: Research Gap: 
After reviewing above literature, one may observed that there is very less work on 
India’s trade in health products, neither any theoretical work nor any empirical study 
is undertaken. There are not many studies based on Revealed Comparative Advantage 
(RCA) Analysis, Grubel-Lloyd (G-L) Index on Intra-industry trade and Marginal 
Intra-industry trade for health products in India separately so far. There is no study 
which covers trade in health services in a systematic manner and widely cover all the 
aspect of related with that with empirical verification. Therefore, an empirical 
analysis is needed for India’s trade in health products and services. 
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Chapter 3 
India’s Trade in Health Products: A Cross Country Analysis 
Demand for health products around the world has been growing strongly both in 
developed and in developing countries over the past decades. The key ingredient of 
every health system is physical goods that are directly used for diagnosis and 
treatment of patients or that are vital for other elements of the health system, such as 
laboratory equipment to conduct medical research. 
Despite the growing importance of public and private expenditures related to health, 
there is not yet an agreed international definition of the "universe" of health products. 
The present study constitutes an important attempt to construct such a "universe" 
using the product classification of the Harmonized System (HS) as a basis.  
However, one may believe that it offers enough detail to assemble a list of health 
products. It covers a substantial share of all health products that enter the public 
health sphere and thus offers interesting opportunities for analysis.Using this newly 
defined universe of health products, this present study analyses international trade 
flows to these productsin detail. 
 
3.1 Medicine Market 
It has observed that international trade in health products, and especially trade in 
dosified medicines, has developed in a very dynamic manner over the past fifteen 
years. The market of health products, measured by exportations and importations, is 
heavily dominated by developed countries, while developing countries are gaining 
ground only slowly.  
The Indian medicine market is gaining more importance due to rise in various 
diseases and ailments. India’s medicine market is one of the fastest growing markets 
in the world. Many factors, including a strong economy and the country’s growing 
healthcare needs have contributed to the accelerated growth, which is especially 
strong in the over-the-counter (OTC) market. Overall, the domestic medicine market 
fragmented; more than 10,000 firms collectively control about 70 per cent of the 
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market. Only three foreign multinationals rank in the top 10 companies, as measured 
by sales, and collectively they have only 11.9 per cent of the market between them. 
Despite widespread poverty and inadequate public healthcare provision, India has 
much to offer the leading drug makers. An increase in lifestyle diseases resulting from 
the adoption of unhealthy western diets, combined with a growing middle class that 
has more disposable income to spend on treatment, will provide new opportunities for 
global medicine manufacturing firms.  India has emerged as a major supplier of 
several bulk drugs, producing these at lower prices compared to formulation 
producers worldwide. The US Food and Drug Administration (FDA) already has 
approved 85 Active Pharmaceutical Ingredient (API) and formulation plants in India, 
the highest such number outside the US. India is poised to become a major exporter of 
medicines, particularly generic and OTC drugs, to global markets. Many 
multinational generics companies have been sourcing products from Indian 
manufacturers for some years. Some also use Indian contract manufacturers to 
manufacture the finished product.  Some companies encouraged by the relaxation of 
the rules on foreign ownership and a favourable tax regime have gone beyond 
contract manufacturing, setting up their own local manufacturing facilities. The 
financial incentive is compelling. Goldman Sachs estimates that the cost of setting up 
and running a new manufacturing facility in India is one-fifth of the cost of doing so 
in the West.  
Research and Development (R&D) 
Research in medicines is one area that is expected to achieve tremendous growth in 
the coming decade, due to India’s huge and growing population, low per capita drug 
usage, and increasing incidence of disease. Global pharmaceutical alliances with 
Indian drug firms are finally beginning to look like a two-way street, with major R&D 
deals being struck. For instance, Glenmark Pharmaceutical has teamed with Dyax to 
identify biological entities for its three targets in cancer treatment, and with Merck 
KGaA for its prospective diabetes molecule GRC 8200. GlaxoSmithKline is working 
with Ranbaxy Laboratories to identify new targets and has partnered with TCS for 
data management, through a global drug development support centre in Mumbai. 
The process of R&D is closely interwoven with the regulatory process. Marketing 
approval is typically followed by a negotiation between the firm and a government 
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body responsible for reimbursement and pricing, before actual marketing takes place. 
The time required for this phase is much less than that required for marketing 
approval, ranging in developed countries from a few months up to about 10 months.  
An initial patent application is typically made during the pre-clinical period. Patent 
protection is effective for at least 20 years from the date of the filing under the TRIPS 
Agreement (Article 33). Assuming that it takes about 1.5 years before a patent is 
granted (Lanjouw, 2005), the effective patent life will be 18.5 years; moreover, the 
period of economic benefit from a patent will be further diminished due to delays 
associated with the regulatory approval process for new drugs prior to their market 
entry. Further delays may arise from pricing negotiations with reimbursement 
schemes and distributors. 
Clinical trials 
India historically lacked the expertise to perform clinical trials, because most 
companies only tested different processes for producing copycat versions of Western 
products, and the rules were quite lenient. Several drug makers have also been caught 
behaving unethically or even illegally.  However, in recent years, India has become a 
more attractive market for clinical testing. The high growth in Indian clinical trial 
activity by contract research organizations, such as Quintiles, Omnicare, PharmaNet 
and Pharm-Olam, and by multinational corporations such as Novo Nordisk, Sanofi-
Aventis, Novartis and GSK. Some multinationals, such as Pfizer and Eli Lilly, have 
been conducting tests locally for a while. Government taxation incentives are further 
boosting R&D in India.  
3.2 Medical Equipment Market 
Medical devices’ industry is a multi-product industry, producing wide range of 
products. Manufacturing and trade in medical devices is also growing quite steadily. 
Double digit growth rates indicate its importance in health care. Medical devices’ 
industry mostly depends on imports. Most hi- tech innovative products and 
technology originate from a well-developed eco-system and innovative cycle which 
needs to be developed in India to promote indigenous industry and to reduce our 
dependence on imports. 
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The ‘Make in India’ campaign of the government has a mandate to boost the medical 
device manufacturing sector in India for all types of medical devices and equipment 
used in manufacturing of Pharmaceuticals. To implement the initiative a Task Force 
was constituted under the chairmanship of the Secretary, Department of 
Pharmaceuticals (DoP) to address issues relating to the promotion of domestic 
production of high end medical devices and pharmaceutical manufacturing equipment 
in the country. 
Medical devices sector in India is very small by size as compared to the rest of 
manufacturing industry, though India is one of the top twenty markets for medical 
devices in the world and is the 4th largest market in Asia after Japan, China and South 
Korea. 
 
Segments 
The Medical Devices market can be classified into two major categories: 
1. Devices that do not require any external energy source. 
2. Devices that require external energy source to be operational (powered). 
Powered devices are further divided into three product categories: 
a. Equipments, 
b. Implants, and 
c. Disposables. 
 
a. Equipments 
Equipments account for the largest share of the total market followed by medical 
implants and disposable segments respectively. This segment is also the fastest 
growing and is largely dependent on imports currently. 
This can be further segmented into the following categories – 
• Surgical Equipments: Prominent factors that drive demand are advancements 
in surgery and surgical device designs, availability of high skilled surgeons, 
growing breed of corporate hospitals and advanced surgical facilities like 
advanced robotics, minimally invasive surgical techniques and imaging. 
• Diagnostics: Increase in the prevalence of diseases, their complexity and the 
need for quick diagnosis has created a high demand for diagnostic services and 
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devices like Cardiac imaging, CT scans, X-ray, Molecular Imaging, MRI and 
Ultrasound-imaging including hand - held devices. 
• Life Support: As life support technologies evolve and improve, use of 
equipments like ventilator and automated external defibrillator outside of the 
hospital environment has increased. Also, as consumer spending power 
increases demand for such systems is expected to grow. 
 
b. Implants 
The market for implants is witnessing some amount of innovations in terms of 
catering to large unmet needs in certain disabilities e.g. blindness. A microchip retina 
implant is under trial which will allow blind patients to read letters & recognize 
foreign objects. 
 
c. Disposables 
Medical disposable products for medical electronic equipment are used by all 
hospitals and private nursing homes in the country, including diagnostic and 
pathological laboratories. The market is becoming increasingly competitive due to 
low entry barriers (for MNCs), increasing number of players and an expanding 
consumer base. Examples include disposable medical and electronic probe assemblies 
for minimally invasive applications, disposable catheter cables, disposable EEG 
sensors/lead wires, disposable SpO2 sensors, panel mount receptacles, etc. 
 
The rebuilding of India’s healthcare infrastructure, combined with the emergence of 
medical tourism and telemedicine, will drive strong demand for medical equipment, 
such as x-ray machines, CT scanners and electrocardiograph (EKG) machines. 
Leading international companies market most high value medical equipment, while 
only consumables and disposable equipment are made locally. Many international 
companies have expanded their operations in the Indian market in recent years and 
established manufacturing facilities to assemble equipment for the domestic market 
and export. The competition is expected to intensify with the entry of more global 
firms into the medical equipment marketplace. The government is encouraging the 
growth of this market, through policies such as a reduction in import duties on 
medical equipment, higher depreciation on life-saving medical equipment (40 per 
cent, up from 25 per cent), and a number of other tax incentives.  
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During the period 2011-12 to 2014-15 both import and export of medical devices 
have grown at more than 10 per cent rates. Import as well as export of Medical 
Electronics and Hospital Equipment has been the highest amongst all the devices in 
terms of value. Along with surgical instruments they form more than 50 per cent of 
total sales with majority being imported (87.4 per cent). 
 
3.3 India’s Export, Import and Balance of Trade of Health Products 
India not only imports health products, but also exports a number of health products 
to various parts of the world. As a responsible member of the global community, India 
must take all possible steps to export only those products which do not pose a risk to 
health safety, which are effective and high quality. A change in balance of trade of 
different health products and percentage change of exports and imports helps in policy 
formulations regarding health products.    
 
Chapter 29 (Organic chemicals) 
India’sexport of chapter 29 i.e., organic chemicals has a rising trend over the period 
except in the year 2008 as shown by blue line (figure 3.1-A). The down fall has 
occurred due to global recession in that periodcaused external demand for organic 
chemicals has declined which lead to decreased in export.India’s volume of import for 
Chapter 29 from the world has increased indicated by red line. It has increased from 
US$176.9 million in 2001 to US$1823.9 million in the year 2014. India’s trade 
balance in chapter 29 with rest of the world from 2001 to 2014 exhibited through grey 
line. There was unfavorable trade between India and the world for organic chemicals 
throughout the time period. Trade deficit was low in the beginning but after that it has 
deepened.  
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Figure 3.1-A: India's Trade in Chapter 29 (Organic Chemicals) 
 
 
India’s percentage share of export for Chapter 29 shows the upward rising trend 
except a marginal fall in the year 2014 displayed by blue line (Figure-3.1-B). There 
was highest 3 per cent share in the preceding year 2013. India’s percentage share of 
import for organic chemicals in the world has increased over the years as exposed by 
red line. It has become quadrupled from 2001 to 2014. 
 
Figure 3.1-B: India’s Percentage Share of Export and Import for Chapter 29 in 
the World 
 
 
Chapter 30 (Pharmaceutical products) 
Export of Chapter 30 by India to the worldshows an increasing trend throughout the 
period except in the year 2008 due to the effect of global financial crisis ( graph 3.2-
A). After that there is a steep increase in the total volume of export of pharmaceutical 
products. India’s volume of import for Chapter 30 from the world has increased till 
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2012 after that it has started to decline. It has increased from US$16.4 million in 2001 
to US$175.6 million in 2012, and then declined to US$163.1 million in 2014.India’s 
Balance of Trade (BoT) in Chapter 30 with rest of the worldhas favorable balance for 
India. It means that India’s export of pharmaceutical products to the world market is 
greater than it imports from the world market. Hence, India has trade surplus in case 
of chapter 30 with the world. The graph clearly mentions the increasing trend of trade 
surplus over the time period. Trade surplus has increased from US$883340 in 2001 to 
US$10912780 in 2014. 
 
Figure 3.2-A: India's Trade in Chapter 30 (Pharmaceutical Products) Since 2001 
 
 
India’s percentage share of export for pharmaceutical products in the world shows a 
favourable condition for India by rising over the years (graph 3.2-B). The increase in 
share was low in the pre financial crisis but after that it gained momentum. India’s 
percentage share of import for pharmaceutical products in the world has increased in a 
step like manner. It has become tripled from 2001 to 2014.  
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Figure 3.2-B: India’s Percentage Share of Export and Import for Chapter 30 in 
the World 
 
Chapter 35 (Albuminoids, Modified Starches, Glues, Enzymes) 
India’s export of Chapter 35 to the world has increased in a step manner over the 
years (figure 3.3-A). India’s import of Chapter 35 from the world has 
increasedcontinuously during the study period. It has increased from US$3.1 million 
in 2001to US$34 million in 2014. India’s BoTin Chapter 35 with rest of the world 
from 2001 to 2014. The graph clearly indicates that India has favorable balance of 
trade in chapter 35 from 2001 to 2010, after that it has faced deficit for two 
consecutive years. In the year 2013 there was a sign of recovery as far as trade 
balance is concerned. The highest trade surplus recorded US$95449 million in the 
year 2007.  
Figure 3.3-A: India's Trade in Chapter 35 (Albuminoids, Modified Starches, 
Glues, Enzymes) 
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India’s percentage share of export for Chapter 35 in the world has increased with 
some fluctuations over the time period (figure 3.3-B). India’s percentage share of 
import for Chapter 35 in the world shows increasing trend. It has increased from 0.3 
per cent in 2001 to 1.1 per cent in 2014. 
 
Figure 3.3-B: India’s Percentage Share of Export and Import for Chapter 35 in 
the World 
 
 
 
Chapter 38 (Miscellaneous chemical products) 
India’s export of Chapter 38 to the world has increased from mere US$43.8 million in 
2001 to US$339.8 million in the year 2013 (fig 3.4-A). But, in the year 2014 it has 
fell down to US$316.4 million. India’s import of Chapter 38 from the world has 
increasing trend during the study period. It has increased from US$46.5 million in 
2001 to US$425.7 million in 2014.India’s BoT in Chapter 38 with rest of the 
worldhas trade deficit throughout the study period with the world (as shown in the 
fig.). The important thing is to notice that trade deficit was low in the initial years and 
after that it has started to increase. It hasbeen observed a downward trend in trade 
balance for chapter 38. 
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Figure: 3.4-A: India's Trade in Chapter 38 (Miscellaneous Chemical Products) 
Since 2001 
 
 
India’s percentage share of export for Chapter 38 in the world has remained constant 
i.e., 0.8 per cent from 20001 to 2004 (figure 3.4-B). But, after that it gained 
momentum and increased to 1.8 per cent in the year 2013. India’s percentage share of 
import for miscellaneous chemical products in the world has increasedpersistently 
over the time period. It has started to rise from mere 0.8 per cent in 2001 to 1.8 per 
cent in 2009 and 2.2 per cent in the year 2014. 
Figure 3.4-B: India's Percentage Share of Export and Import for Chapter 38 in 
the World 
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Chapter 40 (Rubber and article thereof) 
India’s export of for Chapter 40 to the world has increased from US$37.4 million to 
US$297.5 million in 2013 (figure 3.5-A). It has declined to US$276.3 million in the 
year 2014 due to low demand in the many parts of the world. India’s volume of 
import for Chapter 40 from the world has increased during the study period. It has 
increased from mere US$30 million in 2001 to US$336.9 million in 2014, but the 
highest volume of import recorded in the year 2012 i.e., US$388.5 million.India’s 
BoT in Chapter 40 with the rest of the worldhad a surplus in trade balance from 2001 
to 2006, after that deficit has recorded. The highest trade surplus has registered worth 
US$ 223543 in 2005 and lowest trade deficit 1143727 in 2012.  
 
Figure 3.5-A: India's Trade in Chapter 40 (Rubber and Article thereof) since 
2001 
 
 
India’s percentage share of export for Chapter 40 in the world has increased from 0.7 
per cent in 2001 to 1.4 per cent in 2014 (figure 3.5-B). India’s percentage share of 
import for rubber and article thereof in the world has increasing gradually over the 
time period. It has become more than triple in the study period.   
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Figure 3.5-B: India's Percentage Export and Import for Chapter 40 in the World 
 
 
Chapter 70 (Glass & glassware) 
India’s export of Chapter 70 to the world has increasing trend with a dip in 2008-09 
(figure 3.6-A). The highest volume of export has registered i.e., US$70.2 million in 
2014 and lowest US$17.3 million in 2001. India’s volume of import for Chapter 70 
from the world has also increasing trend. It has increased from US$13.5 million in 
2001 to 81.6 million in 2014.India BoT in Chapter 70 with rest of the world had trade 
surplus in the beginning till 2004 after that deficit in rest of the years. India had 
surplus in trade forglass and glassware worth US$ 54960 in the year 2003. 
 
Figure 3.6-A: India's Trade in Chapter 70 (Glass & Glassware) Since 2001 
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 India’s percentage share of export for glass & glassware in the world has become 
doubled from 0.5 per cent to 1 per cent over the time period (figure 3.6-B). India’s 
percentage share of import for glass & glassware in the world has increased in a step 
manner. For the initial three-four years it has remained constant at 0.4 per cent and 
finally attained highest level i.e., 1.1 per cent in the 2014. 
 
Figure 3.6-B: India's Percentage Share of Export and Import for Chapter 70 in 
the World 
 
 
Chapter 84 (Machinery, nuclear reactors etc.) 
India’s volume of export for Chapter 84 to the world has increasing trend over the 
time period (figure 3.7-A). It has increased from US$158.3 million in 2001 to 
US$1359.6 million in 2014. India’s volume of import for Chapter 84 from the world 
has increased over the time periods. It has increased from mere US$422.9 million in 
2001 to US$3119.3 million in 2014. It touched the highest peak i.e., US$3622.6 
million in the year 2012. India’s BoT in Chapter 84 with rest of the worldhas 
unfavorable balance of trade with decreasing trend. The highest trade deficit 
registered worth US$ 25156241 in the year 2012.  
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Figure 3.7-A: India's Trade in Chapter 84 (Machinery, nuclear Reactors etc.) 
Since 2001 
 
 
India’s percentage share of export of Chapter 84 in the world has increased in a step 
manner during the study period (figure 3.7-B). It has increased from 0.2 per cent in 
2001 to 0.6 per cent in 2014. India’s percentage share of import for Chapter 84 in the 
world has increased from 2001 to 2012 after that it has started to decline. In the initial 
two years it was only 20.5 per cent but it gained momentum after that and reached at 
highest level 1.7 per cent in the years 2011 and 2012. 
 
Figure 3.7-B: India’s Percentage Share of Export and Import for Chapter 84 in 
the World 
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Chapter 87 (Vehicles other than railway, tramway) 
Figure 3.8-A reveals increasing trend in India’s volume of export for Chapter 87 to 
the world. It has increased mere US$87.2 million in 2001 to US$1448.2 million in 
2014. There was a slight dip in 2008-09 due to global recession. India’s volume of 
import for Chapter 87 from the world has also increasing trend. It has started to 
increase from US$25.1 million in 2001 to US$480.8 million in 2014.India BoT in 
Chapter 87 with rest of the world has proved strength for India with surplus balance 
of trade throughout the time period. India’s trade surplus has increased from US$ 
620664 in 2001 to US$ 9108261 in 2014. 
 
Figure 3.8-A: India's Trade in Chapter 87 (Vehicles other than Railway, 
tramway) 
 
 
 
India’s percentage share of export for Chapter 87 in the world has increased sharply 
especially after 2003 (fig 3.8-B). It has increased from 0.2 per cent in 2001 to 1.1 per 
cent in the year 2014. India’s percentage share of import for Chapter 87 in the world 
has increased in step manner till 2012, after that it stared to decline in the same 
manner. India’s share of import for Chapter 87 was very low only in the beginning, 
but after that it has increased.  
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Figure 3.8-B: India's Percentage Share of Export and Import for Chapter 87 in 
the World 
 
 
Chapter 90 (Optical, photo, technical, medical etc. apparatus) 
Therewas a continuous increasing trend of India’s volume of export for Chapter 90 to 
the world (Figure 3.9-A). It has increased from US$30.2 million in 2001 and US$87.9 
million in 2007 to US$233.5 million in 2014. India’s volume of import for Chapter 90 
from the world has persistently increased over the years. It has increased from US$ 
114.2 million in 2001 to US$464.8 million in 2008 and US$705.1 million in 
2014.India’s BoT in Chapter 90 with rest of the world indicates that India has trade 
deficit with rest of the world during the whole study period. The trade deficit 
consistently increased, it was mere US$ 840082 in 2001 and reached to US$ 4863444 
in 2014. 
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Figure 3.9-A: India's trade in Chapter 90 (Optical, photo, Technical, medical etc. 
apparatus) since 2001  
 
 
 
India’s percentage share of export for Chapter 90 in the world has increased in a step 
like manner (fig 3. 9-B). It has remained constant in the initial years from 2001 to 
2008, after that it has increased in step manner. India’s percentage share of export for 
Chapter 90 has become double from 2001 (i.e., 0.2 per cent) to 2014 (i.e., 0.4). India’s 
percentage share of import for optical, photo, technical, medical etc. apparatus in the 
world has increased in a step like manner. It has increased from 0.6 per cent in 2001 
to 1.3 per cent in 2014.  
 
Figure 3.9-B: India's Percentage Share of Export and Import for Chapter 90 in 
the World 
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 Chapter 94 (Furniture, Lighting, Signs, Pre-fabricated buildings) 
India’s volume of export for Chapter 94 to the world has increasing trend over the 
time period (figure 3.10-A). India’s total export of chapter 94 has increased from 
mere US$5.5 million in 2001 to US$120.4 million in the year 2014. India’s volume of 
import for Chapter 94 from the worldhas also an increasing trend. It has increased 
from US$ 5.1 million in 2001 to US$123.3 million in 2014. India’s BoT in Chapter 
94 with rest of the worldhad trade surplus for half of the study years and deficit for 
the rest of years. There was a fluctuation in India’s balance of trade with rest of the 
world during study period. The highest trade surplus has observed worth US$ 80981 
in 2004. 
Figure 3.10-A: India's Trade in Chapter 94 (Furniture, Lighting, Signs, Pre-
fabricated buildings) Since 2001 
 
 
India’s percentage share of export for Chapter 94 in the world has increased in a step 
manner (figure 3. 10-B). The percentage share of export for Chapter 94 has increased 
from 0.1 in 2001 to 0.5 in 2014. India’s percentage share of import for Chapter 94 in 
the world has also increased in a step manner. It has increased from 0.1 per cent in 
2001 to 0.6 per cent in 2014.  
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Figure 3.10-B: India's Percentage Share of Export and Import for Chapter 94 in 
the World 
 
 
 
 
3.4 Direction of Trade in Health Products 
3.4.1 Direction of Export 
United States of America has remained leading importer of organic chemicals 
exported by India since 2001, but the share has slightly declined from 14.1 per cent in 
2001 to 13.6 per cent in 2014 (table A.3.1.). China (7.9 per cent), Germany (5 per 
cent), Netherlands (3.1 per cent) and Japan (2.8 per cent) are other four major 
destinations for export of organic chemicals by India in the year 2014. Belgium, 
Spain, Saudi Arabia, Brazil, Republic of Korea are other major destination for India’s 
export of organic chemicals.  
United States of America hold leading destination position in export of 
pharmaceutical products by India to the world (table A.3.2). Its share has increased 
persistently over the years. It has increased from mere 11.9 in 2001 per cent to 33 per 
cent in 2014. South Africa (3.9 per cent), UK (3.8 per cent), Nigeria (3.3 per cent), 
Russia (3.8 per cent) are other top destination countries for export of Pharmaceutical 
Products by India in 2014. 
United States of America (23.7 per cent) holds top rank as far export of products falls 
in the category of chapter 35 in 2014 (table A.3.3). Japan bears the second rank with 
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9.2 per cent share in the total export. Saudi Arabia (6.7 per cent), UAE (6.7 per cent), 
Indonesia (3.7 per cent) are other top rankers in the destination of export in chapter 35 
products by India.  
United States of America (14.8 per cent) has got the top position in import of 
miscellaneous chemicals from India in 2014 (table A.3.4). Brazil (10.5 per cent), 
Germany (3.7 per cent), China (3.2 per cent), Netherlands (3.7 per cent) are other 
leading destinations in 2014. Netherland and France constitutes a very high share in 
the beginning, but later on their declines over the years.  
United States of America (12.1 per cent), Germany (5.9 per cent), United Arab 
Emirates (4.3 per cent), United Kingdom (3.7 per cent), Philippines (3.3), Netherlands 
(3.1), Bangladesh (2.9), Brazil (3.6), Italy (2.6), and France (2.7) are ten destination 
countries in export of rubber and articles thereof in the world (table A.3.5). USA is 
the largest importer of rubber and articles thereof from India in the World. UAE’s 
share has significantly declined, while the share of Germany has increased over the 
time period.  
United States of America (19.1 per cent), China (10.2), Germany (6.3), United Arab 
Emirates (5.4), and United Kingdom (4.1) are the top five leading importers of glass 
and glassware from India in 2014 (table A.3.6). The other top five rankers are 
Bangladesh (1.3 per cent), Nepal (3.8), Brazil (3.9), Belgium (2.2), and Spain (2 per 
cent). The share of UAE and Belgium have declined while the share of China has 
increased over the time period.  
United States of America (15 per cent) holds the top rank in import of chapter 84 
products from India followed by the UAE (5.1 per cent), UK (5.1), Germany (4.5), 
China (3.8), Saudi Arabia (2.7), Turkey (2.7), Singapore (3.2), Bangladesh (2.5), and 
Italy (2.8) in 2014 (table A.3.7). Bangladesh and Singapore as a share of export by 
India in chapter 84 declines while China’s share has increased over the years.  
United States of America (8.4 per cent), Mexico (6.9 per cent), Sri Lanka (4.1), South 
Africa (6.1), and Turkey (4) are five leading importers of products falls under 
category of chapter 87 in 2014 (table A.3.8).  Bangladesh (4.1 per cent), United 
Kingdom (4.4), Italy (2.6), Nigeria (3.8), Colombia (3) are rest five leadings importers 
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in the same year. The share of Nigeria, Bangladesh and Italy significantly decline 
while the share of South Africa has increased from 2001 to 2014.   
United States of America is the highest importer of medical apparatus from India 
throughout the time period (table A.3.9.). It constitutes 16.1 per cent in 2014, which is 
almost half from 2001. Singapore (6.8 per cent), Germany (6.2), United Kingdom 
(5.2), China (4.9), France (5.4), Republic of Korea (3.3), United Arab Emirates (3.3), 
Malaysia (2), and Japan (1.7) are other leading importers of medical apparatus from 
India 2014. 
United States of America (34 per cent), Germany (9.6), UK (7.5), France (7.1), 
Netherlands (3.3), UAE (3.1), Australia (3.2), Canada (1.8), Belgium (1.7,) and Saudi 
Arabia (1.1) are top leading importers of chapter-94 products from India in 2014 
(table A.3.10). The share of United Kingdom has decline while the share of USA, 
France and Germany has increased over the years.  
 
3.4.2 Direction of Imports 
India imports highest amount of organic chemicals from China which constitutes 34.3 
per cent in 2014 (table A.3.11). Singapore (8.4), Saudi Arabia (7.4), USA (4.4), 
Kuwait (4.8), Germany (4.2), Republic of Korea (5.9), Iran (3.2), Taipei (3.1), Japan 
(2.3) are the leading nation from which India import organic chemicals in 2014. The 
share of China has increased while the share of Japan and Germany has increased in 
import of organic chemicals from India over the time period.  
United States of America (20 per cent), Germany (13.9 per cent), China (7.7), 
Indonesia (7), Switzerland (7.8), France (6.5), Italy (6), Belgium (3.8), Brazil (3.6), 
and Denmark (3.4) are the leading exporters of pharmaceutical products to India in 
2014 (table A.3.12.). The share of Switzerland remain fluctuating and decline 
recently.   
China (25.8 per cent) is the leading exporter of chapter 35 products to India in 2014 
(table A.3.13). United States of America (16 per cent), Germany (9 per cent), 
Thailand (6.7), Netherlands (5.2), Denmark (4.8), Japan (3.7), Taipei (3), France 
(3.4), and Republic of Korea (2.9) are other major countries through which India 
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imports chapter 35 products in 2014. The share of Japan, Germany and Denmark has 
decreased while the share of China has increased from 2001 to 2014.    
United States of America (20.2), China (18.1), Germany (7.9), Japan (4.3), Indonesia 
(5.4), Singapore (4.7), Malaysia (4.6), Republic of Korea (3.2), France (2.9), Belgium 
(2.4) are ten leading nation which are exporting Miscellaneous chemical products to 
India in 2014 (table A.3.14.). The share of Germany, Japan and Indonesia has 
decreased while the share of China has increased over the study period.     
China (3.3 per cent), Indonesia (2.4), Republic of Korea (5.6), Thailand (6.4), Japan 
(20.4), United States of America (7.7), Viet Nam (0.2), Germany (7.1), Russian 
Federation (8.6), and Malaysia (4.2) are the leading exporter of rubber and articles 
thereof to India which constitutes their respective percentage share in 2001 (table 
A.3.15).China (7.9 per cent), Indonesia (12.5), Republic of Korea (14.1), Thailand 
(11), Japan (7.8), United States of America (6.7), Viet Nam (5.3), Germany (4.9), 
Russian Federation (4.9), Malaysia (2.7)  are the same ten major countries, but their 
share in total export of rubber and articles thereof to India has changed in 2014. 
China’s share has increased while Japan, Russia and Malaysia has decreased from 
2001 to 2014.      
China (36.3 per cent), United States of America (15.7 per cent), Germany (5.9), 
Indonesia (4.8), Thailand (3.2), Malaysia (2.8), Iran (1.1), France (2.7), South Africa 
(1.7), and United Arab Emirates (2.4) are the leading exporter of glass and glassware 
to India in 2014 (table A.3.16.). China’s share has increased while share of Indonesia 
and Malaysia has declined over the time period.  
China (31.3), Germany (11.7), United States of America (9.1), Japan (8.1), Republic 
of Korea (5.2), Italy (5), Thailand (4.3), Singapore (3.5), United Kingdom (2.2), 
Malaysia (2.3) are ten largest exporters of chapter 84 products to India in 2014 (table 
A.3.17). China’s share has significantly increased while the share of USA and 
Singapore has decline over the time period.        
China (23.6) holds rank one in export of chapter 87 products to India in 2014 (table 
A.3.18.).  Germany (16 per cent), Republic of Korea (13.4), Japan (11.5), Thailand 
(8.1), United States of America (3.7), Italy (3.5), Sweden (1.4), United Kingdom 
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(2.5), and Czech Republic (1.4) are other major countries from which India imports 
chapter 87 products in 2014. 
United States of America (20.3) is the leading exporter of medical apparatus to India 
in 2014 (table A.3.19). China (16.9), Germany (14.1), Japan (7.5), Republic of Korea 
(4.4), Singapore (4.6), United Kingdom (3.9), Switzerland (2.8), France (2.9), Ireland 
(2.6) are other leading exporter of medical apparatus to India in 2014. The share of 
Japan and UK has decreased while China’s share has increased over the year.    
China (54.7), Germany (6.9), Malaysia (6.4), Italy (5.2), United States of America 
(4.4), Republic of Korea (2.4), Thailand (2.7), United Kingdom (1.9), Sri Lanka (1.3), 
Japan (1.3) are the leading exporters of Chapter 94 products to India in 2014 (table 
A.3.20.). On the one hand, China has gained momentum in the share of total export 
for chapter 94 products to India. On the other hand, Malaysia, Italy and USA has 
declined their share in total export of chapter 94.  
India’s rapidly growing healthcare market is providing significant trade opportunities 
for the whole world. Many international companies have expanded their operations in 
the Indian market in recent years and established manufacturing facilities to assemble 
equipment for the domestic market and export. International trade in health products, 
and especially trade in dosified medicines, has developed in a very dynamic manner 
over the one and half decade.India’s total export and import of pharmaceutical 
products has increased over the time period. United States of America has leading 
position in the destination of health products exported by India. Most of the health 
products are imported from China in India.  
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Chapter 4 
Trade in Health Products: An Empirical Analysis 
This chapter examines empirically the India’s trade in health products by adopting 
various indices likeRevealed Comparative Advantage (RCA), Intra-industry trade or 
Grubel-Llyod Index, Marginal Intra-industry trade. For the analysis, a comparisonis 
made between India and its twelve competitive countries in various health products. 
RCA has been computedat 2-digit level, 4-digit level and 6-digit level based on HS 
classification of different health products for the period 2001 to 14. To calculate RCA 
at 4-digit level, top five health products in each categoryareselected andcomputed 
RCA at 6-digit level for only one category i.e., pharmaceutical products (30), and 
selected top five products in the same category. 
The analysis of comparative advantage has been undertaken using the Balassa (1965) 
index of revealed comparative advantage to study the pattern of comparative 
advantage for India and twelve competitive nations in the global market. The present 
attempts to identify the leading health products in terms of their revealed comparative 
advantage in India and the pattern of comparative advantage has undergone a 
structural shift between 2001 and 2014 for India and other competitive countries. This 
study also examines the pattern of specialization that has been observed in India and 
other countries competitive or complementary in the world market. 
In this Chapter, an attempts has been made to analyse the systematic evaluation of the 
similarities of the patterns of revealed comparative advantage for India and other 
major competitors in the global market, intra-industry trade and marginal intra-
industry trade. 
 
4.1. RCA at 2-digit Level 
Countries typically keep detailed records of goods that enter their domestic markets. 
In order to make national trade data comparable and in order to facilitate the exchange 
of goods across borders, the World Customs Organization has developed a 
classification for international trade in goodsknown as Harmonized System (HS) 
which is now being widely used across the world.  
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The HS classification dissects all trade flows into clearly distinguishable groups and 
breaks them down into 97 chapters and almost 6000 subheadings. It thereby follows a 
certain economic logic, mainly from crude products to more complex products and by 
sector of economic activity. 
The HS is a classification that was developed to clearly identify products that enter a 
country at the border and to be able to accord the respective treatment. Having been 
developed from a trade perspective, it does not offer the refinement which, from a 
public health perspective, would be desirable. 
However, it is believed that it offers enough detail to assemble a list of health 
products which covers a substantial share of all health products that enter the public 
health sphere and thus offers interesting opportunities for analysis. In this study, we 
are interested in all internationally traded goods that can contribute in one way or 
another to public health. 
Analysing in detail the HS classification, following goods are- 
 Chapter-29 (Organic chemicals),  
 Chapter-30 (Pharmaceutical Products),  
 Chapter-35 (Albuminoids, modified starches, glues, enzymes),  
 Chapter-38 (Miscellaneous chemical products),  
 Chapter-40 (Rubber and articles therof),  
 Chapter-70 (Glass and glassware),  
 Chapter-84 (Machinery, boilers, nuclear reactors, etc.), 
  Chapter-87 (Vehicles other than railway tramway), 
 Chapter-90 (Optical, photo, technical, medical, etc. apparatus),   
 Chapter-94 (Furniture, lighting, signs, prefabricated buildings) 
On the basis of HS classification at 2-digit level and 207 subheadings (at 4 and 6-digit 
HS-2007) containing products which can be directly linked to a health purpose.  
All these products come under six sub-groups as follows: 
• Dosified Medicines 
• Bulk Medicines 
• Inputs specific to the pharmaceutical industry 
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• Chemical inputs of general purpose 
• Hospital and laboratory inputs 
• Medical technology equipment 
Table A.4.1 reveals India’s Revealed Comparative Advantage (RCA) with respect to 
the world in different health products at 2-digit level from 2001 to 2014. These are 
Chapter 29 (Organic chemicals), 30 (Pharmaceutical products), 35 (Albuminiods, 
modified, starches, glues, enzymes)38 (Miscellaneous chem. pro.), 40 (Rubber and 
art. pro.), 70 (Glass and glassware), 84 (Machinery, nuclear reactors, boilers), 87 
(Vehicles other than railway, tramway), 90 (Optical, photo tech. medical app.), 94 
(Furniture, lighting, signs). India has comparative advantage in chapter 29 and 30 
throughout the years except 2005 and 2009 for pharmaceutical products. It has 
comparative advantage in chapter 35 only in the year 2007, and in chapter 40 in 2002, 
2003 and 2005. It also has comparative advantage for chapter 38 in some years. In all 
the health products, India’s comparative advantage has improved over the time 
period.   
Apart from India other top countries like Germany, Switzerland, Belgium, USA, 
France, U.K., Ireland, Netherlands, Italy, Spain and Denmark. Ireland and 
Switzerland have highest comparative advantage in chapter 29 (Organic Chemicals) 
throughout the years (table A.4.2.). India’s comparative advantage is lesser than 
countries like Netherlands, Ireland, UK, France, US, Belgium and Switzerland while 
greater than countries like Germany, Italy, Spain, and Denmark during the study 
period. India’s comparative advantage has improved till 2012 and after that it has 
come down. It is beneficial for India to export organic chemicals to those nation 
which have lesser comparative advantage than India.  
India has comparative advantage in pharmaceutical products for all the study years 
except 2005 and 2009 (table A.4.3). The 2005 affected due to {The Patents 
(Amendment) Act, 2005, An Act further to amend the Patents Act, 1970} and 2009 
affected due to global financial crisis. Switzerland and Ireland have highest 
comparative advantage among all competitive nations in pharmaceutical products. All 
the competitive nations have greater comparative advantage over India except USA, 
which is India’s number one trading partner in pharmaceutical products.  
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There is comparative advantage of India in chapter 35 throughout all the years except 
2005, 2009 and 2010 (table A.4.4). These years are influenced by Indian Patent 
(Amendment) Act 2005 and global financial crisis 2008-09. Denmark has the highest 
comparative advantage in chapter 35 among all the competitive nations over the time 
period. UK is the only country which has lesser comparative advantage than India 
throughout the time period and Italy has more or less equal comparative advantage 
than India. Apart from these two countries all other competitive nations have greater 
comparative advantage than India during the study period. India should import 
chapter 35 products from Denmark for getting benefits of its highest comparative 
advantage.  
India has comparative advantage in chapter 38 (Miscellaneous chemical products) 
only for few years like 2001, 2005, 2006, 2007, 2008 and 2013 (table A.4.5). 
Switzerland has highest degree of comparative advantage among all the competitive 
nations throughout the study period.  Switzerland export of miscellaneous chemical 
products has jumped in alternative years that is why it has very high comparative 
advantage in alternative years. Spain and Italy have lesser comparative advantage than 
India throughout the period and Denmark has lesser comparative advantage in the 
beginning but later on it improved a lot and having greater advantage over India. It is 
in favor of India that it imports miscellaneous chemical products from Switzerland.  
India has comparative advantage in chapter 40 (Rubber and articles thereof) for few 
years like 2002, 2003 and 2005 (table A.4.6). United Kingdom has the highest 
comparative advantage among all the competitive nations throughout the study 
period. Its export of rubber and articles thereof jumped on every alternative year 
which cause increase its value of RCA quite high in alternative years. Germany, 
France and Spain have comparative advantage throughout the time period. Italy also 
has comparative advantage except few years from 2009 to 2013.  
India does not have comparative advantage in glass and glassware throughout the 
years (table A.4.7). Germany, Belgium, France and Italy have comparative advantage 
in glass and glassware throughout the time period. Denmark also has comparative 
advantage but only for few years.   
Germany, USA, UK and Italy have comparative advantage in Chapter 84 (Machinery, 
nuclear reactors, boilers, etc.) over the study period (table A.4.8). Switzerland, 
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France, Ireland and Denmark have comparative advantage for few years. India does 
not have comparative advantage in Chapter 84. So, it is better for India to import 
these products from countries like Germany, USA, UK and Italy.    
Germany, Belgium, France, Spain have comparative advantage in chapter 87 
throughout the time period (table A.4.9). USA and UK do not have comparative 
advantage in the beginning but later on they gained comparative advantage. Italy has 
comparative advantage for some years. India does not have comparative advantage in 
chapter 87 (Vehicles other than railway, tramway) but it has improved the degree of 
comparative advantage over the years.       
Germany, Switzerland, USA, UK, Ireland, Netherlands and Denmark have 
comparative advantage in Chapter 90 (Optical, photo, technical, medical etc. 
apparatus) throughout the time period (table A.4.). Belgium has comparative 
advantage in 2014, while France has 2006 onwards. India does not have comparative 
advantage in Chapter 90. So, it is beneficial for India to import chapter 90 products 
from those countries which have comparative advantage.     
Italy and Denmark have comparative advantage in Chapter 94 (Furniture, lighting, 
signs, pre-fabricated buildings) over the years (table A.4.11). Spain and Germany 
have comparative advantage for few years. India does not have comparative 
advantage in Chapter 94. It is fruitful for India to import chapter 94 products from 
countries like Italy and Denmark.   
 
4.2. RCA at 4-digit Level 
The RCA at 4-digit level has calculated to go at disaggregated level and fulfill the 
inquisitiveness to know the results of trade in health products. The top five products 
among each category of health products have been selected for calculating RCA at 4-
digitlevel. The identified sub-categories of health products are as follows:- 
Chapter 29 (Organic Chemicals) 
• 2902 (Cyclic Hydrocarbons) 
• 2933 (Heterocyclic Compounds)  
• 2942 (Organic Compounds) 
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• 2941 (Antibiotics) 
• 2915 (Saturated A cyclic monocarboxylic acids) 
Germany, USA, France and Netherlands have comparative advantage in 2902 (Cyclic 
Hydrocarbons) over the time period (table A.4.12). Germany has highest comparative 
advantage among all the competitive countries. India has comparative advantage in 
cyclic hydrocarbons except for 2001 and 2002. Belgium and Spain have comparative 
advantage for few years. Ireland export of cyclic hydrocarbons is negligible in the 
world market that’s why it has no comparative advantage. For getting benefit from 
trade Switzerland, Ireland and Denmark should import cyclic hydrocarbons from 
countries like India, Germany, USA, France etc.       
Germany, Switzerland, Belgium, France and Ireland have comparative advantage in 
2933 (Heterocyclic Compounds) throughout the time period (table A.4.13). Ireland 
has the highest comparative advantage in heterocyclic compounds. UK also has 
comparative advantage in heterocyclic compounds except the years 2002, 2003 and 
from 2012 to 2014. USA, Netherlands, Italy, and Spain does not have comparative 
advantage in heterocyclic compounds. India has comparative advantage in late years 
of 2013 and 2014. Its comparative advantage has improved over the time period.        
India has highest comparative advantage in 2942 (Organic Compounds) among all 
competitive nations throughout the study period (table A.4.14). India should export 
organic compounds to rest of the world. Apart from India, only Germany has 
comparative advantage for organic compounds in the world market. USA and UK 
have comparative advantage for few years in beginning. India has leading edge in 
organic compounds, so other competitive nations should import 2942 (Organic 
Compounds) from India.     
All the countries have comparative advantage in 2941 (Antibiotics) except Netherland 
(table A.4.15). United States of America and UK have comparative advantage in 
Antibiotics only in initial years. Switzerland has the highest comparative advantage 
among all the competitive countries. India also has a significantly high degree of 
comparative advantage. It is beneficial for India to export 2941 (Antibiotics) in the 
world market.  
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Germany, Belgium, USA, UK, Netherlands, Spain and India have comparative 
advantage in 2915 (Saturated A cyclic mono-carboxylic acids) over the years (table 
A.4.16). Germany has highest degree of comparative advantage throughout the study 
period. Switzerland, Ireland, Italy and Denmark does not have comparative 
advantage. It is suggested that, India should export 2915 to the world and especially 
those countries which do not have comparative advantage.   
Chapter 30 (Pharmaceutical Products) 
• 3004 (Medicaments Mixtures) 
• 3002 (Human & Animal Blood) 
• 3003 (Medicaments Mixtures (not included in 3002, 3005, 3006) ) 
• 3006 (Pharmaceutical goods,) 
• 3005 (Dressing Packaged for Medical Use) 
Comparison of RCA in 3004 (Medicaments Mixtures) for India and other top twelve 
competitive countries w.r.t. the world has depicted in table A.4.17. All the top 
competitive countries except USA have comparative advantage in medicaments 
mixtures. India has comparative advantage in medicaments mixtures except in the 
years 2004 and 2009. Germany has highest degree of comparative advantage among 
all the competitive countries. It is advisable for India to export 3004 (Medicaments 
Mixtures) in the world market.   
All the top competitive nations except Italy and India have comparative advantage in 
3002 (Human & Animal Blood) during the study period (table A.4.18.). Germany has 
the highest comparative advantage among all the nations. India’s degree of 
comparative advantage in Human & Animal Blood quite fluctuates over the time 
period. It is suggested that, India should import 3002 (Human & Animal Blood) form 
countries like Germany, Switzerland, France, etc.  
Table A.4.19 reveals comparison of RCA in 3003 {Medicaments Mixtures (not 
included in 3002, 3005, 3006)} for India and other top twelve competitive nations 
w.r.t. the world. All the top competitive nations except Netherland have comparative 
advantage in 3003. India has significantly high comparative advantage in 3003 
throughout the study period, but it has declined over the years. It is recommended that 
India should export 3003 to the world.      
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All the competitive nations except Italy, Spain, Denmark and India have comparative 
advantage in 3006 (Pharmaceutical goods,) during the study period (table A.4.20). 
Italy, Spain, and Denmark have comparative advantage only for few years. Germany 
has highest degree of comparative advantage in 3006 (Pharmaceutical goods,) among 
all competitive countries. India does not have comparative advantage in 3006 
(Pharmaceutical goods,), but the degree of comparative advantage has improved over 
the time period.  
All the competitive countries except Netherlands, Italy and Indiahave comparative 
advantage in 3005 (Dressing Packaged for Medical Use) during the study period 
(table A.4.21). Germany has highest degree of comparative advantage among all its 
competitive nations. India does not have comparative advantage in Dressing Packaged 
for Medical Use, so it is advisable that India should import 3005 from countries like 
Germany, Belgium, France etc. which have comparative advantage. 
Chapter 35 (Albuminoids, modified starches, glues enzymes) 
• 3501 (Casein, Caseinates and other casinates derivatives and glues) 
• 3503 (Gelatin and Gelatin derivatives) 
• 3506 (Prepared glues & adhesive) 
• 3507 (Enzymes prepared enzymes) 
• 3505 (Dextrins& other modified starches) 
Germany, France, Ireland, Denmark and India have comparative advantage in 3501 
(Casein, Caseinates and other casinates derivatives and glues) during the study period 
(table A.4.22). Germany, France and Italy have greater degree of comparative 
advantage Denmark and India. Switzerland, Belgium, USA, UK, Italy and Spain does 
not have comparative advantage. India’s degree of comparative advantage fluctuates 
over the years. It is suggested that India should export 3501 to the world.    
India, Denmark, Italy, France and Belgium have comparative advantage in 3503 
(Gelatin and Gelatin derivatives) throughout the years (table A.4.23). France has 
highest degree of comparative advantage in 3503 among all competitive member 
countries. Germany, Switzerland, Netherlands and Spain have comparative advantage 
for few years. India’s degree of comparative advantage fluctuates over the time period 
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but it maintain the position of keeping advantage. It is suggested that, India should 
export 3503 (Gelatin and Gelatin derivatives) to the world market.  
All the competitive nations have comparative advantage except Spain and India. 
Belgium and Netherlands have comparative advantage for some years (table A.4.24). 
Germany has highest degree of comparative advantage among all its competitive 
nations. As India does not have comparative advantage in 3506 (Prepared glues & 
adhesive), so, it is better for India to import 3506 from countries like Germany, 
France, Switzerland, etc.     
All the competitive nations have comparative advantage in 3507 except Italy, Spain 
and India (table A.4.25). Switzerland and UK have comparative advantage for some 
years in the beginning. Denmark has leading position in comparative advantage 
among all its competitive nations throughout the years. India does not have 
comparative advantage in 3507 (Enzymes prepared enzymes) except in 2003. It is 
advisable that, India should import 3507 from countries which high comparative 
advantage like Denmark, Germany, France, etc.        
Germany, USA, France and Netherland have comparative advantage in 3505 
(Dextrins & other modified starches) throughout the time period (table A.4.26.). Italy 
has comparative advantage for few years. Switzerland, Belgium, UK, Ireland, Italy, 
Spain and India does not have comparative advantage in 3505. Germany and France 
are two leading countries which have high degree of comparative advantage in 
Dextrins & other modified starches. Germany has higher comparative advantage than 
France over the years. As India does not have comparative advantage, so it has 
suggested that India should import 3505 (Dextrins & other modified starches) from 
countries like Germany, France, Netherlands etc. 
Chapter 38 (Miscellaneous Chemical Products) 
• 3808 (insecticides, fungicides, herbicides packaged for retail sale) 
• 3824 (Chemical industry products and residual) 
• 3823 (Binders for foundry molds or cores) 
• 3815 (Reaction initiators & accelerators catalytic prep.) 
• 3802 (Activated carbon, activated natural mineral products,) 
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Germany, Switzerland, Belgium, USA, France, UK, Spain, and India have 
comparative advantage in 3808 (insecticides, fungicides, herbicides packaged for 
retail sale) over the study period (table A.4.27). Denmark has comparative advantage 
for few years. France and Germany have very high positions in case of degree of 
comparative advantage in 3808. India has significantly high degree of comparative 
advantage throughout the time period. It is beneficial for India to export 3808 
(insecticides, fungicides, herbicides packaged for retail sale) in the world market.     
All the competitive countries have comparative advantage in 3824 (Chemical industry 
products and residual) except Spain and India (table A.4.28). Italy, Denmark and UK 
have comparative advantage for few years. Germany has the leading position with 
very high degree of comparative advantage among all competitive countries 
throughout the years. As India does not have comparative advantage in 3824, thus, it 
has suggested that India should import 3824 (Chemical industry products and 
residual) from countries like Germany, France, Netherlands, etc.     
Germany, Switzerland, Belgium, France, Netherlands and India have comparative 
advantage in 3823 (Binders for foundry molds or cores) throughout the time period 
(table A.4.29). USA, UK, Ireland, Italy, Spain and Denmark does not have 
comparative advantage in 3823. Switzerland has highest degree of comparative 
advantage among all competitive nations. As, India has comparative advantage in 
3823, so it is fruitful for India to export it in the world market.   
All the competitive nations except Switzerland, Ireland, Spain and Denmark have 
comparative advantage in 3815 (Reaction initiators & accelerators catalytic prep.) 
during the study period (table A.4.30). Germany has leading advantage in 3815 over 
the years. As, India has comparative advantage in 3815 (Reaction initiators & 
accelerators catalytic prep.), so it is better that India should export it to the world.   
Germany, USA, UK, France and Netherlands have comparative advantage in 3802 
(Activated carbon, activated natural mineral products,) during the study period (table 
A.4.31). India and Belgium does not have comparative advantage in the beginning but 
later on they gained in comparative advantage. Germany has highest degree of 
comparative advantage in 3802 throughout the years. As India gained momentum in 
late years for comparative advantage, but improved over the time period. Now, for 
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India, it is in favor to export 3802 (Activated carbon, activated natural mineral 
products,) to the world. 
Chapter 40 Rubber and articles thereof 
• 4011 (New Pneumatic tires, of rubber) 
• 4016 (Articles of vulcanized rubber, hard rubber) 
• 4010 (Conveyor or transmission belts or belting of vulcanized rubber) 
• 4013 (Inner tunes of rubber) 
• 4009 (Tubes, pipes & hoses of vulcanized rubber other than hard rubber) 
Germany, Belgium, France, Spain and India have comparative advantage in 4011 
(New Pneumatic tires, of rubber), while Switzerland, USA, UK, Ireland, Netherlands 
and Denmark does not have comparative advantage (table A.4.32). Italy has 
comparative advantage for the beginning of years. Belgium has highest degree of 
comparative advantage among all competitive countries throughout the time period. 
India has comparative advantage in 4011 except 2009 and 2010. It is beneficial for 
India to export 4011 (New Pneumatic tires, of rubber) to the world.     
Germany, Belgium, USA, France, Netherlands, Spain have comparative advantage in 
4016 (Articles of vulcanized rubber, hard rubber), while Switzerland, UK, Ireland, 
Denmark and India does not have comparative advantage (table A.4.33). Belgium has 
highest degree of comparative advantage among all nations followed by Netherlands 
and Germany. As, India does not have comparative advantage, thus it has suggested 
that India should import 4016 (Articles of vulcanized rubber, hard rubber) from 
countries like Belgium, Netherland, France, etc.    
All the competitive nations except USA, Ireland, Netherlands and Denmark have 
comparative advantage in 4010 (Conveyor or transmission belts or belting of 
vulcanized rubber) during the study period (table A.4.34). Belgium has leading 
position in RCA among all countries. India also has comparative advantage in 4010 
except in the 2009 and 2010. It is advisable for India to export 4010 (Conveyor or 
transmission belts or belting of vulcanized rubber) in the world market.   
Belgium, Germany, USA, France and India have comparative advantage in 4013 
(Inner tunes of rubber) over the time period (table A.4.35). Belgium has very high 
degree of comparative advantage. Italy has comparative advantage in the beginning 
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only. India has significantly high comparative advantage in 4013 over the years. It has 
suggested that India should export 4013 (Inner tunes of rubber) to the world market.  
Germany, Belgium, USA, France and Italy have comparative advantage in 4009 
(Tubes, pipes & hoses of vulcanized rubber other than hard rubber) over the time 
period (table A.4.36.). Denmark and UK have comparative advantage foe few years. 
Belgium has highest RCA value over the years. As, India does not have comparative 
advantage in 4009, so it has recommend that India should import 4009 (Tubes, pipes 
& hoses of vulcanized rubber other than hard rubber) from countries like Belgium, 
Germany, France, etc. 
Chapter 70 (Glass & Glassware) 
• 7020 (Articles of glass) 
• 7010 (Carboy, bottle & other container of glass) 
• 7011 (Glass, env, open & pts for electric lamps, cathode ray tubes etc.) 
• 7019 (Glass fibres (incl. glass wool) 
• 7005 (Float glass & surf grd) 
Belgium, Germany, France and Italy have comparative advantage in 7020 (Articles of 
glass) throughout the time period (table A.4.37). India has comparative advantage in 
7020 from 2007 onwards. Belgium has quite high degree of RCA. As India has 
comparative advantage in 7020 (Articles of glass), thus it beneficial for India to 
export it in the world market.  
Germany, France, Italy, Spain and Denmark in 7010 (Carboy, bottle & other container 
of glass) throughout the years (table A.4.38). Belgium has comparative advantage 
from 2004 onwards. India also has comparative advantage throughout the years 
except 2007 and from 2009 to 2011. Germany and France have leading positions in 
RCA for 7010 over the time period. As, India has comparative advantage in 7010 
(Carboy, bottle & other container of glass), thus it is fruitful for India to export it to 
the world.   
Germany and France have comparative advantage in 7011 (Glass, env, open &pts for 
electric lamps, cathode ray tubes etc.) throughout the years (Table A.4.39). India also 
has comparative advantage in 7011 except two or three years in beginning, but later 
on it overtook all the counties to get leading position. From 2008 onwards India 
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maintains its leading positions in 7011. It has suggested that India should export 7011 
(Glass, env, open &pts for electric lamps, cathode ray tubes etc.) to the world.     
Germany, Belgium, France, USA, UK and Denmark have comparative advantage in 
7019 (Glass fibres (incl. glass wool) with respect to the world (table A.4.40). 
Netherland has comparative advantage for few years. Germany and France have 
leading position in the degree of comparative advantage. India had comparative 
advantage only in beginning for two consecutive years but later on it loses its 
advantage in 7019 (Glass fibres (incl. glass wool). It has suggested that, India should 
import 7019 (Glass fibres (incl. glass wool) from the counties like Germany, France, 
Belgium, etc.     
Table A.4.41 exhibits a comparison of RCA in 7005 (Float glass & surf grd)for India 
and other top twelve competitive nations w.r.t. the world. Germany, Belgium, France 
and USA have comparative advantage in 7005 throughout the time period. The 
highest degree of RCA kept by Germany. India had advantage only for two years in 
the beginning, but after that she has lost its comparative advantage. As, India does not 
have comparative advantage in 7005, thus India should import 7005 (Float glass & 
surf grd) from countries which have comparative advantage. 
Chapter 84 (Machinery, nuclear reactors, boilers etc.) 
• 8481 (Tap, Cock valve for pipe) 
• 8409 (Part of use solely) 
• 8407 (Engines, spark-ignition reciprocating) 
• 8414 (Air, Vacuum pumps) 
• 8413 (Pumps for liquids) 
All the competitive nations except Belgium, Irelands, Netherlands and India have 
comparative advantage in 8481 (Tap, Cock valve for pipe) during the study period 
(table A.4.42.). Germany has leading position in comparative advantage among all 
countries. As, India does not have comparative advantage in 8481, but it moving 
towards comparative advantage. It is suggested that India should import 8481 (Tap, 
Cock valve for pipe) from countries like Germany, France, Italy, etc. 
Germany, France and USA have comparative advantage in 8409 (Part of use solely) 
for all the years (table A.4.43). Germany has highest position in comparative 
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advantage followed by France and USA. In the beginning of two or three years Italy 
and UK does not have comparative advantage in 8409, but later on they gained 
comparative advantage. India does not have comparative advantage in 8409, so it is 
better for India to import it.    
Germany, USA, France and UK have comparative advantage in 8407 (Engines, spark-
ignition reciprocating) over the years (table A.4.44.). Italy and Spain have 
comparative advantage for few years. India does not have comparative advantage in 
8407, thus it is beneficial for India to import 8407 (Engines, spark-ignition 
reciprocating) from countries like Germany, France, USA, etc.  
All the competitive countries except Ireland, Netherlands, Spain and India have 
comparative advantage in 8414 (Air, Vacuum pumps) during the study period (table 
A.4.45). Denmark, Belgium and UK have Comparative advantage for some years. 
Germany has highest degree of comparative advantage among all nations. India does 
not have comparative advantage in 8414, so it is advisable for India to import 8414 
(Air, Vacuum pumps) from those countries which have comparative advantage.   
Germany, USA, France, UK, Italy and France have comparative advantage in 8413 
(Pumps for liquids) over the years (table A.4.46).  Germany has keeping leading 
position followed by France in comparative advantage. India does not comparative 
advantage in 8413, thus it is fruitful for India to import 8413 (Pumps for liquids) from 
countries like Germany, France, USA, etc.   
 
Chapter 87 (Vehicles other than railway, tramway) 
• 8703 (Cars) 
• 8708 (Parts & access of Motor Vehicles) 
• 8711 (Motor cycles, side cars) 
• 8701 (Tractors other than 8709) 
• 8704 (Trucks, motor vehicles) 
Germany, Belgium, France, UK and Spain have comparative advantage in 8703 
(Cars) for all the years (table A.4.47). Germany has leading position followed by 
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France in comparative advantage. India does not have comparative advantage in 8703, 
so for getting maximum benefit in trade India should import it. 
Germany, USA, France, Italy and Spain have comparative advantage in 8708 (Parts & 
access of Motor Vehicles) for all the study years (table A.4.48). Belgium has 
comparative advantage in 8708 from 2003 onwards. Germany has leading position 
followed by France in comparative advantage for 8708. India does not have 
comparative advantage in 8708 (Parts & access of Motor Vehicles), in this way India 
should import it from countries like Germany, France, Spain etc.    
India,Germany, Belgium, France, and Italy have comparative advantage in 8711 
(Motor cycles, side cars) over the years (table A.4.49). Germany has leading position 
followed by India in comparative advantage. Spain has comparative advantage in 
8711 till 2011 only. India has significantly high comparative advantage in 8711 over 
the time period. It is suggested that India should export 8711 (Motor cycles, side cars) 
in the world market.  
United Kingdom, Germany, Belgium, USA, France, Netherlands and Italy have 
comparative advantage in 8701 (Tractors other than 8709) during the study period 
(table A.4.50). UK has leading position followed by Germany in comparative 
advantage. India does not have comparative advantage in 8701 except in the year 
2010. But it is very close to comparative advantage.     
Germany, Belgium, USA, France, Italy and Spain have comparative advantage in 
8704 over the time period (table A.4.51). Germany has highest degree of comparative 
advantage in 8704 followed by France. India does not have comparative advantage in 
8704 (Trucks, motor vehicles), so it is better for India to import it from countries like 
Germany, France, Spain, etc. 
Chapter 90 (optical, photo, technical, medical etc apparatus) 
• 9018 (Electro medical apparatus) 
• 9001 (Optical fibre, cables) 
• 9032 (Automatic regulating or controlling instruments) 
• 9022 (Apparatus based on the use of X-rays/alpha, beta gamma radioactives) 
• 9026 (Instruments for measuring/checking the flow/level/pressure of liquid /gas) 
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All the competitive nations except Italy and Spain have comparative advantage in 
9018 (Electro medical apparatus) during the study period (table A.4.52). UK has 
comparative advantage for few years. India has leading position with quite high 
degree of comparative advantage in 9018 (Electro medical apparatus). Its comparative 
advantage declined over the year but maintains its leading position in 9018. It is in 
favor of India to export 9018 (Electro medical apparatus) in the world market.  
Germany, USA, France, UK and Ireland have comparative advantage in 9001 (Optical 
fibre, cables) throughout the years (table A.4.53). Switzerland has comparative 
advantage in 9001 till 2006. Germany play a leading role in comparative advantage 
among all the countries. India does not have comparative advantage in 9001, so it is 
better for India to import 9001 (Optical fibre, cables) from countries like Germany, 
Ireland, France, etc.  
A comparison of RCA in 9032 (Automatic regulating or controlling instruments) for 
India and other top twelve competitive nations w.r.t. the world has demonstrated in 
table A.4.54. Germany, USA, France and Denmark have comparative advantage in 
9032 during study period. Switzerland and Italy have comparative advantage for few 
years. India does not have comparative advantage in 9032 (Automatic regulating or 
controlling instruments), thus it is fruitful for India to import it. 
Germany, Switzerland, USA, France, UK and Netherlands have comparative 
advantage in 9022 (Apparatus based on the use of X-rays/alpha, beta gamma radio-
actives) throughout the time period (table A.4.55). Germany has highest comparative 
advantage followed by France. India has comparative advantage in 9022 (Apparatus 
based on the use of X-rays/alpha, beta gamma radio-actives) till 2006, after that the 
degree of comparative advantage has decreased over the time period.   
Germany, Switzerland, USA, France, UK, Netherlands and Denmark have 
comparative advantage in 9026 (Instruments for measuring/checking the 
flow/level/pressure of liquid /gas) over the time period (table A.4.56). Germany has 
top position followed by France in comparative advantage. India does not have 
comparative advantage in 9026 (Instruments for measuring/checking the 
flow/level/pressure of liquid /gas), so it is beneficial for India to import 9026 
(Instruments for measuring/checking the flow/level/pressure of liquid /gas) from 
countries like Germany, France, Switzerland, etc. 
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Chapter94 (Furniture, lighting, signs, prefabricated buildings) 
• 9403 (Other furniture & parts) 
• 9404 (Matress, supports, mattresses, quilt etc.) 
• 9405 (Lamps and lighting, fittings, name plates, signs) 
• 9401 (Seat (of dentistists, chair etc.) 
• 9406 (Prefabricated buildings) 
Germany, Belgium, France, Italy and Denmark have comparative advantage in 9403 
(Other furniture & parts) over the years (table A.4.57). Spain has comparative 
advantage till 2011. Germany has leading position in comparative advantage among 
all countries. India does not have comparative advantage in 9403 (Other furniture & 
parts), so India should it from countries which have comparative advantage.   
Switzerland,Germany, Belgium, France, Spain, Denmark and India have comparative 
advantage in 9404 (Mattress, supports, mattresses, quilt etc.) over the time period 
(table A.4.58). Initially, India does not had comparative advantage but 2006 onwards 
it has comparative advantage in 9404. Now, it is in favor of India to export 9404 
(Mattress, supports, mattresses, quilt etc.) in the world market.    
Germany, Belgium, France, Italy, Spain and Denmark have comparative advantage in 
9405 (Lamps and lighting, fittings, nameplates, signs) throughout the years (table 
A.4.59). Germany has highest degree of comparative advantage followed by France. 
India does not have comparative advantage in 9405. It is better for India to import 
9405 (Lamps and lighting, fittings, nameplates, signs) from countries like Germany, 
France, Italy, etc.   
Germany, France, Italy and Denmark have comparative advantage in 9401 (Seat (of 
dentistists, chair etc.) during the study period (table A.4.60). Germany has highest 
degree of comparative advantage followed by France in 9401. India does not have 
comparative advantage in 9401 (Seat (of dentistists, chair etc.), thus it is fruitful for 
India to import it for getting benefit in trade.   
Table A.4.61 represents a comparison of RCA in 9406 (Prefabricated buildings)for 
India and other top twelve competitive nations w.r.t. the world. Germany, Belgium, 
France, Netherlands and Spain have comparative advantage in 9406 throughout the 
study period. Italy and Denmark have comparative advantage for some years. 
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Germany has highest degree of comparative advantage followed by France in 9406. 
India does not have comparative advantage in 9406. It is advisable for India to import 
9406 (Prefabricated buildings) from countries like Germany, France, Belgium, etc. 
4.3. RCA at 6-digit Level 
Chapter-30 (Pharmaceutical Products) has been selected to calculate RCA at 6-digit 
level to know whether, is there any change in the comparative advantageat 
disaggregated level or not. The rationale behind for the selection of this Chapter (30) 
is that, because it constitutes a major share among all the health products exported by 
India.   
From the significance point of view, medicines contribute enormously to the health of 
the nation. The discovery, development and effective use of drugs have improved 
many people’s quality of life, reduced the need for surgical intervention and the 
length of time spent in hospital and saved many lives. The global pharmaceutical 
industry structure can be divided into two- 
 Bulk drugs  
 Formulations  
The Indian pharmaceutical industry is a successful, high-technology-based industry 
that has witnessed consistent growth over the past two decades. 
For this, we have selected top five products within chapter-30 at 6-digit level. These 
are as follows: 
 300490 (Medicaments nes, in dosage) 
 300420 (Antibiotics nes, in dosage) 
 300410 (Pencililines, or other streptomycin, in dosage) 
 300220 (Vaccines, human use) 
 300390 (Medicaments nes, formulated in bulk) 
All the competitive nations except USA have comparative advantage in 300490 
(Medicaments nes, in dosage) during the study period (table A.4.62). Ireland has 
highest degree of comparative advantage followed by Switzerland. India has 
comparative advantage in 300490 from 2010 onwards. It is gainful for India to export 
300490 (Medicaments nes, in dosage) to the world.  
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All the competitive countries except USA and Spain have comparative advantage in 
300420 (Antibiotics nes, in dosage) over the time period (table A.4.63). Switzerland 
has highest degree of comparative advantage among all the nations. India has 
significantly high comparative advantage in 300420 (Antibiotics nes, in dosage) over 
the years. It is favorable for India to export 300420 (Antibiotics nes, in dosage) in the 
world market.      
A comparison of RCA in 300410 (Penicillin, or other streptomycin, in dosage) for 
India and other top twelve competitive nations w.r.t. the world has given in table 
A.4.64. India, Italy, Ireland, UK, France and Belgium have comparative advantage in 
300410 throughout the years. India has highest degree of comparative advantage in 
Penicillin, or other streptomycin, in dosage among all competitive nations. It is 
beneficial for India to lead in the world with export of 300410 (Penicillin, or other 
streptomycin, in dosage).   
Belgium, France, UK and India have comparative advantage in 300220 (Vaccines, 
human use) during the study period (table A.4.65). India has comparative advantage 
in 300220 except in the years from 2008 to 2011. Switzerland had comparative 
advantage till 2005. Similarly, Italy had comparative advantage till 2006. Belgium has 
highest degree of comparative advantage followed by France. As India has 
comparative advantage in 300220 (Vaccines, human use), so, it is suggested for India 
to export it in the world market.  
India, Spain, Ireland, France, Belgium and Switzerland have comparative advantage 
in 300390 (Medicaments nes, formulated in bulk) over the time period (table A.4.66). 
USA, Germany and UK have comparative advantage for few years. Ireland has 
highest degree of comparative advantage among all countries. India also has 
significantly high degree of comparative advantage in 300390. It is favorable for India 
to export 300390 (Medicaments nes, formulated in bulk) to the world. 
Ranking of Health Products as per their relevance in Healthcare Trade 
The table 4.1 depicts descending order of relevance of different health products at two 
digit level in India’s trade in health products. The chapter 87 holds the first rank 
followed by the chapter 84, 30, 29, etc. When, we calculate relevance of health 
products at disaggregated level means at four digit level and six digit level or sub 
85 
 
categories of these products the relevance of these health products is different. At 
disaggregated level, chapter 30 holds ranks number one followed by the chapter 29, 
38, 90, etc. the reason behind is that the two digit level data also covers sub-categories 
of those products which are used for other purposes as well (apart from health 
products).      
 
Table 4.1: Relevance of different Health Products in Healthcare Trade at two 
digit level  
Products Rank 
Chapter 35 10 
Chapter 70 9 
Chapter 94 8 
Chapter 90 7 
Chapter 38 6 
Chapter 40 5 
Chapter 29 4 
Chapter 30 3 
Chapter 84 2 
Chapter 87 1 
 
 
4.4. Intra-Industry Trade 
Table A.4.67 reveals a comparison of India’s Intra-Industry Trade Index or Grubel-
Llyod Index for different Health Products since 2001. India has intra-industry trade 
for all the health product during the study period. India has intra-industry in chapter 
29 (Organic chemicals) over the time period. The degree of intra-industry trade is 
quite high till the year 2005. In the year 2006, India has complete intra-industry trade 
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(GLI=1), and there is no inter-industry trade. After that India loses its grip on intra-
industry trade. For chapter 30 (Pharmaceutical Products) India has intra-industry trade 
but the degree of it remains low over the years. In case of chapter 35 (Albuminoids, 
Modified starches, glues, enzymes), India has intra-industry trade with quite high 
degree. India has to move toward complete intra-industry trade over the time period. 
The value of GL index has increased from 0.71 in 2001 to 0.99 in 2014. India also has 
intra-industry trade in Chapter 38 (Miscellaneous chemical products) over the years. 
The degree of intra-industry trade was quite high in early years but decline over the 
time. GLI for chapter 38 was 0.97 in 2001, 0.98 in 2005 and 0.85 in 2014. If we talk 
about chapter 40 (Rubber and Articles and thereof), India holds quite high degree of 
intra-industry trade with GLI value exceeding 0.75 throughout all years. It remains 
very high more 0.90 in some years.  
In chapter 70 (Glass and Glassware), India has intra-industry trade over the years. The 
value of GL index remains as high as above 0.80 during the study period. For chapter 
84 (Machinaery, boilers, nuclear reactors etc.), intra-industry trade is present over the 
years. It remains at moderate level throughout the years. In chapter 87 (Vehicles other 
than railway, tramway), India keeps intra-industry trade. It remains moderate or above 
level throughout the time period. The value of GLI varies between 0.45 and 0.70. As 
far as chapter 90 (Optical, photo, technical, medical apparatus) is concerned, India 
hols intra-intra industry trade over the time period. It remains at moderate or low 
level. For chapter 94 (Furniture, lighting, signs, prefabricated buildings), India has 
intra-industry trade over the years. The value of GL index remains quite high 
throughout the years. It maintains more than 0.90 over the time period except few 
years.   
4.5. Marginal Intra-Industry Trade (MIIT) 
India’s Marginal Intra-Industry Trade Index for different Health Products has given in 
table A.4.68. It is clearly mention that new trade flows in health products are due to 
intra-industry trade. It advocates for the presence of marginal intra-industry trade over 
the time period. For chapter 29 (organic chemicals), MIIT index has improvement 
towards the intra-industry trade. As the value of MIIT index for organic chemicals has 
increased from 89 per cent in 2001 to 98 per cent in 2014 with some fluctuations. In 
chapter 30 (pharmaceutical products), the value of MIIT index remains at low level 
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with jumps in some years. In case of chapter 35 (Albuminoids, Modified starches, 
glues, enzymes), new trade flow is in favour of intra-industry trade. The value of 
MIIT was very high in few years like 98.81 per cent in 2003 and 99.61 in 2010. In 
case of chapter 38 (Miscellaneous chemical products), India has intra-industry trade. 
The value of MIIT for chapter 38 keeps on fluctuating but more than 25 per cent, 
which tells us that new trade flows due to presence of intra-industry trade. For chapter 
40 (rubber and articles thereof), India holds intra-industry trade with significantly 
high MIIT index value. The value of MIIT index fluctuates over the time period. In 
case of chapter 70 (Glass and Glassware), India has intra-industry trade. The value of 
MIIT index keeps on varying over the time period. It was quite high more than 90 per 
cent in 2003, 2007 and 2008.      
In chapter 84 (Machinery, boilers, nuclear reactors etc.), new trade flows due to 
presence of intra-industry trade over the time period. The value of MIIT index has 
increased from 31.13 per cent in 2001 to 76.90 per cent in 2014. For chapter 87 
(Vehicles other than railway and tramway), India has intra-industry trade throughout 
the years. The value of MIIT index is significantly high over the years. As far as 
chapter 90 (Optical, photo, technical, medical apparatus) is concerned, MIIT index 
advocates presence of intra-industry trade over the time period. The value of MIIT 
index remains at moderate level or low. In chapter 94 (Furniture, lighting, signs, 
prefabricated buildings), new trade flows due to presence of intra-industry trade over 
the years. The value of MIIT index keep on changing, but remains quite high except 
few years.   
International trade in health products have grown in a very dynamic way, especially 
trade in dosified and bulk medicines. Our results further indicate that international 
trade in healthproducts is strongly dominated by trade among a small number of 
developed countries. 
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Chapter 5 
Trade in Health Services 
5.1 An Overview of Trade in Health Services  
Health services have become increasingly globalized and therefore, the nations are 
influenced by transnational processes occurring at every level of economic activity. 
Globalization is one of the key challenges facing policymakers for trade in health 
services in the twenty-first century.Trade of health services is reflected in the 
emergence of new kinds of health care markets over the past decade and increased 
cross-border delivery of health services through movement of personnel and 
consumers and through cross-border electronic and other means. It is also reflected in 
the growing number of companies engaged in joint ventures and collaborative 
arrangements in the health services sector and in the increased cross-border exchange 
and dissemination of information, education, and training in this sector. 
Globalization of health services is driven by many factors. These include the decline 
in public sector expenditures and the rise in private sector participation in health care 
in many countries, the liberalization of related sectors such as insurance and 
telecommunications, increased mobility of consumers and health service providers 
due to declining travel costs and greater ease of travel, and technological advances 
enabling the cross-border delivery of many health services. In addition, differences in 
costs, availability, and quality of health care across countries, the emergence of 
investment opportunities in the health care sector with the liberalization of investment 
regulations, and the general increase in demand for health services arising from rising 
income levels and aging population, have also contributed to the globalization of 
health services. Although trade in health services is modest at present, given the 
rapidly growing global health care industry and the likely removal of some of the 
regulatory barriers to such trade at the regional, multilateral, and the national levels, 
trade in health services is likely to take on greater importance in the future. 
The demand for health services is immense, a large majority of which is unmet by 
public health systems, which are often understaffed, mal-distributed and ineffective. 
With rising incomes, greater availability of technology and a quickly expanding 
health professionals’ base, this could represent a very appealing market for the private 
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health sector, both foreign and domestic. Moreover, the high and expanding 
reputation of Indian health professionals abroad and the ever rising shortages of health 
professionals in developed countries had led to a fairly large migration of Indian 
doctors and nurses abroad. The implications of this growth in trade in health services 
on Indian health systems are yet to be understood. 
Trade in health services should not only be seen as a source of income in the balance 
of payments, but primarily as a means to remedy shortages and improve domestic 
health systems. Therefore, the main challenge will be to find adequate accompanying 
policies that aim to maximize the positive domestic spillovers and minimize the 
negative domestic spillovers of trade in health services. A number of countries are 
competing to become key exporters of health services. In particular, the growing 
phenomenon of health tourism appeals to many developing countries where clinics 
servicing foreign clientele flourish. 
There has been a significant growth in opportunities and in the forms of trade and 
foreign direct investment (FDI) in health services in recent years, involving developed 
and developing countries.As a result, health services are in the realm of multilateral 
trade negotiations under the World Trade Organization (WTO). 
The impact of trade on countries’ health systems may vary a lot according to various 
factors, including the mode of services delivery, the structure of the domestic market 
for the provision of health services, and the adequacy of accompanying regulations 
and policies. In other terms, trade in health services may create opportunities and have 
a number of benefits not only for the business partners involved in trade, but for the 
population as a whole.Trade in health services is already an important phenomenon in 
India. Government of India have established a framework for progressively 
liberalizing trade in health services.  
India is one of the prominent participants. The multilateral negotiations are conducted 
under the General agreement on Trade in Services (GATS). The aims are to regulate 
measures affecting international trade in services such as, hospital services, 
telemedicine, and acquisition of medical treatment abroad. 
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5.2 GATS and India’s Trade in Health Services 
A recent, and critical, development in international legislation concerning trade and 
health services has been the World Trade Organization (WTO) negotiations aimed at 
the further liberalization of trade in services: the General Agreement on Trade in 
Services (GATS).The pace of development of the new GATS commitments, and 
especially their binding nature, has created a fresh imperative to establish how health 
services will be affected. 
Until the emergence of World Trade Organization in 1995, there was no multilateral 
agreement to facilitate trade of services. Negotiations at the WTO led to the General 
Agreement on Trade in Services, a comprehensive agreement on the international 
trade in services. GATS explicitly provides for successive rounds of negotiation with 
a view to achieving a progressively higher degree of liberalization. An increase in 
trade in health services offers a handful of developing countries a limited set of export 
opportunities, mainly in attracting foreign consumers to their health facilities. These 
gains seem trivial when compared with the effects that the increased trade in health 
services could have on general people's right to health. Trade in health services risks 
exacerbating many of the problems which already plague health systems across the 
world. The damage may outweigh the benefits, particularly for those with little ability 
to pay more for publicly provided health care.  
Modes of Health Services under GATS 
Trade discussions in health services typically adopt a wide definition of what 
constitutes trade, involving the following four modes of supply. 
Mode 1: cross-border supply 
Mode 2: consumption abroad 
Mode 3: commercial presence 
Mode 4: movement of health personnel 
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Chart 5.1: Modes of Supply of Trade in Health Services 
 
 
 
 
 
 
 
 
 
 
 
 
Source: World Trade Organization, GATS, Part I, Article I.2. and Chanda 2001. 
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Table5.1: The GATS Modes of Supply for Health Services 
Mode of supply Definition Examples of 
health services 
Carriers’ 
Mode 1 Cross-border supply: 
suppliers resident in one 
country provide services 
in another country with-
out physical movement of 
neither supplier nor 
consumer  
Tele-
medicine/Tele-
health  
Telecommunication 
networks, regular 
mail  
Mode 2 Consumption abroad: 
consumers resident in one 
country travel to the 
country of suppliers to 
consume a service  
Medical Tourism  People or firms  
Mode 3 Commercial presence:  
firms (legal persons) 
moving to the location of 
consumers through the 
establishment of a foreign 
affiliate or branch  
Hospitals or 
clinics  
Firms  
Mode 4 Temporary movement of 
natural persons:  
individual suppliers 
travel-ling temporarily to 
the country of the 
consumers to provide a 
service  
Doctors or 
nurses working 
temporarily 
outside their 
country of 
origin.  
People  
Source: WTO 
 
Fig5.2: Identification of Exporter and Importer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Under mode 1, the exporter and the importer do not move across borders – the service only 
crosses the border: 
• A patient in country A (importer) receives treatment from a doctor located in country 
B (exporter). 
• A hospital in country A (importer) outsources transcription services in country B 
(exporter). 
Under mode 2, the importer moves across the border toward the exporter: 
• Country A (importer) sends patients for treatment in country B (exporter). 
• A tourist from country A (importer) received treatment while travelling to country B 
(exporter). 
Under mode 3, the exporter moves across the border toward the importer: 
• Country A (importer) authorizes the establishment on its territory of a medical 
facility partially owned – and eventually operated – by a healthcare provider from 
country B (exporter). 
Under mode 4, the exporter moves across the border toward the importer: 
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5.3 Mode 1: Cross-border Supply 
Telemedicine is the application of telecommunications technology to deliver health 
services at a distance. Thus, telemedicine may represent health care practised in real 
time, using a video link for example, or asynchronously, perhaps by 
email.Telemedicine has become successively ‘tele-health’, ‘online health’, ‘e-health’, 
‘connected health’, etc.Trade in telemedicine services has the potential to benefit both 
the exporting and importing countries by allowing for faster service delivery and 
raising foreign exchange, there are concerns regarding data security, recognition of 
qualifications and legal liability. 
There are different types of health care services that can be outsourced, although the 
most important ones are tele-radiology and tele-pathology. These involve scans or 
samples being sent to radiologists or pathologists for interpretation in a remote 
location, who then send the results back to the physician. A sector of telemedicine that 
has received increasing attention is tele-care. Tele-care involves the use of 
information and communication technologies to monitor patients (often suffering 
from chronic diseases) from their home. 
The UK is currently outsourcing its back office work to India. It also has massive 
contracts with Indian companies to carry out X-rays, diagnostic reporting, 
communication processes.Lab work will also be transferred to India. Doctors also 
send their recordings from their consultations, and overnight they are transcribed, 
printed and filed. 
Tele-imaging (e.g. reading and interpreting magnetic resonance imaging (MRI), CT 
scan and X-ray images) and tele-pathology (e.g. analysis of tissue samples) are some 
high-profile examples of medical functions off-shored by many hospitals in 
industrialized countries such as Canada, the USA and Singapore. 
A Major tele-medicine service provider in India are- Apollo hospitals (which has 
established linkages with 21 hospitals across various states and with 8 Army 
hospitals), Heart Care India, Medisoft Telemedicine, Hrudayalaya, Online 
Telemedicine, Sankara Nethralaya, Telepathology India, AIMS, Asia Heart 
Foundation, Gangaram hospitals and Escorts-Fortis.  
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There are many new firms like Medsynaptic, which are emerging as leaders in 
medical image management, picture archiving, communication systems and Tele-
radiology market with several original equipment manufacturers. 
Growth of Telemedicine 
Telemedicine provides the remote diagnosis, monitoring andtreatment of patients via 
videoconferencing or the Internet. Telemedicineis a fast-emerging trend in India, 
supported by exponential growth in thecountry’s information and communications 
technology (ICT) sector, andplummeting telecom costs. 
Several major private hospitals have adopted telemedicine services, anda number of 
hospitals have developed public-private partnerships (PPPs),among them Apollo, 
AIIMS, Narayana Hridayalaya, Aravind Hospitals and Sankara Nethralaya. The early 
successes of telemedicine pioneers have led to increasedacceptance and proliferation 
of telemedicine. Today there more than 120 telemedicine centres are available 
throughout India. The AsianHeart Institute (AHI) is planning to establish 60 more 
telemedicine satellitecentres across the interiors of Maharashtra. The government has 
also made a major commitment to the growth oftelemedicine. The Indian Space 
Research Organization (ISRO) plans toestablish 100 telemedicine centres across the 
country. The government also is reducing importtariffs on infrastructure equipment. 
And while India has yet to passlegislation on telemedicine related issues, the Ministry 
of InformationTechnology has developed “Recommended Guidelines & Standards for 
Practice of Telemedicine in India,” with the goal of standardizing digital 
communication in telemedicine. The Medical Council of India has formedcommittees 
to explore this and other legal aspects of tele-health.  
There is a growing movement within India to establish a health grid thatconnects 
medical institutions and practitioners throughout the country.This would allow super 
specialists to exchange case studies, compareexperiences, and hold virtual 
conferences to discuss critical diseasepatterns and provide treatment. Eventually, 
telemedicine likely willbe practiced in the majority of Indian hospitals, initially in a 
separatedepartment, and eventually, integrated into medical specialties. With the 
advent of private insurance and the emergence of India as amedical tourism 
destination, there also has been a surge of growth inso-called “super specialty” 
hospitals, which have teams of specialists,sophisticated equipment, links to other 
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medical centres, and the ability totreat a broad range of ailments. Some of these new 
facilities, such as the Rajiv Gandhi Super Specialty Hospital, are public-private 
partnerships. Government fiscal constraintsare driving the growth of PPPs to help 
meet India’s growing demand forhealthcare infrastructure. Such partnerships have 
gained legitimacy worldwidein recent years as a major strategy for health sector 
development.In addition to participating in infrastructure PPPs, opportunities 
areemerging for foreign companies to create super-specialty hospitals incollaboration 
with Indian corporations. For instance, Wockhardt Hospitals Group has partnered 
with Harvard Medical International to create a chain ofsuper specialty hospitals in 
India. Two hospitals, in Mumbai and Bangalore,are attracting large volumes of 
medical tourists from the UK and US.    
There also is strong demand for tertiary care hospitals, which emphasizethe treatment 
of lifestyle diseases, focusing on specialties such asneurology, cardiology, oncology 
and orthopaedics. Tertiary hospitals areprojected to grow faster than the overall 
healthcare sector, in response tothe growing incidence of lifestyle disease and the 
accelerating growth ofmedical tourism. In addition to a deteriorating physical 
infrastructure, India faces a hugeshortage of trained medical personnel, including 
doctors, nurses andespecially paramedics. There is an immediateneed for medical 
education and training, which could provide additionalopportunities for private sector 
providers or public-private partnerships.The communications technology that enables 
telemedicine could also beused to deliver training courses.  
ICT in the health sector 
In the health sector, information and communication technology (ICT) is a 
cornerstone of efficient and effective services. In many countries, use of ICT within 
the sector continues to grow, and the Internet in particular is driving significant 
change. For example, in middle and high-income countries, the Internet is 
dramatically changing the way in which consumers interact with health services, 
including access to health information and the ability to purchase pharmaceuticals and 
other health products. The Internet also plays a key role in expanding the reach of 
health services to remote areas. The spread of broadband networks and the 
development of new e-health applications, defined as the use of ICT for health, have a 
mutually stimulating effect on further developments. However, it is clear that, despite 
102 
 
the numerous creative and sometimes quite costly efforts to improve the situation, 
access to these developments is not universal, and many countries do not benefit as 
they might from advances in ICT in health. 
Telemedicine is one aspect of the use of ICT in health care. It is widely believed that 
ICT generally has the potential to improve clinical care and public health. In addition 
to facilitating medical education, administration and research, appropriate use of ICT 
may: 
• improve access to health care; 
• enhance the quality of service delivery; 
• improve the effectiveness of public health and primary care interventions; 
• improve the global shortage of health professionals through collaboration and 
training. 
India has made great stride in the field of telemedicine and e-health. Most of the 
telemedicine activities are in project mode supported by Indian Space Research 
Organization, Department of Information Technology which are being implemented 
through state governments. Few corporate hospitals have recently developed their 
own telemedicine network. Around 400 telemedicine nodes are in place across the 
country. No systematic evaluation of the telemedicine projects have been undertaken 
till date so as to gather evidence on cost-benefit aspects of integrating telemedicine 
tool into current health delivery system. Ministry of Health, Government of India is 
currently initiating evaluation exercise so as to decide investment on e-health in the 
11th five year plan. 
Besides, some of the nationwide projects are being taken up by the Ministry of Health 
e.g. Integrated Disease Surveillance Project (IDSP), National Cancer Network 
(oncoNET), Medical Colleges Network and Digital Medical Library Network. 
Telemedicine Standardization and Practice guidelines are being developed by the IT 
department. National Telemedicine Task Force has been set up by the Health 
ministry. External Affairs Ministry has taken up e-Africa and SAARC Telemedicine 
Network Projects. A National Resource Centre on Telemedicine & Biomedical 
Informatics is coming up at Lucknow with support of IT department of Govt. of India 
which is going to piggy back on the School of Telemedicine & Biomedical 
Informatics set up by the Uttar Pradesh state government. Besides meeting the need of 
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capacity building in telemedicine & e-Health for the country, this school will also be 
accepting overseas candidates. India is catching up a sizeable market segment in 
healthcare BPO and KPO industry. Both the above said two areas hold great degree of 
potential in use of telemedicine and e-health tools to facilitate healthcare across 
country boundary. 
E-Health Activities in India 
1. Electronic Medical Records and Hospital Automation 
Majority of the hospitals in the country are rooted in manual processes, which are 
difficult to access. The insurance sector demands a more efficient information storage 
and retrieval. Automation alone can help hospitals to meet these challenges. Centre 
for Development of Advanced Computing (C-DAC), an autonomous government 
scientific organization developed and deployed the first indigenously developed total 
Hospital Information System (HIS) software in collaboration with Sanjay Gandhi Post 
Graduate Institute of Medical Sciences (SGPGIMS), Lucknow in 19981. Electronic 
medical records and hospital automation have been rapidly adopted in most of the 
corporate and few public sector hospitals. Health system development projects in state 
governments aided by the World Bank are promoting rural electronic health records. 
5.4 Telemedicine Initiatives 
i. Department of Information Technology (DIT), Ministry of Communication 
and IT(MCIT), Government of India: 
DIT has established more than 75 nodes all over India in collaboration with the state 
governments. Telemedicine network in West Bengal for diagnosis and monitoring of 
tropical diseases, Kerala and Tamil Nadu Oncology Network for facilitating cancer 
care, North-Eastern and Himachal Pradesh hilly states for specialty healthcare access. 
ii.Indian Space Research Organization (ISRO): 
Towards societal benefit of indigenously developed space technology, Indian Satellite 
System (INSAT), ISRO is deploying telemedicine nodes under GRAMSAT (rural 
satellite) program which are very specific to the development of the society. In 
collaboration with state governments it has established a Telemedicine Network 
consisting of 225 Hospitals -185 Remote/Rural. District Hospitals / Health Centres 
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connected to 40 super specialty hospitals located in major states. Six mobile Tele-
ophthalmology units are part of this network. Andaman and Nicobar Islands are now 
linked to mainland specialty hospitals through satellite connectivity. 
iii. Ministry of Health and Family Welfare (MoH&FW), Government of India 
MoH&FW is currently implementing Integrated Disease Surveillance Programme 
network which will connect all district hospitals with medical colleges of the state to 
facilitate tele-consultation, tele-education/ training of health professionals and 
monitoring disease trends. It has funded few pilot tele-ophthalmology and rural 
telemedicine projects. National cancer network is under implementation which will 
network 25 regional cancer centres with peripheral hospitals to facilitate national 
cancer control programme. Very soon all the government medical colleges are getting 
networked with high bandwidth fibre to facilitate e-CME programme. 
iv. State Governments: 
To strengthen the healthcare facilities in their states, the governments of Orissa and 
Uttarakhand supported networking of their secondary level hospitals and then further 
linked them to Sanjay Gandhi Post-Graduate Institute of Medical Sciences 
(SGPGIMS), Lucknow for specialty consultation. The Government of Chhattisgarh 
with the support of ISRO has established state wide network linking state Government 
Medical Colleges at Raipur and Bilaspur which in turn have been linked with premier 
hospitals across the country. Rajasthan State Government also, in collaboration with 
ISRO, has established Telemedicine network between 6 state medical colleges and 32 
district hospitals and 6 Mobile Vans. Karnataka State Telemedicine Network Project 
run by an autonomous trust formed by the State Government has set up 30 nodes in 
collaboration with ISRO. 
v. Hospital Initiatives: 
Various tertiary level super specialty hospitals in public and corporate sector have 
taken initiatives to start telemedicine program with the help of government agencies 
or on their own. SGPGIMS, a premier institution in public sector started its 
telemedicine activities in 1999 in project mode with the support of various 
government agencies. It has networked 14 national and international partner nodes 
and has been carrying out tele-education and tele-healthcare activities and has 
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developed various modules for these activities. It is also involved in various research 
and development activities in collaboration with its technical partners. It has 
established School of Telemedicine and Biomedical Informatics to train man power in 
this upcoming field which is also recognized as National Resource Centre in 
Telemedicine by DIT. Two other premier institutions of India viz. All India Institute 
of Medical Sciences (AIIMS), New Delhi (Jammu & Kashmir, Haryana, Orissa, 
North East states network) and PGIMER, Chandigarh (Punjab and Himachal state 
network) and Sri Ramachandra Medical College and Research Institute (Andaman & 
Nicobar Islands) are also involved in similar activities.  
In corporate sector, the major players are Amrita Institute Medical of Sciences 
(AIMS), Kochi (34 nodes), Apollo Hospital Group (64 nodes), Asia Heart 
Foundation, Bangalore, Tata Memorial Hospital, Mumbai (2 nodes), Fortis Hospital 
(13 nodes), Narayana Hrudayalaya (26 nodes) and Escorts Heart Institute and 
Research Center (8 nodes). Recently Sir Ganga Ram Hospital, New Delhi has 
launched its telemedicine centers in Haryana and Rajasthan states. With the support of 
ISRO, Shankar Nethralaya at Chennai, Meenakshi Eye Mission at Madurai and four 
other corporate eye hospitals have launched Mobile Tele-ophthalmology service for 
early diagnosis and treatment of ophthalmic diseases under National Blindness 
Control Program. Sir Ganga Ram Hospital, New Delhi andAIMS, Kochi have 
launched mobile Tele-hospital for rural access of specialty healthcare services. 
5.5 Mode 2: Consumption Abroad 
This refers to the movement of consumers to the country, providing the service for 
diagnosis and treatment. Consumption abroad in health services also consists of 
movement of health professionals and students in receiving medical and paramedical 
education and training abroad. Developing countries, India provide technical 
assistance in the area of medical education services by reserving seats for students 
from other developing countries. 
Medical tourism is actually thousands of years old. In ancient Greece, pilgrims and 
patients came from all over the Mediterranean to the sanctuary of the healing god, 
Asklepios; the god of healing was located in Epidaurus.Trade flows in mode 2 occur 
among developed, among developing, and across developed and developing countries. 
It is common for instance for affluent patients in developing countries to seek 
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specialized high quality treatment overseas in developed country hospitals or in 
neighbouring developing countries with superior health care standards. 
It is also common for persons in developed countries to seek quality treatment at a 
fraction of the cost in developing countries, or to seek alternative medicines and 
treatments and take advantage of natural endowments in developing countries.  
For instance, patients from developed countries such as the US and the UK can get 
by-pass surgeries or transplants done at one-fourth or one-fifth of the cost in high 
quality corporate and super specialty hospitals in developing countries such as India, 
indicating the tremendous scope for gains from trade due to cost differences. 
Need for seeking treatment abroad 
Medical tourists seek treatment abroad for two main reasons: 1) vastly disparate costs 
or 2) access to timely treatment. Patients seeking to capitalize on cost advantages 
found in emerging markets are frequently American citizens bridled by the rising 
costs of health care in the United States. Patients seeking more timely medical 
treatment often reside in countries that provide universal healthcare but lack the 
infrastructure and resources to perform all needed procedures in a timely manner, like 
in the United Kingdom or Canada. Each reason can be reconciled by well-trained 
physicians in developing nations, offering readily available medical care at discounted 
costs. 
Several countries around the world provide destinations for medical tourists, but most 
of the increasing traffic is concentrated in Southeast Asia and South America. Popular 
destination countries include India, Thailand, Singapore, Argentina, Brazil, Columbia, 
Costa Rica, and Panama among others. Patients who seek treatment in these countries 
can expect highly trained physicians, often educated in the United States or Great 
Britain, and hospitals accredited by the Joint Commission International (JIC), an arm 
of the Joint Commission, an American non-profit organization that accredits a variety 
of health related organizations. These hospitals are staffed with highly trained medical 
staff and utilize the latest medical technologies and equipment. 
In addition to the medical infrastructure provided in these emerging markets, many 
hospitals provide extensive hospitality services and additional amenities to medical 
tourists, such as extended stays in five-star hotels and expertly managed recovery and 
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post-operative therapy periods. Several hospitals have gained international 
recognition for their prowess in treating foreigners seeking alternative medical 
treatment. One such hospital is Bumrungrad International, a JIC accredited, multi-
specialty hospital located in Bangkok, Thailand. The hospital was constructed in 1997 
in accordance with United States hospital building and safety standards. Staffed by 
nearly a thousand doctors, two hundred of which are U.S.-trained and board certified, 
and over seven hundred nurses, Bumrungrad International services over one-million 
patients annually, forty per cent of which represent international patients, making it 
the largest single campus hospital in Southeast Asia in both categories. Facilities at 
Bumrungrad include nineteen operating facilities (two specifically designed for 
cardiac procedures), four types of intensive care units (adult, pediatric, cardiac, and 
neo-natal), two heart catheterization labs, a surgical navigation system, and units with 
endoscopy, arthroscopy, and lithotripsy capabilities. 
Apollo Hospitals Group, headquartered in Chennai, India, is another renowned player 
in the global health care services industry opened by Dr.Prathap C. Reddy as India’s 
first for-profit hospital in 1983, the group now operates fifty-three individual hospitals 
treating patients from around the world. To date, seven of Apollo’s facilities, located 
in Delhi, Chennai, Hyderabad, Ludhiana, Bangalore, Kolkata, and Dhaka, have 
gained international accreditation from the Joint Commission International (Apollo 
Hospitals Group, 2010). 
According to Medical Travel Intermediaries,American patients interested in seeking 
treatment abroad face two options whensearching for facilities and physicians. 
Prospective patients may personally research themany hubs of cross border trade of 
medical services. Many of the larger facilities in Asia including Bumrungrad 
International and Apollo Hospitals Group offer interactivecustomer service websites 
where customers can find specific doctors and theircredentials and information about 
the facilities and services offered. Patients who arenot familiar with the industry or 
specific facilities abroad, however, can coordinateinternational medical travel via the 
services of medical travel intermediaries. These intermediaries work much like 
specializedtravel agencies. One such intermediary, MedRetreat, offers prospective 
patients choices among 183 medical procedures in seven different countries: India, 
Thailand, Malaysia, Brazil, Argentina, Turkey, and South Africa. Global Choice 
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Healthcare, an intermediary located in Albuquerque, New Mexico, lists a price 
comparison on their website.  
Cost Differential 
The great disparity of costs between the United States and other parts of the world 
exists for several reasons. A wide variety of studies and cost analyses have been 
conducted comparing specific costs for commensurate procedures between the United 
States and other areas that often service international patients. Depending on the 
country, costs can be as much as 80-90 per cent less than equal treatment in the 
United States. Listed below are some of the main drives behind inflated healthcare 
costs in the United States. 
Labour costs 
The Center of Medicaid and Medicare Services (CMS) calculated that Americans 
spent $2.5 trillion on health care in 2009, far more than any other country in the 
world. Labour costs in the United States, according to some studies, account for over 
half of the total cost of medical treatment. According to Fitch Ratings, a respected 
management Solutions Company based in New York, published results finding that 
across 215 not-for-profit hospitals in the United States, labour costs constituted 52.2 
per cent of total hospital patient billing. Virtually all hospital personnel, doctors, 
nurses, orderlies, management, unskilled labour, require significantly more labour 
costs in the United States than in other parts of the world. The premium price on 
labour seen in the healthcare industry is determined by the same macroeconomic 
factors that cause high labour costs in other industries. These causes, however, are 
exacerbated in the health care industry because of third party involvement and other 
regulations. 
Third party involvement 
Of the $ 2.5 trillion spent on health care in the United States in 2009, third party 
payers (insurance, employers, and government) accounted for 71.9 per cent of the 
total expenditures. Markets such as health care, characterized by an intrusive third 
party involvement, often operate very bureaucratically and inefficiently. As a result of 
third party involvement, customers do not act like logical consumers when shopping 
for health services, and providers do not compete for business on a price basis. Other 
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countries, however, especially those who have become leaders in cross border trade of 
health services, often have a much lower proportion of third party payers. Domestic 
patients in India, Mexico, Thailand, and Singapore all pay in excess of 50 per cent of 
total health expenditures (WHO, 2008). Health care markets in these countries operate 
much more competitively, based largely on price considerations. This environment of 
competition allows for lower prices throughout the industry. Elective medical 
services, including plastic surgery and non-medical vision corrections, for which 
patients usually pay for out of pocket, are much more competitive than procedures 
that endure high third party involvement in the United States. 
Lack of price transparency 
When visiting a hospital or considering a medical procedure in the United States, 
prospective patients often cannot know the exact price of health services prior to 
treatment. Health care providers are resistant to price transparency for several reasons: 
1) health care costs and payment systems are not standardized, 2) insurers do not want 
to disclose their negotiated prices, and 3) costs often vary widely between 
geographical regions. Undisclosed health care prices bridle competition in the market, 
allowing for inflated prices. 
Abundant cross-subsidies 
The American health care industry consists of a large number of non-profit general 
hospitals. These hospitals often subsidize procedure costs with revenues from other 
procedures. For example, a highly invasive heart surgery may bill more than it 
actually costs the hospital. The hospital then uses the excess funds to compensate for 
operations that typically lose money such as emergency care and charity care for the 
uninsured. 
Malpractice litigation 
American doctors are often subject to high malpractice risks because of the patient 
oriented legal framework in the United States. While physicians in the United States 
might face upwards of $100,000 annually, amalgamating to approximately $55.6 
billion industry wide, in malpractice insurance alone, doctors in Thailand pay an 
annual average of $5000. Many developing countries, including Thailand, do not 
compensate patients for noneconomic damages (i.e. psychological pain and suffering). 
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Quality Concerns 
Any time a patient makes a critical decision concerning personal health, quality and 
reliability of health care are chief concerns. Though quality metrics are not uniformly 
disclosed in the international medical marketplace, several studies have been 
conducted examining key quality indicators in the large foreign hospitals that 
regularly service western patients. According to a study by Project Hope, Bumrungrad 
(Thailand), Apollo (India), and Wockhardt (India), each of which are accredited by 
the JIC as meeting international standards for hospital facilities and surgical 
accommodations, experiences less than a one per cent mortality rate in coronary 
artery bypass graft (CABG) procedures. The same study finds that the average 
mortality rate for the same procedure in high volume hospitals in California is 2.91per 
cent. Mortality rates for CABG patients’ at the most renowned American hospitals, 
such as Cleveland Clinic and Johns Hopkins, are comparable to the best international 
hospitals. 
Hospitals in the global market seek to distance themselves from the negative 
connotations associated with third world health care. Top international hospitals 
employ highly trained physicians, many of whom received training from renowned 
medical schools in the West at facilities like Johns Hopkins University, the University 
of Birmingham, and the University of London. Additionally, many medical facilities 
in developing countries have secured partnerships with reputed American medical 
centres. Wokhardt Hospital in India is associated with Harvard Medical School, and 
Apollo Hospitals Group partners with Johns Hopkins Medicine International. Duke 
University has partnered with the National University of Singapore and the Singapore 
government to operate a top quality medical school in the country’s capital that 
opened in 2007 and will graduate its first class in 2011. 
Health Tourism 
As per the WTO definition ‘Tourism Statistical Consultation’, “Tourist” is a person in 
another country, with various purposes not forbidden by the given country, from 24 
hours to one-year period, not performing any paid activity in the country or place of 
arrival, who in the lodging of collective or single distribution has slept at least once 
and who travels. The word tourism derives from the verb tour meaning "travel." 
Tourism offers tremendous opportunities of generating revenues, earning foreign 
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exchange and providing employment. Today all countries of the world are striving to 
develop tourism in a big way. Besides economic, the social and environmental gains 
of tourism are also significant for peace and international brotherhood. It brings better 
understanding between different nations and civilizations. Likewise it helps in 
protecting environment, old monuments and cultural heritages. Tourism serves as an 
important means to increase economic growth, raise the quality of life, create 
employment and improves the overall balance of payments by helping to offset 
deficits in other sectors.  
Health/Medical Tourism in India 
India has historically been a regional medical tourism hub for neighbouring countries 
such as Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan and the Middle-
East. Evidence of ancient hospitals offering healthcare facilities funded by local kings 
and monarchs can be found in foreign travellers’ accounts as well as scripts. Most 
ancient and medieval healthcare centres provided treatment to local and foreign 
patients almost free of cost. Traditional treatment methods developed from Ayurveda, 
Yoga, Unani, Sidhha, and Homeopathy (AYUSH) styles of medicines and practices. 
During the early mid Mughal period Delhi was a well-known regional destination for 
conclaves of physicians and surgeons.          
Medical tourism is growing and diversifying. Estimates vary, but McKinsey & 
Company and the Confederation of Indian Industry (CII) put gross medical tourism 
revenues at more than $40 billion worldwide in 2004. Others estimate the worldwide 
revenue at about $60 billion in 2006. McKinsey & Company projects the total will 
rise to $100 billion by 2012.  CCI reported that 1, 50, 000 medical tourists came to 
India in 2005, based on feedback from the organization's member hospitals. The 
number grew to 2, 00,000 by 2008. A separate study by ASSOCHAM reported that 
the year 2011 saw 8, 50, 000 medical tourists in India and projected that by 2015 this 
number would rise to 32, 00,000.McKinsey & Company estimates that Indian medical 
tourism alone will grow to $2.3 billion by 2012.  
Medical tourism is one of the major external drivers of growth of the Indian 
healthcare sector. India’s medical tourism sector is expected to experience an annual 
growth rate of 30 per cent, making it a $2 billion industry by 2015. India has the 
potential to attract one million medical tourists each year, which could contribute $5 
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billion to the economy, according to CII. The emergence of India as a destination for 
medical tourism leverages the country’s well educated, English-speaking medical 
staff, state-of-the art private hospitals and diagnostic facilities, and relatively low cost 
to address the spiralling healthcare costs of the western world. India provides best-in-
class treatment, in some cases at less than one-tenth the cost incurred in the US. 
India’s private hospitals excel in fields such as cardiology, joint replacement, 
orthopaedic surgery, gastroenterology, ophthalmology, transplants and urology.  
Factors Driving Medical Tourism in India 
Some developing countries might want to target niche markets and continue to attract 
tourist round the world. For these countries, the two main drivers of trade will be 
more rapid access and lower costs. Apart from these there are other factors like India 
has many hospitals equipped with international standards. Most of Indian doctors and 
other medical staff have world class exposure and are fluent in English which is 
connecting language globally. It also has a whole lot of natural solutions to health like 
Ayurveda, and Sidha, it has many exotic tourist spots, many medical tourists have 
already chosen India as their destination for treatments, favourable currency exchange 
rates in foreign countries, government support, etc. The cost-driven market is limited 
by the lack of portability in health insurance that confines the market to discretionary 
procedures, such as plastic surgery, or that creates an important threshold.  
Table 5.2: Comparative Costs of Surgical Procedures 
Costs compared tothe United States (US$)                       Costs (per cent) 
Procedure United 
States  
Singapore  Thailand India Singapore  Thailand India 
Heart Bypass 130,000 18,500 11,000 10,000 14.2 8.5 7.7 
Heart valve 
replacement 
160,000 12,500 10,000 9,000 7.8 6.3 5.6 
Angioplasty 57,000 13,000 13,000 11,000 22.8 22.8 19.3 
Hip 
replacement 
43,000 12,000 12,000 9,000 27.9 27.9 20.9 
Hysterectomy 20,000 6,000 4,000 3,000 30.0 22.5 15.0 
Knee 
replacement 
40,000 13,000 10,000 8,500 32.5 11.0 21.3 
Spinal fusion 62,000 9,000 7,000 5,500 14.5 11.3 8.9 
Sources: Herman (2009), based on Einhorn (2008) and authors’ calculation 
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A number of countries have packaged their medical services with other services, such 
as tourism, so that the cost becomes only part of the equation. India is also providing 
packages for medical tourists and has additional benefit of lowest cost for medical 
treatment as compare to its competitors in this industry (table 5.2). Lower treatment 
cost does not necessarily mean lower healthcare standards. There are 18 JCI 
accredited hospitals in India. However, for a patient travelling to India, it is important 
to find the optimal Doctor-Hospital combination.There are many such institutions or 
facilitators like Surgery Assistance India who assist patients to find this optimal 
combination. After the patient has been treated, the patient has the option of either 
recuperating in the hospital or at a paid accommodation nearby. Many hospitals also 
give the option of continuing the treatment through tele-medicine.  
Table 5.3: Cost of Medical Procedure in Different Country 
(US Dollar) 
Medical 
Procedure 
USA Mexico Cost Rica India Thailand Korea 
Angioplasty   57,000 17,100 14,000 10,000 9,000 21,600 
Heart Bypass  144,000 21,100 26,000 10,000 26,000 26,000 
Heart Valve 
Replacement  
170,000 31,000 31,000 3,000 24,000 38,000 
Knee 
Replacement  
50,000 11,50 12,000 9,000 14,000 19,800 
Hip Resurfacing  30,000 31,400 13,000 10,000 18,000 22,900 
Hip 
Replacement  
43,000 13,800 13,000 10,000 16,000 18,450 
Special Fusion  100,000 8,000 16,000 14,000 13,000 19,350 
Face Lift  15,000 8,000 6,500 9,000 8,600 5,000 
Breast Implants 10,000 9,000 4,000 6,500 5,700 13,600 
Rhino Plasty 8,000 5,000 6,000 5,500 5,400 6,000 
Lap 
Band/Bariatric  
30,000 9,200 9,000 9,500 14,000 11,500 
Source: www. Inidahelathtourism.com 
India is fast emerging as one of the most attractive destinations for medical tourism as 
at present the earnings from it is an all-time high. With some of the most sought-after 
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specialists in cardiology, neuro-surgery, orthopedics and eye surgery, India alone has 
increased the arrival of medical tourists by more than 30 percent per year for the past 
few years. India is just one of several countries that has recognised the incredible 
benefits from medical tourism, and is now making special efforts to make the country 
as appealing as possible to potential patients/tourists. Medical tourism in India is 
becoming such a major industry, some hospitals have now taken it as far as working 
with tour operators to offer potential visitors an all-inclusive health-tourist package, 
which would include the desired medical procedure, as well as things like hotel, air 
travel, and admission to various popular tourist attractions. 
 
Foreign Tourist Arrivals (FTAs) for Medical Treatment in India 
Disembarkation card has the provision for recording the purpose of the visit for each 
foreign tourist. This data was compiled for the first time in the year 2009. There are 
various purposes for which foreigners come to India like business & professional, 
leisure holiday & recreation, visiting friends & relatives, medical treatment and others 
but here we are mainly focusing on medical treatment. 
The maximum inflow of health tourists is from Pakistan, Sri Lanka, Maldives and 
Bangladesh. A large number of medical tourists now also come from the Gulf 
countries and Africa. The inflow of health tourists from the West, especially the UK, 
US and some of the European countries, has been on the rise for the last couple of 
years. India gets around 70,000 visitors annually from the Gulf region. After the 
September 11 attacks, Arabs are avoiding going to the US and Europe. This factor has 
also helped increase the number of tourists from the Middle East. States like Andhra 
Pradesh, Karnataka, Kerala, Tamil Nadu, Maharashtra and New Delhi are fast 
emerging as India's best medical centres with several hospitals and specialty clinics 
coming up in the cities and some are there like Apollo, Escorts, Wockhardt, Fortis 
Healthcare, Manipal Group, SRL Ranbaxy Laboratories, Arvind Eye Hospital etc. In 
addition to receiving traditional medical treatments, a growing number of western 
tourists are traveling to India to pursue alternate medicines such as ayurveda, which 
has blossomed in the state of Kerala, in south-western India. The Medi City will 
integrate allopathic care with alternative treatments, including unani, ayurvedic and 
homeopathic medicine, and it will provide telemedicine services as well.  
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The Apollo group alone has so far treated 95,000 international patients, many of 
whom are of Indian origin. Apollo has been a forerunner in medical tourism in India 
and attracts patients from Southeast Asia, Africa, and the Middle East. The group has 
tied up with hospitals in Mauritius, Tanzania, Bangladesh and Yemen besides running 
a hospital in Sri Lanka, and managing a hospital in Dubai. Table 5.4gives percentage 
distribution of the FTAs for medical treatment in India for the period 2009 to 2012.  
Table 5.4: FTAs for Medical Treatment in India 
Year FTAs (Numbers) Medical Treatment 
(Percentage) 
2009 5167699 2.2 
2010 5775692 2.7 
2011 6309222 2.2 
2012 6577745 2.6 
Source: India Tourism Statistics, 2011 
 
The medical travellers 
In the late 1980s and early 1990s, most medical travellers coming to India were from 
the Arab countries, Africa and south-east Asia. But today, medical travellers to India 
can be divided into three distinct geographical groups who travel for distinctly 
different reasons. 
The first group: 
The first is made up of the Americans and Europeans. Lifestyle surgeries and costs 
were the factors driving the Americans to travel abroad. As baby boomers- those 76 
million Americans born between 1946 and 1964 – age, they are increasingly going in 
for facelifts, dental treatment, botox treatments, tummy tucks, et al. And since, 
cosmetic surgery is not covered by medical insurance. Many Americans prefer to 
travel abroad. 
The British- were being forced to seek medical treatment in other countries by the 
sheer waiting lists caused by the National Health Service (NHS). Unlike in the US, 
the British health care system ensures free treatment to all its citizens. The only 
problem is that the NHS, which was set up in 1948, is struggling to cope because of a 
shortage of both doctors and hospital beds. Private medical facilities are available in 
the UK, but they are prohibitively expensive and also relatively fewer in number. At 
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least 40per cent of the people requiring inpatient care needed to wait over three 
months for their turn to come. Hip replacement and eye care had longest waiting 
periods. Many thousands of British patients take the initiative to seek their own 
treatment abroad without waiting for the NHS to sort out its problems. 
The second group: 
The second big group of medical travellers comes from the Middle East. These are 
citizens of oil rich nations flying India to seek medical facilities that are either 
unavailable or in short supply in their own countries. An agency in Saudi Arabia 
estimated that every year more than 500,000 people from the Middle East travel 
seeking medical treatment for everything from open-heart surgery to infertility 
treatments. By some estimates, India itself attracted 70000 plus medical travellers 
from the Middle East last year. 
The third group: 
Finally, the last group of medical travellers forms a motley lot. They are from the 
least developed countries and countries with generally poor infrastructure, who seek 
treatment facilities at some neighbouring country with better infrastructure. Last year, 
it was estimated that at least 50000 people from Bangladesh and Nepal came for 
medical treatment to India. 
Table 5.5:  Major Group of Counties FTAs for Medical Treatment in India 
 
Country of Nationality Total FTA (numbers) Medical Treatment 
(percentage) 
2011 2012 2011 2012 
North America 1239705 1295968 0.3 0.3 
Central & South America 60988 63699 0.3 0.3 
Western Europe 1838695 1853066 0.3 0.4 
Eastern Europe 274598 312686 1.1 1.9 
Africa 278773 261428 8.0 8.5 
South Asia 1139659 1171499 7.4 9.3 
South East Asia 521755 540914 0.7 0.6 
East Asia 475951 535622 0.1 0.1 
Australasia 233165 244511 0.4 0.4 
Grand Total 6309222 6577745 2.2 2.6 
Source: India Tourism Statistics, 2011& 2012 
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The group of countries of world FTA for medical treatment purpose in India in the 
year 2011 and 2012 (table 5.5). It is clear from the table; Africa is the group which 
depicts that largest percentage of total FTAs visit to India for medical treatment i.e. 8 
per cent followed by South Asia 7.4 per cent. There is significant increase of FTAs 
for medical treatment in 2012 i.e. 2.6 from 2.2 per cent in 2011. South Asia shows 
highest percentage increment from 2011 to 2012.  
Table-5.6 represents the top 15 countries of percentage distribution of FTAs for 
medical treatment purpose. These fifteen countries are ranked in descending order 
according to their distribution in total FTAs for medical treatment in India in the year 
2011 and 2012. 
 
Table 5.6: Top 15 Source Countries for Medical Treatment in India, 2011 and 
2012 
 
Countries Total FTAs Medical Treatment 
(Percentage) 
2011 2012 2011 2012 
Maldives 53999 50428 56.6 59.3 
Iraq 30808 38826 29.2 33.3 
Nigeria 33537 36762 26.8 29.0 
Oman 40577 49759 13.7 11.4 
Afghanistan 89605 95231 12.5 16.5 
Tanzania 19470 21862 11.3 13.7 
Bangladesh 463543 487397 7.5 7.7 
UAE 66383 41664 7.4 8.3 
Yemen 14955 18654 6.9 10.5 
Bhutan 15489 15266 6.5 4.9 
Saudi Arabia 26268 32127 5.2 4.2 
Kenya 30045 34037 4.4 6.5 
Kazakhstan 9810 11653 4.1 5.1 
Myanmar 25043 30588 3.9 2.5 
Mauritius 22091 25013 3.8 4.1 
Source: India Tourism Statistics, 2011& 2012 
 
This ranked is not given by maximum to minimum of total FTAs for medical 
treatment. Maldives has topped rank as out of total FTAs from Maldives 56.6 per cent 
people come only for medical treatment followed by Iraq (29.2 per cent), Nigeria 
(26.8 per cent), Oman (13.7 per cent), Afghanistan (12.5 per cent) and others.     
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Medical Tourism Market 
Indian corporate hospitals are now looking at tapping insured overseas patients to 
expand the medical tourism market. The next phase of globalisation of healthcare 
services will be the treatment of insured patients across the world. Market forces will 
themselves ensure that a large number of insured patients come to Indian hospitals. 
According to Wockhardt Hospital CEO Vishal Bali, the key would be to provide top 
quality healthcare services at low cost. Insurance companies are accountable for the 
safety of their patients and they would not send them to any hospital if the quality is 
not world class, no matter how low the cost is.  
There are an estimated 71 million underinsured or uninsured population in the US 
alone. Says Escorts Heart Institute executive director (medical services) Dr. Kler, 
Most of the health services in insurance driven countries are bleeding and evaluating 
hospitals in India as an alternative. This is a big opportunity for the Indian healthcare 
industry and Indian corporate hospitals should make a co-ordinated effort to tap the 
insured patients segment. 
The key "selling points" of the medical tourism industry are its "cost effectiveness" 
and its combination with the attractions of tourism. The latter also uses the ploy of 
selling the "exotica" of the countries involved as well as the packaging of health care 
with traditional therapies and treatment methods. Price advantage is, of course, a 
major selling point. Theslogan, thus is, "First World treatment' at Third World prices". 
The cost differential across the board is huge: only a tenth and sometimes even a 
sixteenth of the cost in the West. The price advantage is however offset today for 
patients from the developed countries by concerns regarding standards, insurance 
coverage and other infrastructure. This is where the tourism and medical industries 
are trying to pool resources, and also putting pressure on the government. 
The key ‘selling point’: 
The key ‘selling point’ is its “cost effectiveness.” Also, clinical outcomes in India are 
on par with the world’s best centres, besides having internationally qualified and 
experienced specialists. Price advantage is a major selling point. The slogan, thus is, 
"first world treatment at third world prices". The cost differential across the board is 
huge: only a tenth and sometimes even a sixteenth of the cost in the west.  
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It is advisable to collaborate with all relevant stakeholders to offer more value to the 
consumers. Mutual co-existence and collaborative opportunities will attract 
consumers to Indian healthcare tourism. The essence behind co-existence and 
collaboration is not just about making a value offering but also to create the right 
environment for driving consumer traffic in Indian healthcare tourism industry. 
A successful business model for healthcare tourism needs to identify all relevant 
stakeholders and make them a part of the value chain. It is relevant to set all the 
stakeholders together in-order to increase the size of the market rather than each 
stakeholder carving out a market share for itself. 
Government Initiatives for the promotion of Medical Tourism in India 
Ministry of Health and Family Welfare and the Ministry of Tourism have jointly 
formed a Task Force with a view to promoting India as a Health Destination for 
persons across the globe so as to enable them to gainfully utilize the health care 
expertise and infrastructure available in the country. To encourage the growth of 
medical tourism, the government is providing a variety of incentives including lower 
import duties and higher depreciation rates on medical equipment.The Ministry of 
Tourism Government of India (GoI) website regularly updates the list of travel agents 
recognised by it. The GoI has issued medical or “M-visas” to medical tourists. It is 
valid for a year. It can be extended for another year by the State 
Government/Foreigner Regional Registration Offices (FRRO) on the basis of medical 
certificate or advice from the reputed or recognised hospitals in the country. Any 
further extension is granted by Ministry of Home Affairs only on the 
recommendations of State Government/FRROs supported by appropriate medical 
documents. “M-visas” are valid for maximum three entries during one year. State 
Government/FRROs may permit one additional entry, if required.  Attendant or 
family members of patient coming to India for medical treatment are granted 
miscellaneous visa co-terminus with “M-visa” of the patient. It is called “MX-visa” 
and is granted to the spouse and /or children or those who have blood relations with 
the patient. The Ministry of Tourism has also initiated several measures to promote 
medical tourism, which include promotion in overseas markets and production of 
publicity materials such as brochure, CDs and films, etc., and their distribution in 
target market.Ministry has conducted a campaign called ―Incredible India, to 
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promote Yoga and Meditation/ Wellness Tourism in India, and have promoted print 
and electronic media to persuade and attract the tourist for the same. Under the 
Market Development Assistance (MDA) in 2009, financial support is provided only to 
approved Medical tourism service Providers i.e. hospitals accredited by JCI and 
NABH. A 2007 notice of the Ministry of Health and Family Welfare has allowed 
medical practitioners from several countries to work in Indian hospitals. This step is 
expected to bring in knowledge sharing and enhanced capabilities in the overall 
industry.   
The stakeholders: 
1. The Indian government including ministry of health, ministry of external affairs, 
and ministry of tourism and state governments of different states. 
2. The corporate run health institutions. 
3. The financial institutions like tourism finance corporation of India, IDCI, and 
IDBI etc. 
4. The medical council of India (MCI). 
5. The Indian healthcare federation and different industry chambers. 
National Accreditation Board for Hospitals and Healthcare Providers (NABH) is a 
constituent board of Quality Council of India, set up to establish and operate 
accreditation programme for healthcare organizations. The board is structured to cater 
to much desired needs of the consumers and to set benchmarks for progress of health 
industry. Quality Council of India (QCI) was set up in 1997 jointly by the 
Government of India and the Indian Industry represented by the three premier 
industry associations i.e. Associated Chambers of Commerce and Industry of India 
(ASSOCHAM), Confederation of Indian Industry (CII) and Federation of Indian 
Chambers of Commerce and Industry (FICCI), to establish and operate national 
accreditation structure and promote quality through National Quality Campaign. The 
Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, 
is the nodal ministry for QCI. The NABH has given accreditation to various health 
service providers in different categories as follows: hospitals (73); blood banks (27); 
small health care organizations (7); ayurveda hospitals (1); primary healthcare (2); 
medical laboratories (116); medical imaging services (16 applicants); wellness centre 
(8 applicants) and dental institutions/hospitals (2 applicants). Few preferred hospitals 
for medical tourism in India are:  
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Apollo:  
One of the biggest hospitals chains in India, it also leads in the area of Medical 
tourism. According to a recent interview by the Chairman of the Apollo hospital, they 
have conducted 94000 heart surgeries with a success rate of 99 per cent since their 
establishment. The Apollo Hospital Enterprises treated an estimated 60,000 overseas 
patients in the last couple of years. It attracts patients from East Africa, Gulf (Oman 
and Yemen) and South Asia (Bangladesh and Nepal) and has a dedicated team 
catering to the Medical Tourism demand.  
Escorts Heart and Research Institute:  
A hospital known for heart operations, situated in the capital city of Delhi. It performs 
approximately 15,000 heart operations every year with a mortality rate of 0.8 per cent, 
which is less than most hospitals in the US can boast off. It has also doubled the 
number of overseas patients from 675 in 2000 to 1,200 and the count is ever 
increasing.  
B. M. Birla Heart Research Centre: 
Located in Kolkata, it is a super specialty hospital for the diagnosis, treatment and 
research related to cardio-vascular diseases. An advanced heart care centre treats 
patients from Bangladesh, Bhutan, Nepal, Mauritius, Hong Kong, Kenya and other 
neighbouring countries. The centre specializes in cardiac surgery, especially 
promoting research on reconstructive operations on infants. 
The Competitive Advantages: 
The source of competitive advantage arises from the skilful use of its core 
competencies. These competencies are used to gain competitive advantage against 
rivals in the global market. A combination of many factors contributed to competitive 
advantage and has led to the recent increase in popularity of healthcare tourism in 
India. 
1. World-class treatment at competitive price: 
India offers world-class healthcare that costs substantially less than those in 
developed countries, using the same technology delivered by competent specialists 
and attaining comparable success rates. 
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2. Availability of skills, knowledge and resources: 
Indian medical education turns around 30000 doctors and nurses every year adding to 
the existing pool of over 14 lakh doctors and nurses. About a dozen corporate 
hospitals provide world class treatments across all specialties. Availability of over 
15,000 hospitals and 870,000 hospital beds provides adequate infrastructure support 
to the healthcare tourists. 
3. Strong reputation in the advanced healthcare segment: 
India have a lot of hospitals offering world class treatments in nearly every medical 
sector such as cardiology and cardiothoracic surgery, joint replacement, orthopedic 
surgery, gastroenterology, ophthalmology, transplants and urology to name a few. The 
various specialties covered are neurology, neurosurgery, oncology, ophthalmology, 
rheumatology, endocrinology, ENT, pediatric surgery, pediatric neurology, urology, 
nephrology, dermatology, dentistry, plastic surgery, gynecology, pulmonology, 
psychiatry, general medicine & general surgery. 
4. Indianism:  
With ayurveda becoming increasingly popular across the globe, this ancient Indian 
therapy can be used as a non-surgical treatment for various ailments along with 
medication and yoga. This will give help of indianism to the Indian healthcare tourism 
offerings. 
5. The diversity of tourist destinations availability: 
Leisure tourism is already very much in demand in India as the country offers diverse 
cultural and scenic beauty. India has almost all sort of destinations like high 
mountains, vast deserts, scenic beaches, historical monuments, and religious temples 
etc. known for its hospitality for tourists. 
Problems of Medical Tourism in India 
Experts have identified a number of problems with medical tourism- 
• There is little follow-up care. The patient usually is in hospital for only a few 
days, and then goes on the vacation portion of the trip or returns home. 
Complications, side-effects and post-operative care are then the responsibility of 
the medical care system in the patients' home country. 
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• Government and basic medical insurance, and sometimes extended medical 
insurance, often does not pay for the medical procedure, meaning the patient has 
to pay cash. 
• Most of the countries that offer medical tourism have weak malpractice laws, so 
the patient has little recourse to local courts or medical boards if something goes 
wrong. 
• There are growing accusations that profitable; private-sector medical tourism is 
drawing medical resources and personnel away from the local population, 
although some medical organizations that market to outside tourists are taking 
steps to improve local service. 
Prospects and Challenges for Medical Tourism 
Of late the Indian medical sector has been witnessing remarkable growth. Based on 
surveys conducted by The Associated Chambers of Commerce and Industry of India 
and National Sample Survey Organization, the market size is likely to double from Rs 
4500 crore in 2011 to Rs 10,500 crore (US$ 2 billion) by 2015; the inflow of medical 
tourists which stood at 3 lakhs in 2009 rose to 8.5 lakhs in 2011 and is likely to touch 
32 lakhs by 2015. India is attracting numerous tourist which is increasing regularly 
and mainly from the Middle East, Europe and USA. States which are emerging as 
India’s best medical tourism centres are majorly southern part of the nation (Andhra 
Pradesh, Karnataka, Tamil Nadu, and Maharashtra) and New Delhi. Health and 
wellness services in India that attract foreign tourist mainly include dental and eye 
treatment, cardiac, orthopaedics, urology, plastic and cosmetic surgery, neurosurgery, 
laparoscopic surgery, kidney transplant and knee/hip surgeries. 
According to the World Travel and Tourism Council (WTTC), tourism industry will 
create about 40 million jobs for the people by 2019. Though India shares only 1.24 
per cent of international tourist receipts and 0.59 per cent of international tourist 
traffic but this contribution cannot be neglected. The major constraint in the 
expansion of Medical Tourism in India is non-availability of adequate infrastructure 
including adequate air seat capacity, accessibility to tourist destinations, 
accommodation and trained manpower in sufficient number. Poor visitor experience, 
particularly, due to inadequate infrastructural facilities, poor hygienic conditions and 
incidents of touting and harassment of tourists in some places are factors that 
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contribute to poor visitor experience. Further Indian hospitals are facing the problem 
of shortage of skilled professionals. According to the Planning Commission, India is 
facing a short of a phenomenal 600 000 doctors, 1 million nurses and 200 000 dental 
surgeons. Our community health centers are suffering from the shortfall of 
professionals such as obstetricians and gynecologists (56 per cent), pediatricians (67 
per cent), surgeons (56 per cent) and medical specialists (59 per cent). 
Lack of capital, Community participation and awareness, involvement from rural 
sector, concern for sustainability, good language translators and complex visa 
procedures are the other reasons which are serving as the constraints in the way of 
medical tourism. Hospitals of India are lagging behind in providing the hygienic 
medical facilities and room services including hygienic food to the patient. The 
government of India can play a significant role in improving the status of medical 
tourism by removing terrorism bureaucratic roadblocks, and taxation anomalies. 
Government of India should launch long term revenue generating projects and 
investor friendly policies to get benefitted from medical tourism. Government should 
make provisions to provide quality accreditations to the Indian health centres, training 
and development to the doctors, nurses and para-medical staffs, and should apply the 
customer oriented approach to improve the image of Indian hospitals. 
Other major constraint in the development of medical tourism in India is the partial 
attitude of the government towards corporate and public hospitals. Government 
cannot neglect the role of corporate hospitals as a source of foreign exchange earner, a 
provider of high class medical facilities and technology, a medium of fulfilling the 
demands of foreign patients. In future government may be compelled to grant them 
greater subsidies and exemptions for their development. This would create a pressure 
on public funds and subsides. This diversion of funds from public-sector to corporate-
sector will create a line/difference between aristocrats and budgetary class. Indian 
Government has already given them the advantage of subsidies in the field of land, 
import of health equipment, and other machineries. Development of medical tourism 
can put an extra pressure on government to subsidize them even more which will lead 
to the wastage of scarce resources available for health.  
Challenges before Indian Medial Tourism 
1.  No strong government support or initiative to promote medical tourism, 
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2.  Poor coordination between the various players in the industry- hospitals, air line 
operators, and hotels, 
3.  Customer perception as an unhygienic country, 
4.  Lack of proper regulatory system for hospitals, 
5.  Lack of uniform pricing policies across hospitals, 
6.  Strong competition from countries like Thailand, Malaysia, and Singapore, 
7.  Lack of international accreditation, 
8.  Overseas medical care not covered by many insurance players, 
9.  Under-investment in health infrastructure. 
SWOT Analysis for Medical Tourism in India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opportunities 
- Booming market focused on seniors and 
retirees  
- Booming market for cosmetic surgery, and 
other forms of medical tourism 
- Booming market for dental surgery  
- Specialization in some advanced surgical 
procedures, including cardiology, cancer 
treatment, epidemiology etc. 
- Expected shortages of certain medical 
personnel in other competitors countries 
- Deterioration in the level of reimbursement 
of treatments in other competitive countries in 
development of portability in health insurance 
- India is currently negotiating 17 FTAs, 
including review/expansion of some of the 
existing FTAs/PTAs. 
Strengths 
- Low cost of services  
- Cultural heritage, diversity of the landscape, 
tourist attractions, climate 
- Geographical and cultural, including 
English language 
- Facility of access to residential property and 
resulting strong foreign presence in residential 
areas (retirees and temporary residents) 
- Qualification and reputation of the doctors or 
hospitals gained through training or exchanges 
with foreign universities and medical 
institutions and participation in networks with 
hospitals and research centres abroad 
- India has signed 10 FTAs and 5 Preferential 
Trade Agreements (PTAs) and these 
FTAs/PTAs are already in force 
Weaknesses  
- No statistics and sectoral strategy atthe 
government level 
- Only individual initiatives; difficulty in 
financing large-scale projects 
- Skill shortages: insufficient number of doctors 
and key health personnel (absolute terms); low 
relative density of health personnel than other 
competitors 
- Qualification of nurses and other medical staff 
- Late in the race with other competitors 
- Lack of application of international standards 
and certifications (for example, the International 
Organization for Standardization) 
- Absence of a clear legal framework, which 
could result in malpractice and represents an 
important risk for the reputation of the country 
Threats 
- Protectionist reaction and bans on medical 
tourism 
- Competition of emerging countries in 
Asia, Eastern and Central Europe, and the 
Middle East and North Africa 
- Loss of resources in case of unsatisfactory 
treatment 
SWOT Analysis for Medical Tourism in India  
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5.6 Medical Tourism Index(MTI) 
The Medical Tourism Index is a new type of country-based performance measure to 
assess the attractiveness of a country as a medical tourist destination. The 
development of the MTI was a multi‐year, multi-steps and multi-stakeholder 
approach.  
IHRC (The International Health Research Centre) followed a rigorous 8 step 
methodological, statistical and index construction procedure to develop this 
psychometric sound measurement. The MTI is a multi-dimensional construct 
consisting of three main dimensions (country, industry and medical facility and 
personal) with 34 underlying indicators.  
The MTI considers push and pull factor. They focus on the offer of medical tourism 
services. They can be grouped into three groups. The first relates to overall country 
environment; the second includes factors related to the medical tourism industry; and 
the third includes factors related to the quality and availability of the medical facilities 
and services. Push Factors: These are factors related to the demand for medical 
tourism. They are mainly related to consumers and includes factors such as 
socio‐demographical (e.g., age, gender, education, marital status, ethnicity, 
geographical location) or health related factors (e.g., insurance status, health status) 
driving the demand for medical tourism. These variables are used as control variables 
allowing sorting and exploring the MTI values in the ‘members only section’. For 
example, you will be able to explore and discover and assess how gender, age, or 
geographical location matters for the medical tourism perception. 
 
 
  
 
 
 
 
 
 
 
Medical Tourism Index 
 Country Environment 
 Economy, safety, 
Image 
 Culture 
Facility and Services 
 Quality Care 
 Reputation 
 Internationalisation 
and Accreditation 
 Patients Experience 
Medical Tourism Industry 
 Destination 
Attractiveness 
 Medical Tourism 
Costs 
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MTI of Top 25 Countries in the World 
For the first time this index has been constructed by IHRC to help policymakers, 
healthcare and tourism industry, place marketers and underlying organizations and 
people to have an assessment of their place as a medical tourism destination in the 
world. 
Table 5.7: Rank-wise MTI of Top 25 Countries in the World 
Overall 
Position 
  
Countries 
  
MTI 
Overall 
Country 
Environment 
Medical 
Tourism 
Industry 
Facility & 
Services 
1. Canada 76.87 79.52 73.02 78.08 
2. UK 74.85 77.17 69.83 77.55 
3. Israel 74.17 65.58 72.37 84.57 
4. Singapore 73.96  71.06 72.65 78.17 
5. Costa Rica 72.78 66.49 79.09 72.77 
6. Italy 72.01 65.82 73.29 76.61 
7. Germany  70.69 68.48 66.98 76.93 
8. Philippines  70.66 65.34 74.53 72.11 
9. Japan 70.4 64.91 70.94 75.34 
10. France 70.22 65.04 69.74 75.88 
11. South Korea 69.97 63.13 70.23 76.56 
12. Spain 69.33 64.02 71.25 72.71 
13. Brazil 67.87 58.77 74.26 70.59 
14. Jamaica 67.68 62.46 74.8 65.79 
15. India 67.5 58.79 71.58 72.14 
16. Columbia 67.36 60.86 72.59 68.64 
17. Dubai 66.1 60.19 64.52 73.58 
18. Dominican Republic 66.02 62.77 72.4 62.88 
19. Poland 65.48 64.23 63.65 68.54 
20. Thailand  65.46 53.52 73.1 69.74 
21. Argentina 64.35 57.17 68.4 67.49 
22. China 63.13 56.19 65.49 67.72 
23. South Africa 62.05 57.44 64.82 63.9 
24. Mexico 61.03 49.95 72.91 60.24 
25. Russia 50.28 40.04 55.44 55.37 
Source: IHRC 
The MTI is the worldwide reference point on the attractiveness of countries as 
medical tourism destinations, rating and analysing the state of a country as a medical 
tourism destination, how it is positioned and should be positioned to increase the 
prosperity of its population.MTI is considered an invaluable research tool for 
benchmarking performance of countries as medical tourism destinations.  
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The world’s most attractive countries for medical Tourism are Canada, UK, Israel, 
Singapore and Costa Rica. Among Americans, Canada is the most attractive medical 
tourism destination. India has 15th rank in MTI overall in the world. 
 
The Role of Hotels in Global Healthcare 
As more and more patients cross borders to access healthcare services it is becoming 
increasingly important for hotels and other hospitality providers to understand their 
role in the patient’s medical tourism continuum of care.  In many countries it is 
common for patients to be interned a day or two at the hospital for the surgical 
procedure or treatment and then spend another week to ten days recuperating at a 
hotel. 
Environment and Other Facilities for Medical Tourists 
Hotels that wish to cater to medical guests need to be clear that their main mission is 
not to provide medical care, but instead, to create a healing environment for patients 
while monitoring their recovery.  Their goal should be to make the patient as 
comfortable as possible while working with the patient or the patient’s caregiver to 
ensure that all of the doctor’s post-op care instructions are followed. This may require 
that a nurse or patient assistant administer injections, change bandages or take a 
patient’s blood pressure. While these activities may should very “hospital oriented,” 
they are actually part of the normal aftercare process and can be administered safely 
outside a hospital environment. If medical guests, on the other hand, are being pushed 
around the hotel in a wheelchair with drip, then the hotel has probably gone beyond 
its calling and may be treading dangerous legal waters if a patient has a medical 
emergency.  Hotels also risk scaring off their traditional guests if the hotel lobby 
suddenly looks like a hospital’s emergency room. 
While most hotels were not built with the idea of catering to medical travellers, the 
majority of larger hotels have been designed to accommodate guests with disabilities. 
If a hotel is located in the U.S., then it must comply with the ADA (Americans with 
Disabilities ACT) requirements which were recently updated.  These include strict 
guidelines regarding accessibility to entryways, rooms, bathrooms, and public spaces 
such as pools and gyms. Hotels in other countries, however, may be subject to less 
stringent government regulation with regard to being accessible for guests with 
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disabilities. Hotels that cater to of medical travellers should consider making the 
following modifications to hotel spaces and a percentage of their guest rooms: 
• Hotel entryways should be wheelchair accessible 
• Hallways and corridors free of any steps or abrupt vertical level changes 
• Full size elevator that can comfortable accommodate a wheelchair or patient 
with a walker 
• All doors into and within select guest rooms should be at least 32” to 
accommodate wheelchairs, crutches or walkers 
• Ample room space to manoeuvre a wheelchair 
• Drapery wands and controls on fixed lamps are easily operable with one hand 
• Wheelchair accessible peep holes 
• Portable shower benches 
• Faucet controls and shower diverter can be turned on and off easily and are 
operable and usable with one hand 
• Elevated or raised toilet seats with grab bar 
While not all medical travellers will be using wheelchairs, many will have mobility 
limitations, particularly after undergoing surgery.  The more hotels can do to adapt 
certain spaces to meet the needs of medical travellers, the more success they will have 
attracting this market. 
Many of the services required by medical travellers can be accommodated within a 
hotel’s current service platform with little or no modifications.  These include: 
• Offering an expedited check-in service as might be provided to business 
executives 
• Offering airport pick-ups/drop-offs 
• Scheduling transportation service to nearby restaurants and shopping venues 
• Providing frequent linen and towel changes 
• Availability of special diets and flexible room service times 
However, there are some services that will require a higher investment in resources: 
• Scheduled doctor/nursing visits to monitor the patient’s condition 
• Flexible transportation service to hospitals/clinics for doctor appointments and 
treatments 
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• Transportation vans equipped with hydraulic lifts for wheelchairs 
Hotels seeking to add more value to a medical guest’s stay can also look at hiring a 
rehabilitation therapist or providing special massages for medical guests that improve 
the recuperation experience. 
Hotel staff should be sensitized to the medical traveller’s unique needs and 
expectations. In general, medical guests require more hands-on care than regular 
guests.  Hotel staff should make a habit of calling medical guests once or twice a day 
to make sure they are okay and have everything they need. As mentioned previously, 
medical guests may require frequent linen and towel changes due to their wounds; 
they may have special dietary requirements (such as patient who have undergone 
weight loss surgery); they may require flexible transportation options or have special 
mobility requirements. Hotel managers, front desk supervisors and staff, 
housekeeping, room service, and food & beverage personnel should all be trained to 
anticipate these needs and any safety do’s and don’ts (such as what to do and who to 
call in an emergency) when serving or aiding medical travellers. 
5.7 Mode 3: Commercial Presence 
The third mode of trade in health services is commercial presencewhich involves the 
establishment of hospitals, clinics, diagnostic and treatment centres, and nursing 
homes. This mode includes the establishment of a commercial presence in a foreign 
market to provide health-related services to clients in that market. It can be split into 
the following categories:  
(i) foreign commercial presence in the hospital operation/management sector;  
(ii) in the health insurance sector;  
(iii) in the health educational sector; and  
(iv) on an ad hoc basis. 
Countries have become increasingly open to foreign direct investment in order to 
upgrade and modernize their health care infrastructure and training facilities. For 
instance, developing countries like India has opened its markets to foreign 
collaboration in the health services sector. 
Health care companies in developed and some developing countries are also 
increasingly engaging in joint ventures, alliances, and management tie-ups. Such 
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ventures typically involve acquisition of facilities, management contracts, and 
licensing arrangements with some degree of local participation to ensure access to 
certify and adequately trained local persons and to ensure local contacts and 
commitment. 
There are also growing opportunities for diversifying commercial presence in health 
services. For instance, with the liberalization of foreign investment regulations in 
hospital operations and management and with the spread of managed care, there are 
opportunities for commercial presence in management of health facilities and allied 
services. Some countries are entering into contract-based management and 
administration of foreign owned or joint venture hospitals. There are also emerging 
opportunities for firms with experience in accreditation, legislation, and medical 
standards. 
The overall trend is towards opening up various segments of the health services sector 
to foreign equity or other forms of participation. With mounting pressures on public 
resources and a squeeze on public sector expenditures on health care in many 
countries, commercial presence in health services is likely to become more important 
as a means of generating resources for investment and upgrading of health care 
infrastructure. Trade flows in this mode are mainly from developed to developing 
countries. However, a few corporate hospitals in developing countries such as India 
are looking towards regional markets for establishing hospital chains and in the areas 
of hospital operations and management. 
Foreign investment could bring new resources to the health system, foster competition 
among health services providers (raising standards, quality, and lowering prices), and 
encourage technology and knowledge upgrades and transfers (e.g. training of medical 
and management personnel, or economies of scale on medical supplies). It could 
reduce the burden on public spending, including by reducing the need for sponsoring 
expensive treatments abroad, and create more jobs. 
Trade through commercial presence involves the movement of the service supplier to 
the territory of the consumer. Most commonly, this is carried out through the 
establishment of some sort of legal entity, such as subsidiaries, branches, 
representative offices, joint ventures, partnerships and acquisitions of local 
companies. It overlaps to a large extent with foreign direct investment in services. It is 
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evident that commercial presence constitutes a significant mode of international trade 
in healthcare services.  
Table 5.8: Few Approved FDI Hospitals by DIPP 
S. 
No. 
  
Date 
  
Indian Hospital 
  
Country of 
foreign 
investor 
Foreign 
equity 
(US $ 
Millions) 
1 April 2002 Fernandez Maternity Hospital, 
Hyderabad 
Australia   0.01 
2 December 2002 Sir Edward Dunlop Hospitals, 
New Delhi   
 Canada 26.71 
3 January 2004 Max Healthcare, New Delhi  Mauritius 6.63 
4 January 2000 Dr.Ramayya‟sPramila Hospitals 
Ltd, Hyderabad.  
UK-NRI 0.35 
5 September 2003 Kalinga Hospital, Bhubaneshwar NRI 0.11 
6 August 2000 Thaqdees Hospitals Ltd, 
Thaikkatukkara, Kerala  
Saudi Arabia 0.01 
7 January 2003 Duncan Gleneagles, Kolkata  Singapore 1.29 
8 July 2004 Pacific Hospitals, Hyderabad  Singapore 0.13 
9 October 2001 Malabar Institute of Medical 
Sciences Hospital Ltd., Calicut  
UAE 2.97 
10 July 2002 Peoples General Hospital Ltd., 
Bhopal  
UAE 1.53 
11 August 2001 Thaqdees Hospitals Ltd, 
Ernakulam 
UK 0.01 
12 July 2001 Trichur Heart Hospital, Thrissur UK 1.11 
13 December 2002 S&V Loga Hospital Pvt. Ltd, 
Peramanur, Salem  
USA 0.08 
14 November 2003 Vikram Hospital, Mysore  USA 0.64 
15 February 2004 Basappa Memorial Hospital Pvt. 
Ltd., Mysore  
USA 0.50 
16 April 2004 Parekh Hospital Pvt Ltd, Mumbai  USA 0.01 
17 July 2004 Columbia Asia Hospital Pvt. Ltd., 
Bangalore  
USA 0.02 
18 August 2004 Add Life Medical Institute Ltd. 
Sterling Hospital Building, 
Ahmadabad  
USA 7.07 
Source:DIPP 
The Indian foreign investment policy is very liberal for hospitals, and foreign 
investors do not face major regulatory hurdles to entering the Indian market. Some 90 
FDI projects in hospitals and diagnostic centres have been approved during the 2000-
2006 period, for a total of USD 53 million, and covering both developed (Australia, 
UK, US, Canada) and developing countries (UAE, Saudi Arabia, Malaysia, 
Singapore, Mauritius). This list, however, does not include the well-known corporate 
hospitals in the country (identified projects were small or mid-size hospitals, within 
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the 1-2 million dollar investment range), and FDI sometimes is received only for 
routing purposes (e.g. a promoter company based in Mauritius for tax benefits only).  
Since January 2000, FDI is permitted up to 100 per cent under the automatic route in 
hospitals in India. Prior to January 2000, FDI in hospitals was permitted under the 
FIPB route, which meant that the FIPB would consider the investment proposals and 
take a decision and the Indian company with the RBI would make thereafter filings. 
Foreign Direct Investment into India is governed by the Foreign Exchange 
Management Act (FEMA), 1999, the rules and regulations made there under by the 
Reserve Bank of Indiaand the Industrial Policy and Procedures issued by the Ministry 
of Commerce and Industry through the Department of Industrial Policy and 
Promotion, Secretariat for Industrial Assistance. The provisions pertaining to FDI are 
laid down in Schedule I of the FEMA (Transfer or Issue of Security by a Person 
Resident outside India) Regulations, 2000. These provisions are subject to compliance 
with the provisions of the Policy Guidelines and the Press Notes / Press Releases 
issued by the DIPP, from time to time. The DIPP has issued a consolidated policy 
with respect to foreign investment into Indian companies. Currently, foreign 
investment is regulated by Consolidated FDI Policy issued by DIPP in the form of 
Circular 2 of 2011. The FDI inflows in the hospital sector have not been significantly 
high despite government incentives to attract FDI investments (including 100 percent 
FDI in most health-related services). 
Another, vital means of investment into the healthcare as well as medical and surgical 
appliances is through venture capital investment by registered entities with Securities 
Exchange Board of India (SEBI). From the year 2000, SEBI has brought into effect 
new set of guidelines enabling foreign venture capitalists and private equity investors. 
It is not mandatory for a private equity investor to register as a Foreign Venture 
Capital Investor (FVCI) under the FVCI regulations.16 However, by registering the 
fund as a FVCI there are few advantages available. The FVCI’s are exempted from 
compliance of the pricing guidelines for the acquisition of securities at the time of 
entry as well as exit. Secondly, in cases where the promoters of the company intend to 
buyback the securities from FVCI, they are exempted from making an open offer 
under the Takeover code. However, it may be noted that SEBI has been granting 
approvals to FVCI only for investments in certain identified sectors, one amongst 
them being research and development of new chemical entities in the pharmaceutical 
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sector, and in units of SEBI registered Venture Capital Funds (“VCF”). Further to this 
SEBI has made recent amendments to permit FVCIs to invest in Category I Alternate 
Investment Funds.18 Further, under the ICDR Regulations,19 the entire pre issue 
capital of a company going public is locked-in for a period of one-year from the date 
of allotment in the public issue. However, an exemption from this requirement is 
granted to FVCI’s registered with SEBI, provided the shares have been held by them 
for a period of at least one year as on the date of filing the draft prospectus with SEBI. 
India is currently an important destination for Foreign Direct Investment (FDI) which 
is one of the biggest emerging markets. India’s economic progress since gaining its 
independence in 1947, despite of its potential to become one of the most dominant 
economies in the world, has generally been masked by its perception of being a 
closed, developing country. However, this perception has changed in the recent past 
and India is accepted as one of the most stable and robust economies. The healthcare 
sector as an industry is expanding rapidly and has not been as severely impacted by 
recent economic slowdown as some of the other industries. It comprises of hospital 
services, diagnostic services, diagnostic products, medical technology, clinical trial 
services and clinical research organizations. This sector is predominantly privatized 
and accounts for more than 80 per cent of total healthcare spending in India with 
almost 75 to 80 per cent of hospitals being managed by private sector. The Indian 
hospital industry was estimated to be worth about USD 44 billion as of 2010 and is 
predicted to be worth around USD 280 billion by 2020. Further, the Indian hospital 
service industry is projected to grow at a compounded annual growth rate of more 
than 9 per cent. The Indian Healthcare sector is emerging as one of the fast-growing 
service sectors in India, contributing 6 per cent to the country’s growth domestic 
product (GDP). Foreign investors can play significant role in the development of the 
hospital sector. This is evident from the fact that private equity funds (including 
venture capital funds) have invested over $ 2 billion in healthcare and life science 
sector over the past five years. Further, India has received USD 1,32,837 million as 
aggregate FDI from April 2000 to April, 2011 and specifically hospital and diagnostic 
centres have received FDI of USD 1030.05 million from April 2000 up to April 2011 
constituting 0.78 per cent of the total FDI into India. Foreign investors can play 
significant role in the development of the hospital sector. This is evident from the fact 
that private equity funds (including venture capital funds) have invested over $ 2 
135 
 
billion in healthcare and life science sector over the past five years. Further, India has 
received USD 1, 32,837 million as aggregate FDI from April 2000 to April, 2011 and 
specifically hospital and diagnostic centres have received FDI of USD 1030.05 
million from April 2000 up to April 2011 constituting 0.78 per cent of the total FDI 
into India.  
Overall, it appears that foreign investment in Indian hospitals remainslimited, 
notwithstanding the liberal regulatory framework. According to one estimate, foreign 
investors have tapped only 10 per cent of the Indian healthcare market. The Indian 
experience shows that a liberal foreign investment policy is not enough to secure a 
strong foreign participation in the hospital segment. Looking at the impact of foreign 
investment in hospitals in India, it has been observed that: 
• Foreign funded hospitals are likely to focus on more advanced procedures and 
specialty areas; 
• They are more likely to focus on curative and intervention oriented treatment 
than on preventive and long-term kind of treatment; 
• They are likely to employ a higher ratio of technology to personnel in their 
healthcare delivery and thus involve a substitution of human resources with 
technology and equipment; 
• They are likely to invest much more in medical equipment and devices and also 
in specialized and experienced medical personnel, thus involving a focus on 
high-end human resources and high-end technology; 
• They tend to have better systems and processes and usage of IT, which creates 
more efficient and professional work environment; 
• They pay higher rates to staff at all levels and particularly to senior medical 
personnel; 
• They are more likely to attract overseas doctors and specialists than other 
hospitals; 
• They are more likely to be accredited domestically and/or internationally; 
• Their costs are likely to be comparable to or slightly higher than those of non-
foreign funded large hospitals; 
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• Their costs will tend to be higher than for small and medium size nursing homes 
and hospitals, mainly due to greater capital intensity and focus on quality 
systems and processes and focus on hygiene; 
• There could be positive externalities in other areas, some of which could further 
drive foreign investment in hospitals; 
• They could draw away medical personnel at all levels form other hospitals and 
could adversely impact the quality of medical manpower available to competing 
institutions; 
• There is likely to be closure of substandard institutions, some consolidation of 
the hospital segment, and new kinds of arrangements could emerge between 
larger and smaller players as the healthcare sector evolves; 
• There could be greater segmentation between the public and private sector with 
resource flows towards the latter, greater wage disparity, unless innovative 
arrangements emerge between the two segments and reforms are undertaken in 
the public sector hospitals 
 
5.8 Mode 4: Movement of Health Personnel 
There are many regimes that encompass the presence of natural persons supplying 
services, including temporary and permanent flows. They include, but are not limited 
to bilateral and multilateral trade and cooperation Agreements 
The GATS defines services on the basis of the way in which they are provided. In 
Article 2 (d) of the Agreement, one of the definitions is given as the provision of a 
service by a service supplier ofone Member, through presence of natural persons of a 
Member in the territory of any other Member. 
Health services can be traded through the movement of health personnel, (mode 4) 
including doctors, specialists, nurses, paramedics, midwives, technicians, consultants, 
trainers, health management personnel, and other skilled and trained professionals. In 
fact, this mode along with consumption abroad constitutes the bulk of trade in health 
services today. The factors driving cross-border movement of health service providers 
include wage differentials between countries, search for better working conditions and 
standards of living, search for greater exposure, training and improved qualifications, 
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and demand-supply imbalances between receiving and sending countries in the health 
sector. In the nursing profession, mobility is particularly important, given nursing 
personnel constitute 70 per cent of health care staff and 80 per cent of direct patient 
care. In most countries there is a demand and supply imbalance in the nursing 
sector.For instance, there are shortages in the UK, Denmark, Israel, Italy, Norway, 
and the Middle East and also a shortage of specialty nurses in many countries. Cross-
border movement of nurses is driven by such shortages in addition to factors such as 
the poor distribution and utilization of nurses, wage differentials, poor working 
conditions, retraining requirements, poor management and compensation practices, 
and lack of jobs in the home country. 
Trade in health services via movement of persons mainly consists of exports of health 
providers from developing to developed countries and between developing countries 
in certain parts of the world. There is 56 per cent of all migrating physicians flow 
from developing countries to developed countries while the latter receive only 11 per 
cent of all migrating physicians. The emigration percentage is even higher for nurses. 
The approach towards mode 4 based trade in health services by exporting and 
receiving nations varies depending on the individual needs of countries and the 
demand-supply characteristics of the sector. Some source countries encourage outflow 
while others create impediments in the form of authorization requirements, 
clearances, and contractual arrangements with the home country government or 
disincentives in the form of migration taxes. On the receiving side, some developed 
countries such as the US have special visa schemes to facilitate the entry of certain 
classes of health personnel, such as nurses, to meet domestic shortages in those areas 
while impeding the entry of other health professionals through quantity limits on visas 
and certification requirements. To the extent that movement of professionals impinges 
on national labour market and immigration policies as well as recognition and 
certification requirements, the scope for mode 4 based trade in health services 
depends on the relaxation of these regulations. Growing cross-border delivery of and 
training in health services may reduce the need for such flows by alleviating the 
shortage of health professionals in the recipient countries and by enabling health 
professionals in developing countries to get access to the latest technology and 
information.  
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Health professionals can move permanently, or temporarily, for purposes such as 
working holidays, study visits for the acquisition of knowledge and techniques, as 
well as fixed-term contracts. There is many push and pull factors for health sector to 
explain this. Push factors include low wages in the home country, poor working 
conditions, scarcity of resources and career development limitations. Among the pull 
factors are higher absolute and relative wages, better working conditions, career 
opportunities, greater availability of resources for work, the shortage of medical staff 
developed countries and various policies enacted by developed countries to attract 
physicians and nurses. 
India is one of the important sources of physicians who are open to moving abroad. 
Physicians are moving to OECD economies from developing nations like India. India 
plays a significant role as a source country particularly with regard to the Anglo-
Saxon countries: Canada, United Kingdom and the United States.   
Movement of Indian Health Care Professionals 
The movement of doctors from India to developed countries, mainly the US and the 
UK, is not a new phenomenon. They have been movement to developed countries for 
better training and higher medical degree since 1960s. While a majority of doctors 
prefer to stay there, some of them have come back. Since most of the doctors in India 
come from middle and higher income families, they find their own way to migrate. 
Contrary to this, nurses in India belong to lower or lower-middle class background. 
Therefore, they depend upon specialised recruitment agencies to help facilitate their 
movement. The emergence of new opportunities globally for nursing professionals led 
to mushrooming of overseas placement agencies and private nursing colleges in India. 
The critical shortage of Registered Nurses (RNs) in the US has led to a boom in the 
recruitment of Indian nurses to America. A number of American hospitals are these 
days putting in requests with manpower consulting agencies and nursing schools 
across India for recruiting nurses. 
In case of the US, India tops the list of 20 countries where IMGs received medical 
training. The presence of Indian trained doctors in UK and Canada is also significant. 
As many as 30 per cent of doctors working for the National Health System (NHS) of 
the UK and Northern Ireland have obtained their primary qualifications from a 
country outside the EU. Out of this, 26 per cent of doctors employed in the NHS are 
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of Indian origin. The physicians of Indian origin have made significant contributions 
in building and sustaining the NHS. It was estimated that Indian doctors contribute 
£4.5 billion (US$8.9billion) to the UK’s economy, taking into account the cost of 
training for approximately 20,600 Indian doctors on the UK register. 
Of late, Indian nurses have also created a niche for themselves in developed countries 
health care services market. The presence of Indian nurses is not only confined to the 
English-speaking countries but they have registered their presence in a number of 
other developed countries as well. In Austria, for instance, Indian nurses are like 
pioneers, whose sizeable number in that country has led to the movement of their 
families. However, the US and the UK remained the main destinations of Indian 
nurses. In fact, in case of UK, India has surpassed Philippines in terms of annual 
registration of nurses. The US hospital, however, is still dominated by Filipino nurses. 
This could be because of stringent qualification requirements imposed by the US 
government and relatively longer wait for the US’ visa. 
States Kerala and Tamil Nadu have established their own manpower export 
corporation to help the low-skilled professionals to move abroad. Though government 
agencies like nursing and medical councils do not seem to be encouraging health care 
professionals to go abroad, their role is crucial. These councils are involved in the 
negotiation of mutual recognition of medical qualifications, bilaterally as well as 
multilaterally. Non-recognition of qualification is one of the major barriers in free 
movement of professionals from developing to developed countries. 
The recent movement of health care professionals is characterised by host countries 
giving greater emphasis on recruiting nurses than doctors.The rapidly rising ageing 
population in developed nations forcing countries to go for targeted recruitment of not 
only healthcare professionals but professionals in other sectors as well.The ageing of 
population has resulted in huge demand of nurses in OECD countries, giving 
opportunities to developing countries to supply nurses. There are various push and 
pull factors in international nursing recruitment are identified which are mentioned in 
the table 5.9.  
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Table 5.9: Main Push and Pull Factors in International Nursing Recruitment 
 
Push Factors Pull Factors 
• Low pay (absolute and/or relative) 
• Poor working conditions 
• Lack of resources to work effectively 
• Limited career opportunities 
• Limited educational opportunities 
• Impact of HIV/AIDS 
• Unstable/dangerous work environment 
• Economic instability 
• Higher pay (remittances opportunities) 
• Better working conditions 
• Better resourced health systems 
• Career opportunities 
• Provision of post-basic education 
• Political stability 
• Travel opportunities 
• Aid work  
Source: “International Nurse Mobility: Trends and Policy Implications”, WHO, International Council 
of Nurses and Royal College of Nursing, 2003  
 
Movement to Developed Countries 
Healthcare is one area where the Indian diaspora has earned a name for itself. What is 
most remarkable is that they have proved their competence not only in developing 
countries but in highly industrialised countries like US and the UK. Indian doctors are 
the backbone of the UK’s National Health Service. There are estimated 60,000 
doctors of Indian origin in the UK and some 35,000 in the US. Besides, India has 
bilateral agreements with six Middle East countries and some others for providing 
private and government doctors on short-term assignments (Chanda, 2001).  
Indian medical professionals occupy the highest positions in world renowned clinics 
like the Mayo Clinic and a number of other prestigious institutions in the US. For 
instance, Dr. Ranawat who performed two knee surgeries on the former Indian Prime 
Minister Atal Bihari Vajpayee has distinguished himself as one of the top knee 
surgeons in the world. There are many NRI doctors of such competence and standing 
in almost every branch of medicine. Indian doctors and nurses are an integral part of 
the healthcare delivery system in several Commonwealth countries. A number of 
Indian doctors are also serving in the Armed Forces of the English-speaking 
countries. 
In case of the US India tops the list of 20 countries where IMGs received medical 
training. The following list ranks the top 20 countries where the largest numbers of 
US’ IMGs are trained. These data do not represent citizenship or ethnic origin. They 
only represent the location of the medical school where the US practicing physician 
obtained their medical degree. 
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The presence of Indian trained doctors in the UK and the Canada is also significant. 
As many as 30 per cent of doctors working for the NHS of the UK and Northern 
Ireland (UK) have obtained their primary qualifications from a country outside the 
EU. Out of this 26 per cent of doctors employed in the NHS are of Indian origin. The 
Physicians of Indian origin have made significant contributions in building and 
sustaining the NHS of the UK. It was estimated that Indian doctors contribute £4.5 
billion (US$8.9bn) to the UK’s economy, taking into account the cost of training for 
approximately 20,600 Indian doctors on the UK register (Source: EUROSTAT 
Labour Force Survey).  
Of late, Indian nurses have also created a niche for themselves in developed countries 
health care services market. The presence of Indian nurses is not only confined to the 
English-speaking countries but they have registered their presence in a number of 
countries in other developed countries as well. In Austria, for instance, Indian nurses 
are like pioneers, whose sizeable number in that country has led to the movement of 
their families as well. However, the US and the UK remained the main destinations of 
Indian nurses. In fact, in case of UK, India has surpassed Philippines in terms of 
annual registration of nurse. The US hospital, however, is still dominated by 
Philippines nurses. This could be because of stringent qualification requirements 
imposed by the US and relatively longer wait for the US visa. 
Movement to Developing Countries 
Within developing countries till recently Persian Gulf countries have been the major 
destination of Indian medical professionals, particularly nurses. In fact until year 
2000, the bulk of Indian nurses were going to Gulf countries. Only in the last few 
years, the Indian nurses have started looking Westward – the US, UK, Ireland became 
the choice destination. As regards doctors, since higher education and research are the 
main reasons of their movement, western countries from the very beginning have 
been the most preferred destination of Indian doctors. Nevertheless, under the 
bilateral arrangements between India and governments of Gulf countries, India 
doctors do get hired by these countries. There is a huge population of Indians in the 
Middle East, especially in the oil rich monarchies neighbouring the Persian Gulf. 
Most moved to the Gulf after the oil boom of early 1970s to work as labourers and for 
clerical jobs. One of the major reasons Indians still like to work in the Gulf is because 
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of the tax-free income it provides and its proximity to India. Although there is no 
authentic figure on the number of Indian doctors and nurses in Gulf region, as per 
unofficial records over 60,000 RNs work in the Gulf countries. Most of these nurses 
are from the Southern states of Kerala. While doctors are not in large number in Gulf 
region, some countries do have substantial presence of Indian doctors. In Oman, for 
instance, there are about 2000 Indian doctors. 
The process of movement of Indian nurses to Gulf started in mid-1970s, when Gulf 
countries constructed large number of new hospitals. For India nurses, especially from 
Kerala, it was an unexpected opportunity to earn good wages. That trend continued 
for next two decades as thousands of young girls, predominantly Christians from 
Kerala; fill up the nursing schools all over India with the intention of migrating after 
graduation. Hence, the nursing diploma is obviously considered as a passport opening 
the world not only to the nurse herself, but also to her relatives. Families encourage 
this female movement since it is very consciously regarded as a privileged 
opportunity to increase social mobility. The movement opportunity has consequently 
changed the status of nurses, which used to be rather low in India. However, the trend 
is now changing as movement to the Gulf is considered as an intermediate step before 
further movement to the West. 
More and more nurses are returning back to India with the aim of going to West for 
much more economic benefits and opportunity to work in technologically more 
advanced working set up. 
This area of international service trade is becoming increasingly important to the 
countries in South. Since health services sector is labour-intensive and largely based 
on universal scientific knowledge, many qualified health professionals move to seek 
better living standards, career opportunities, and higher remuneration which they 
cannot get in their home countries. Moreover, there are shortages of health personnel 
in many countries, particularly in rich industrialised countries. Hence, the movement 
of health personnel could alleviate the shortage in the more developed countries and 
bring economic benefit to source countries in terms of remittances and enhancement 
of skill of their health professionals. Many countries have experienced both an inflow 
and an outflow of health personnel. Physicians and nurses from the Philippines, India 
and Thailand move to the US, UK and other OECD countries to work and earn better 
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living. Remittances sent by immigrants back home is the only indicator of measuring 
trade in services under Mode 4. Since there is no sectoral break-up of remittances 
receipt, it is always difficult to make even any rough estimate of trade in services 
through temporary movement of health care professionals. As there has been a steady 
growth in the number of doctors and nurses, who are residing outside their home 
country, naturally their contribution in global remittances must have increased. 
According to the World Bank’s Global Economic Prospects 2006 report, worldwide 
total flow of remittances is more than twice that of Official Development Assistance 
(ODA). Of the total remittances more than 70 per cent goes to developing countries. 
For many poor countries remittances as a percentage of GDP is quite high. 
Cross border movement of health care professionals is one of the most important 
means through which India has been exporting its health services. Today, Indian 
doctors have become a powerful influence in the field of medicine across the world. 
Indian doctors and nurses go to the Middle East, North America, UK, Australia, 
Malaysia and Singapore. 
Indians make up the largest non-Caucasian segment of the American medical 
community. Numbering over 38,000, physicians of Indian origin account for one in 
every 20 doctors practicing medicine in the US. Another 12,000 Indians and Indian-
Americans are medical students and residents doctors in specialty training in teaching 
hospitals across the country. And Indians make up roughly 20 per cent of the “IMGs” 
or foreign trained doctors operating in the US. According to the American Nurses 
Association, 3.5 per cent of US nurses are foreign born, over 100,000 in 2004. Out of 
which half are from Philippines, and 1.3 per cent have an Indian diploma. Four years 
ago, just 30 Indian nurses were registered to work in the UK. Today, more than 2,000 
have registered. For the NHS, India is one of the main countries from where it can 
poach health workers. Britain imports nurses because it does not have enough, and 
because India, according to its government, has more than 8 million today, against 3.8 
million 10 years ago. The country also has an edge over many other developing 
nations; English is widely spoken and it has a "youth bulge", with more than half the 
population under 30. 
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Movement of Indian Health Professionals: Major Destinations 
India being an extremely large country with a huge population and an enormous 
potential to supply English speaking health professionals to many developed countries 
stands to gain a lot particularly when their demand rises worldwide. In recent years, 
health care institutions in prosperous countries have discovered India as a new source 
country for recruiting well-trained, English-speaking nurses and physicians. Today, 
Indian doctors have become a powerful influence in medicine across the world - from 
US, UK, Australia and Canada etc. To be precise, the total number of graduates of 
Indian medical colleges now practicing (2005) in these four countries is 59,095, a 
workforce equivalent to 10.1 per cent of the 592,215 physicians registered by the 
Medical Council of India (Mullan, 2005). 
Movement of Indian Health Professionals to US 
Indians are the largest overseas trained health care workers segment of the American 
medical community. Numbering over 50,000 physicians, they are the largest group of 
physicians after native-born American doctors. One Indian doctor is available in the 
US for every 1325 Americans in contrast with one Indian doctor in India for over 
2400 Indians. Moreover these Indian origin doctors account for one in every 20 
doctors practicing medicine in the US. 
Ironically, the US still faces a physician shortage in some regions and specialties 
medical establishment because of which the AMA is still more relying on the IMGs 
who can help meet the needs of a growing and aging population. Also in the US, 44 
per cent of IMG’s provide primary care when compared to that of 33 per cent of US 
medical graduates, since US graduates choose the more high paying specialties. This 
demand for IMGs is being driven in part by demographic changes, particularly the 
rapid aging of the US population. The US Census Bureau projects that the number of 
people above the age group of 65 years and older will grow by 53 per cent by 2020. 
By 2030, there will be some 70 million senior citizens in the US. Significantly, older 
people utilise medical services at a much higher rate than younger people. 
Initially the recruitment of international RNs was focused from countries like Canada 
and UK, but now it’s from countries like Philippines, India and other developing 
countries from Asia and Africa. In April 2006, American officials with the Health 
Resources and Services Administration (HRSA) released projections that the nation's 
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nursing shortage would grow to more than one million nurses by the year 2020. In the 
report titled ‘What is Behind HRSA's Projected Supply, Demand, and Shortage of 
RNs ?’ analysts show that all 50 states in US will experience a shortage of nurses to 
varying degrees in the forthcoming year. 
Movement of Indian Health Professionals to UK 
The UK is another major destination country for Indian doctors and nurses and has 
been active in the international recruitment of health professionals. But recent 
evidence highlights a marked fall in international nurses entering the UK register in 
the last two years, as a result of reduced demand due to NHS funding deficits and due 
to tightened regulations on entry to the UK. Above all, the outflow of nurses from the 
UK to other countries, as measured by NMC verifications, has risen in recent years. In 
other words, the UK recruits nurses from developing countries, and loses nurses to 
developed countries like Australia, New Zealand, Canada, the US and Ireland. 
Movement of Indian Health Professionals to Canada 
Canada is experiencing both doctors and nursing shortage and this is projected to 
worsen dramatically over the next 15 to 20 years. In 2002, about 230,957 RNs were 
employed in nursing in Canada. Of this number, 6.9 per cent of RNs employed in 
nursing (15,847) graduated from a foreign nursing program (CIHI, 2002). While a 
total of 986 were practicing Licensed practical nurses (LPNs) trained abroad, out of 
the 5,132 registered practical nurses (RPNs) employed in psychiatric nursing in 
Canada in 2002, 385 or 7.5 per cent were foreign graduates. Hence there is strong 
evidence that a substantial number of internationally educated nurses (IENs) are 
applying for licensure in Canada. This number has increased in the past few years, 
undoubtedly due in part to active recruitment by Canadian employers.  Likewise, 
Canada also depends rather heavily on foreign-trained physicians to staff its health 
system. Currently about 25 per cent of practicing physicians in Canada are foreign 
trained.While the immigration of health and other professionals to Canada is not new, 
the number of physicians coming from developing countries which themselves are 
facing severe health human resource shortages is rapidly increasing. At present the 
major source countries are UK followed by South Africa and India.  
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It is been estimated that the number of doctors per capita in Canada will decline by 
2015 without more foreign-trained doctors. Hence the country need to employ IMGs, 
as well as nurses and nurse practitioners, to expand the volume of service delivered. 
Movement of Indian Health Professionals to Australia 
Like other developed countries, Australia too is facing the problem of shortage of 
doctors and nurses, particularly in remote areas. In order to address this by 2007 an 
additional 725 appropriately qualified overseas trained doctors will be working in 
Australia under the overseas trained doctor initiatives. Since the late 1990s Australian 
employers have been recruiting an increasing number of overseas-trained doctors to 
hospital located in the “area of need” (AON) at general practice positions. This rapid 
increase in the recruitment of overseas-trained doctors in Australia’s medical 
workforce is a consequence of a government decision taken in the early 1980s to cap 
the number of entrants to Australian medical schools. In 1997–98, most overseas 
trained doctors arriving under temporary resident visas were from the United 
Kingdom and Ireland, and by 2002–03 this had dropped to under 50 per cent; 
overseas trained doctors now come from a greater diversity of countries including 
India. 
Major Procedural Requirements in Destination Country 
Regulations have multiple objectives as it seeks to monitor and control the number of 
migrants and their quality and at the same time facilitates migration. These 
regulations are largely enacted on a unilateral basis as an important component of 
domestic policy measures. However, in some case the domestic regulations are 
framed through bilateral, regional and multilateral cooperation agreements. They 
include visa and work permit regimes, and other quantitative restrictions on the 
deployment of foreign workers by firm, industry and occupation. The extent of 
regulation also varies across countries and occupations. A broad array of regulatory 
interventions is used to regulate professions. Table 5.10provides a summary of the 
most commonly used forms of professional regulations. 
Professional associations do play an important role in the regulation of foreign supply 
of professionals and their role are more pervasive in case of healthcare professionals 
when compared to other occupations. And within this profession their role are more 
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crucial and prominent while dealing with doctors than for nurses and other para-
medicals. One prime factor for this strict regulation is the direct link between the 
provision of health services and human health and well-being. But despite this 
stringent regulation, movement of healthcare professionals across national borders 
continues to grow, both on a permanent and increasingly on a temporary, contract 
basis. 
 
Table 5.10: Examples of Professional and Occupational Regulations 
 
Type of restriction Explanation 
Entry qualifications  Various types of academic and experience 
qualifications are needed to become a professional. 
Registration Requirements Even if a 
person has the appropriate 
qualifications, they must hold a 
license to practice. 
Even if a person has the appropriate qualifications, 
they must hold a license to practice.  
Reservation of Title  
 
Only persons with the appropriate qualifications 
and/or on the register may use the professional title. 
Reservation of Practice  
 
Certain areas of practice are not allowed to be 
performed by persons other than certified 
practitioners. 
Disciplinary Processes Professionals 
may be asked to explain their actions 
if their conduct is questioned, and 
may be disciplined or prevented from 
practicing. 
Professionals may be asked to explain their actions if 
their conduct is questioned, and may be disciplined or 
prevented from practicing. 
Conduct of Business  
 
Some professions have rules that prescribe ways in 
which the professional may or may not conduct their 
business affairs. Common restrictions include 
ownership, profit sharing and advertising. 
Business Licensing  
 
Businesses must be licensed before they are able to 
sell their services. 
Source: Rex Deighton-Smith, Ben Harris and Kate Pearson, Reforming the Regulation of the 
Professions, Staff Discussion Paper, National Competition Council, Australia, May 2001 
 
The reasons are inadequate remuneration in the migrant’s home country, plus the 
desire to work in a more conductive working environment, or to work in a technically 
better managed health system. Short supply of doctors and nurses relative to the 
demand in the host countries is the primary reason for recruiting foreign 
professionals. Thus movement in this sector would continue until developed countries 
(usually the host countries) address the underlying causes of medical professional’s 
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shortages and until developing countries (usually the migrant’s home country) address 
conditions that cause medical professionals to leave. 
However, there are some regulatory measures that curtail this international movement 
of health professionals. This includes the strict and complex procedures for obtaining 
visa and other requirements such as labour market tests that justify the need for 
employment of a foreign professional and problems arising from the lack of 
recognition of professional training and experience obtained in a foreign country. 
Other than such policy related hurdles, obstacles such as language barriers, cultural 
difference and social disruption are needed to be dealt with by an aspiring 
professional. 
Besides, the aspirants are required to register/license with the local Medical Council 
or Nursing Board who are involved in the pre-employment confirmation of the 
applicant’s qualifications and skills. This procedure consists of holding required 
qualifications from a recognised medical school/university with specified period of 
training. However, this registration/license is only valid within the jurisdiction of the 
granting body. Hence medical practitioners who wish to practice in other countries 
have to go through the process of having their qualifications recognised by the 
relevant body in the host country.  
Problems faced by Indian Health Professionals 
India has become one of the major source countries for highly skilled migrant 
workers. This large outflow of health care workers from India has been despite the 
highly regulated structure of international health care services market. During recent 
years the regulations and procedures for monitoring and controlling the number of 
professional migrants particularly within the health sector has undergone significant 
changes. While there is greater demand of health care professionals, especially nurses, 
the recent changes have made it more difficult, time consuming and confusing for 
health care workers to obtain visas to work in developed countries. 
Well-developed transparent guidelines and programmes will benefit both the home 
and countries. This would enable the employers in the recruitment process and the 
aspirant professionals in knowing what they can expect while applying. Winters et al 
(2002) have already estimated that an increase in developed countries' quotas on the 
inward movements of both skilled and unskilled temporary workers equivalent to 3 
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per cent of their work forces would generate an increase in world welfare of over 
US$150billion a year. Hence the elimination of impediments would generate gains 
not just for India and other exporting countries but also for the importing countries as 
estimates suggest that there are huge returns to even relatively small movements of 
labour. So if regulated and managed properly without any unjustified barriers both the 
source and host countries can reap huge benefits. 
However, the measures undertaken by the developed countries till date have offered 
little to the developing countries in terms of opening their markets or facilitating the 
administrative arrangements or providing national treatment in the area of Movement 
of Natural Persons. There are a number of visible and invisible barriers to the 
movement of professionals and others to these developed countries. In case of 
medical profession the most developed countries enforce stringent qualification 
requirements.  
For instance, in US as in other countries, barriers to entry have been maintained 
through a combination of medical school accreditation and mandatory state licensing 
of individual practitioners. While in Australia in 1990’s, a wide range of measures, 
many of which existing even now were implemented to curb the entry of ever 
increasing number of doctors trained abroad. Thus different types of barriers exist in 
different countries. These include: 
• Entry restrictions for certain sectors/categories of natural persons. 
• Restrictions on duration of stay of natural persons. 
• Conditions for entry and other related requirements. 
• Economic needs test, labour market tests, management needs test etc. 
• Quantitative restrictions by way of number, fixed proportion of total 
employment, fixed proportion of total wages etc. 
• Restriction on capital transfers. 
• Prohibition against foreigners obtaining local qualifications. 
• Tax discrimination. 
• Requirement of Government approval. 
• Requirement of work permits/residency/citizenship. 
• Non-recognition of professional qualification by importing country. 
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• Domestic regulations concerning registration, licensing, certification, 
recognition and accreditation, and also residence, nationality or citizenship 
requirements 
• Restriction by way of minimum investment requirements. 
 
As per the communication send by India in November 2000 to the Council for Trade 
in Services Special Session, immigration and labour market policies of individual 
countries is the major barrier faced by Indian professionals abroad among various 
other barriers. The constraints under this are in the form of strict eligibility conditions 
for application, processing of visas and work permits including limitations on the 
length of stay and transferability of employment in the overseas market. These 
constraints raises the direct and indirect costs of entering the foreign market, thereby 
eroding the cost advantage of Foreign Service suppliers. There are few main barriers 
which are discussed below- 
Qualifications 
In the absence of multilateral/bilateral MRAs on qualification, the qualification 
requirements imposed by the host countries are the major hurdle in the way of nurses 
finding jobs in developed countries’ hospitals. Among developed countries Indian 
nurses mainly go to US, UK, Ireland, Australia and Canada. According to recruitment 
agencies, the US has the most stringent qualification requirements for nurses. 
However, in case of US the nurses get long term work permit under H-1B or EB3 
category, which is likely to be converted into permanent residency after six years. 
While Ireland has relatively more flexible qualification requirements, the UK has its 
own yardsticks to assess the training quality of nurses acquired in their home country. 
Most Indian nurses are used to working in the Gulf countries and thus are not familiar 
with the rigorous examinations of the US. It is difficult to pass these tests at one go. 
Migrating to the US is not at all an easy task even for a qualified nurse. Most boards 
of nursing require a foreign nurse graduate to qualify CGFNS certificate. CGFNS 
Qualifying Examination is required from graduates of nursing schools located outside 
the United States of America who are interested in practicing as RNs in the U.S. The 
CGFNS Qualifying Examination is a test of the candidates' nursing knowledge and 
their understanding and use of English language. They will be awarded a CGFNS 
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certificate when they have passed both the nursing section and the English language 
section of the examination. 
 
Language 
The spoken English was the most difficult part as most of the nurses in India come 
from low income family, having their education in vernacular language. While the 
nurses are definitely competent in terms of nursing skills, learning to speak in English 
is the hard part of it as most of them come with no training in the language. In India, 
recruitment agencies have been scouting for candidates from various metros in India - 
Chandigarh, Vellore, Mumbai and Mangalore - it is from the hospitals of Bangalore 
that it found the candidates fulfilling the requirement of excellent spoken English. It is 
very essential to communicate with the patients very clearly and despite good 
qualification and skills, nurses from many cities in India lack the fluency. 
IELTS is, therefore, an essential requirement for those nurses who aspiring to work 
UK, Australia, New Zealand and Canada. US have started accepting IELTS as the 
language proficiency test for nurses who wish to work in the country. According to 
recruitment agencies, who prepare aspiring nurses for international English language 
test, most of the candidates require more than a year of preparation. Even after that 
they fail to pass the exam in one go. 
What is more problematic is that the scores that a nurse achieves in both CGFNS 
qualifying exam and TOEFL are valid for only two years in case of the US. The time 
required for processing the US visa ranges from minimum 1-2 years. Hence, for 
nurses it is necessary to complete all the formalities and join in a job before this 
validity ceases. Otherwise, she will have to appear for the exams again, which is 
expensive and time taking. 
 
Visa 
Nursing is now the fastest route to the Green Card for an Indian in the US. 
Consultants say these days it is easy for the Indian nurse to get a green card compared 
to a software engineer. The US Department of Labor abolished the time consuming 
process of getting a labour certification72 for foreign nursing professional to migrate 
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to the US. The usual procedure for an immigrant visa meant that the applicant had to 
go through a labour certification procedure. But the acute shortage of nursing 
professionals forced the Department of Labour to do away with the procedure. As a 
result, RNs have been put on the Schedule A, which put them on a fast track to a US 
Green Card. 
Employment Based Third Preference Immigrant Visas (EB-3 or Green Card) is the 
Visa commonly given to nurses. It usually takes 9-12 months to get an EB-3 visa, if a 
candidate has CGFNS certification. The EB-3 Application requires: 
• Labour certification by the employer 
• Visa petition by the employer 
• Visa application by the nurse 
 
Since labour certification requirement has been abolished, nurses are required to 
submit only two documents. However, the US Directorate of the Citizenship and 
Immigration Service issued a regulation making it mandatory for immigrating health 
workers to get the Visa Screen certificate, which tests an applicant's education, 
experience, training and English vis-à-vis that of US health care workers. The 
recruitment agencies in India feel that the new visa rule will considerably delay the 
movement of hundreds of nurses and other healthcare professionals from India to the 
US. It also spoils the chances of nurses who want to work in the US only on 
temporary basis, either for three years or for a maximum of six years. 
In order to receive a Visa Screen Certificate to, a candidate has to demonstrate that 
her education is equivalent to a nursing education in the US and that her written and 
spoken English skills are at an acceptable level. A Visa Screen Certificate is presented 
to a consular office, or in the case of adjustment of status, to the Attorney General as 
part of the visa application. 
Role of Nursing Councils 
In India, the main function of Nursing Council is to establish and monitor a uniform 
standard of nursing education for nurses, midwife, Auxiliary Nurse-Midwives and 
health visitors by doing inspection of the institutions. Both Nursing and Medical 
councils are the nodal government agencies to deal with Mutual Recognition of 
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Qualification with their foreign counterparts. Foreign hospitals also require that the 
certificates of educational qualification of nurses and doctors must be certified by 
these councils before they are recruited. 
However, recruitment agencies are of the view that Nursing Council in India not 
effectively coordinating with the nurses who aspire to go abroad for work. They make 
inordinate delay in filling out forms and verifying mark sheets that need to be send to 
the concern hospital abroad who has recruited the candidate. This delay to send the 
requisite details by the Council makes the entire process time consuming. 
5.9 RCA in Health Services 
Data on trade in health services are very limited. Due to unavailability of data we are 
unable to calculate RCA for health services. As we have tried our level best to find 
out the data, but we found data from 2012. The data based on only health related 
travel. In this way, we have calculated India’s RCA of sub-headings 4.2.1. (Health 
related travel) with respect to the world for three years 2012, 2013 and 2014 (table 
5.11).  
Table 5.11: India’s RCA of 4.2.1. (Health related travel) w.r.t. the World 
Year Value of RCA 
2012 0.92 
2013 1.20 
2014 4.62 
Source: Author’s calculations based on ITS, UN-COMTRADE data 
It is clearly mention in the table that India has comparative advantage in the years 
2013 and 2014. The degree of comparative advantage has increased over the years.  
 
The health care sector is among the most rapidly growing sectors in the world 
economy.The presence of world‐class hospitals and skilled medical professionals has 
strengthenedIndia’s position as a preferred destination for medical tourism. The 
growth in this sector is underscored by the cost advantage that India provides to 
patients from developed countries. Notably, India attracts medical tourists from 
developing countries due to lack of medical facilities in these countries.India holds 
154 
 
15th rank in MTI, which is above Thailand (20), China (22), and Russia (25), which 
proves India may be an attractive destination of medical tourism in the World. The 
cost of surgery in India is one-tenth as compare to USA and other developed nation.  
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Chapter 6 
Summary and Conclusion 
 
Demand for health products around the world has been growing strongly both in 
developed and in developing countries over the past decades. The key ingredient of 
every health system is physical goods that are directly used for diagnosis and 
treatment of patients or that are vital for other elements of the health system, such as 
laboratory equipment to conduct medical research. 
The Indian medicine market is gaining more importance due to rise in various 
diseases and ailments. India’s medicine market is one of the fastest growing markets 
in the world. Many factors, including a strong economy and the country’s growing 
healthcare needs have contributed to the accelerated growth, which is especially 
strong in the over-the-counter (OTC) market.  
Manufacturing and trade in medical devices is also growing quite steadily. Double 
digit growth rates indicate its importance in health care. Medical devices’ industry 
mostly depends on imports. Most hi- tech innovative products and technology 
originate from a well-developed eco-system and innovative cycle which needs to be 
developed in India to promote indigenous industry and to reduce our dependence on 
imports. The ‘Make in India’ campaign of the government has a mandate to boost the 
medical device manufacturing sector in India for all types of medical devices and 
equipment used in manufacturing of Pharmaceuticals. 
 India’s export of chapter 29 i.e., organic chemicals has a rising trend during 2001-14 
except in the year 2008. The reason of down fall in 2008 is obvious due to global 
recession in that year. India’s import of Chapter 29 (Organic chemicals) from the 
world increasing continuously during the study period. There was unfavorable trade 
between India and the world for organic chemicals throughout the study period. 
India’s percentage growth of export and import for organic chemicals to the world 
fluctuated between 2001-14. India’s percentage share of export and import for organic 
chemicals in the world shows the upward rising trend.  
Export of Chapter 30 (Pharmaceutical products) by India to the world shows an 
increasing trend though out the period except in the year 2008 may be due to the 
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effect of global financial crisis. India’s volume of import for Chapter 30 has increased 
from US$16.4 million in 2001 to US$175.6 million in 2012, and then decline to 
US$163.1 million in 2014. India has favourable balance of trade in pharmaceutical 
products with rest of the world. India’s percentage share of export for pharmaceutical 
products in the world shows a favourable condition for India by rising over the years. 
India’s percentage share of import for pharmaceutical products in the world has 
increased in a step like manner. It has become tripled from 2001 to 2014. 
India’s export of Chapter 35 (Albuminoids, modified starches, glues, enzymes) to the 
world has increased in a step manner over the years. India’s import of Chapter 35 
from the world increasing continuously during the study period. It has increased from 
US$3.1 million in 2001 to US$34 million in 2014. India’s BoTin Chapter 35 with rest 
of the world clearly indicates that India has favorable balance of trade in chapter 35 
from 2001 to 2010. India’s percentage growth of export and import keeps on 
fluctuating over the years.  
India’s export of Chapter 38 (Miscellaneous chemical products) to the world has 
increased from mere US$ 43.8 million in 2001 to US$339.8 million in the year 2013. 
India’s import of Chapter 38 from the world has increasing trend. It has increased 
from US$46.5 million in 2001 to US$425.7 million in 2014. India’s BoTin Chapter 
38 with rest of the world has trade deficit throughout the study period. The important 
thing to notice that trade deficit was low in the initial years and after that it has started 
to increase. India’s percentage share of export for Chapter 38 in the world remained 
constant i.e., 0.8 per cent from 20001 to 2004. But, after that it gained momentum and 
increased to 1.8 per cent in the year 2013. India’s percentage share of import for 
miscellaneous chemical products in the world has increasing continuously over the 
time period. It has started to rise from mere 0.8 per cent in 2001 to 1.8 per cent in 
2009 and 2.2 per cent in 2014. 
India’s volume of export for Chapter 40 (Rubber and article thereof) to the world has 
increased from US$37.4 million to US$297.5 million in 2013. It has declined to 
US$276.3 million in the year 2014 due to slow down in the many parts of the world. 
India’s import ofrubber and article thereof from the world has increased over the 
years. It has increased from mere US$30 million in 2001 to US$336.9 million in 
2014, but the highest volume of import recorded in the year 2012 i.e., US$388.5 
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million. India’s BoT in Chapter 40 with the rest of the world had a surplus in trade 
balance from 2001 to 2006, after that deficit has recorded. The highest trade surplus 
registered US$ 223543 in 2005 and lowest trade deficit 1143727 in 2012. India’s 
percentage growth of export for Chapter 40 to the world highlights fluctuating picture 
over the time period which registered negative growth in 2009 and highest in 2011. 
India’s percentage share of export for Chapter 40 in the world has increased from 0.7 
per cent in 2001 to 1.4 per cent in 2014. India’s percentage share of import for Rubber 
and article thereof in the world has gradually increased over the time period. It has 
become more than triple throughout the study period.  
Export of Chapter 70 (Glass & glassware) by India to the world has increasing trend 
with a dip in 2008-09. India’s import ofglass & glassware from the world has also 
increasing trend. In the beginning India had trade surplus till 2004 after that deficit in 
rest of the years. India’s percentage share of export for glass & glassware in the world 
has become doubled from 0.5 per cent to 1 per cent over the time period. India’s 
percentage share of import for glass & glassware in the world has increased in step 
manner.  
India’s export of Chapter 84 (Machinery, nuclear reactors etc.) to the world has 
increasing trend over the time period. It has increased from US$158.3 million in 2001 
to US$1359.6 million in 2014. India’s import of Chapter 84 from the world has 
increased over the time periods. India’s BoTin Chapter 84 with rest of the world has 
unfavorable balance of trade with decreasing trend in chapter 84 with rest of the world 
market.The fluctuation in the percentage growth of India’s export for Chapter 84 
throughout the time period has observed. India’s percentage share of export of 
Chapter 84 has increased from 0.2 per cent in 2001 to 0.6 per cent in 2014. India’s 
percentage share of import for Chapter 84 in the world has increased from 2001 to 
2012 after that it has started to decline. 
Export of Chapter 87 (Vehicles other than railway, tramway) by India to the world 
has increased from mere US$87.2 million in 2001 to US$1448.2 million in 2014. 
India’s volume of import for Chapter 87 from the world has increasing trend.  It has 
started to increase from US$25.1 million in 2001 to US$480.8 million in 2014. India 
BoT in Chapter 87 with rest of the world shows India’s strength in chapter 87 with 
surplus balance of trade throughout the time period. India’s trade surplus has 
158 
 
increased from US$ 620664 in 2001 to US$ 9108261 in 2014. India’s percentage 
share of export for Chapter 87 in the world has increased sharply especially after 
2003. India’s share of import for Chapter 87 was very low only in the beginning, but 
after that it has increased.  
There is a continuous increasing trend of India’s export of Chapter 90 (Optical, photo, 
technical, medical etc. apparatus) to the world. It has increased from US$30.2 million 
in 2001 and US$87.9 million in 2007 to US$233.5 million in 2014. India’s volume of 
import for Chapter 90 from the World has persistently increased over the years. It has 
increased from US$ 114.2 million in 2001 to US$464.8 million in 2008 and 
US$705.1 million in 2014. India’s BoT in Chapter 90 indicates that India has trade 
deficit with rest of the world in chapter 90 during the whole study period. The trade 
deficit consistently increased, it was mere US$ 840082 in 2001 and reached to US$ 
4863444 in 2014. India’s percentage growth of export for Chapter 90 to the World has 
high fluctuation over the time period. India’s percentage growth of import for Chapter 
90 from the World increases first from 2001 to 2004 after that it highlights a 
downward trend. The highest growth recorded 41 per cent in the year 2004. India’s 
percentage share of export for Chapter 90 in the World has increased in a step like 
manner. It was constant in the initial years from 2001 to 2008, after that it has 
increment in step manner. India’s percentage share of export for Chapter 90 has 
become double from 2001 (i.e., 0.2 per cent) to 2014 (i.e., 0.4). India’s Percentage 
Share of Import for Optical, photo, Technical, medical etc. apparatus in the World has 
increased in a step like manner. It has increased from 0.6 per cent in 2001 to 1.3 per 
cent in 2014. 
India’s export of Chapter 94 (Furniture, lighting, signs, pre-fabricated buildings) to 
the world has increasing trend. India’s total export of chapter 94 has increased from 
mere US$5.5 million in 2001 to US$120.4 million in the year 2014. India’s volume of 
import for Chapter 94 from the world has an increasing trend. It has increased from 
US$ 5.1 million in 2001 to US$123.3 million in 2014. India’s BoT in Chapter 94 
(Furniture, lightings, signs, prefabricated buildings) with rest of the world. India had 
trade surplus in chapter 94 for half the study years and deficit for rest. There is a 
fluctuation in India’s balance of trade with rest of the world during study period. The 
highest trade surplus has observed worth US$ 80981 in 2004. India’s percentage share 
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of export for Chapter 94 in the world has increased in step manner. The percentage 
share of export for Chapter 94 has increased from 0.1 in 2001 to 0.5 in 2014. India’s 
percentage share of import for Chapter 94 in the world has also increased in a step 
manner. India’s share of import for Chapter 94 has increased from 0.1 per cent in 
2001 to 0.6 per cent in 2014.  
United States of America is a leading importer of organic chemicals from India, since 
2001, but the share has slightly decline from 14.1 per cent in 2001 to 13.6 per cent in 
2014. China (7.9 per cent), Germany (5 per cent), Netherlands (3.1 per cent) and 
Japan (2.8 per cent) are other four major importers of organic chemicals from India in 
the year 2014. United States of America imports major share of India’s export of 
pharmaceutical products to the world. Its share persistently increasing over the years. 
It has increased from mere 11.9 in 2001 per cent to 33 per cent in 2014. United States 
of America (23.7 per cent) holds top rank as far export of products falls in the 
category of chapter 35 in 2014. Japan bears the second rank with 9.2 per cent share in 
the total export. 
USA (14.8 per cent) is on the top in import of miscellaneous chemicals from India in 
2014. Brazil (10.5 per cent), Germany (3.7 per cent), China (3.2 per cent), 
Netherlands (3.7 per cent) are other leading destinations in 2014. Netherland and 
France constitutes a very high share in the beginning, but later on their declines over 
the years. United States of America (12.1 per cent), Germany (5.9 per cent), United 
Arab Emirates (4.3 per cent), United Kingdom (3.7 per cent), Philippines (3.3), 
Netherlands (3.1), Bangladesh (2.9), Brazil (3.6), Italy (2.6), and France (2.7) are ten 
destination countries in export of rubber and articles thereof in the world. USA is the 
largest importer of rubber and articles thereof from India in the World. India’s export 
in Chapter 70 (Glass and Glassware) for top ten countries in the World. United States 
of America (19.1 per cent), China (10.2), Germany (6.3), United Arab Emirates (5.4), 
and United Kingdom (4.1) are the top five leading importers of glass and glassware 
from India in 2014. 
Bangladesh and Singapore as a share of export by India in chapter 84 declines while 
China’s share has increased over the years. India’s export in Chapter 87 (Vehicles, 
other than railway, tramway) for top ten countries in the World. United States of 
America (8.4 per cent), Mexico (6.9 per cent), Sri Lanka (4.1), South Africa (6.1), and Turkey 
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(4) are five leading importers of products falls under category of chapter 87 in 2014. USA is 
the highest importer of medical apparatus from India throughout the time period. It constitutes 
16.1 per cent in 2014, which is almost half from 2001. United States of America (34 per 
cent), Germany (9.6), UK (7.5), France (7.1), Netherlands (3.3), UAE (3.1), Australia 
(3.2), Canada (1.8), Belgium (1.7,) and Saudi Arabia (1.1) are top leading importers 
of chapter-94 products from India in 2014.  
India imports highest amount of organic chemicals from China which constitutes 34.3 
per cent in 2014. United States of America (20 per cent), Germany (13.9 per cent), 
China (7.7), Indonesia (7), Switzerland (7.8), France (6.5), Italy (6), Belgium (3.8), 
Brazil (3.6), and Denmark (3.4) are the leading exporters of pharmaceuticals to India 
in 2014. China (25.8 per cent) is the leading exporter of chapter 35 products to India 
in 2014. United States of America (16 per cent), Germany (9 per cent), Thailand (6.7), 
Netherlands (5.2), Denmark (4.8), Japan (3.7), Taipei (3), France (3.4), and Republic 
of Korea (2.9) are other major countries through which India imports chapter 35 
products in 2014.  
United States of America (20.2), China (18.1), Germany (7.9), Japan (4.3), Indonesia 
(5.4), Singapore (4.7), Malaysia (4.6), Republic of Korea (3.2), France (2.9), Belgium 
(2.4) are ten leading nation which are exporting miscellaneous chemical products to 
India in 2014. China’s share has increased while Japan, Russia and Malaysia has 
decreased in the import of chapter 40 products from 2001 to 2014. China (36.3 per 
cent), United States of America (15.7 per cent), Germany (5.9), Indonesia (4.8), 
Thailand (3.2), Malaysia (2.8), Iran (1.1), France (2.7), South Africa (1.7), and United 
Arab Emirates (2.4) are the leading exporter of glass and glassware to India in 2014.     
China’s share has significantly increased while the share of USA and Singapore has 
decline for the export of chapter 84 products over the time period. China (23.6) holds 
rank one in export of chapter 87 products to India in 2014.  United States of America 
(20.3) is the leading exporter of medical apparatus to India in 2014. China (54.7), 
Germany (6.9), Malaysia (6.4), Italy (5.2), United States of America (4.4), Republic 
of Korea (2.4), Thailand (2.7), United Kingdom (1.9), Sri Lanka (1.3), Japan (1.3) are 
the leading exporters of Chapter 94 products to India in 2014. 
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The present study has calculated the export Revealed Comparative Advantage (RCA) 
index.In the trade literature this index has been extensively used to analyze the 
comparative advantage of exports of a country, its changing pattern of export 
structure over the years. The RCA is an index for calculating the relative advantage or 
disadvantage of a certain class of goods or services as evidenced by trade flows. It is 
based on Ricardian Comparative Advantage concept. It most commonly refers to an 
index introduced by Bela Balassa in 1965. 
India has comparative advantage in chapter 29 (Organic chemicals) and 30 
(Pharmaceutical products) throughout the years except 2005 and 2009 for 
pharmaceutical products. It has comparative advantage in chapter 35 only in the year 
2007, and in chapter 40 (Rubber and art. pro) in 2002, 2003 and 2005. It also has 
comparative advantage for chapter 38 (miscellaneous chem. pro.) in some years. In all 
the health products, India’s comparative advantage has improved over the time 
period.   
India’s comparative advantage has improved till 2012 and after that it has reduced. It 
is beneficial for India to export organic chemicals to those nation which have lesser 
comparative advantage than India. India has comparative advantage in pharmaceutical 
products for all the study years except 2005 and 2009. The 2005 affected due to {The 
Patents (Amendment) Act, 2005, An Act further to amend the Patents Act, 1970} and 
2009 affected due to global financial crisis. Switzerland and Ireland have highest 
comparative advantage among all competitive nations in pharmaceutical products. All 
the competitive nations have greater comparative advantage over India except USA, 
which is India’s number one trading partner in pharmaceutical products.  
The comparative advantage in chapter 35 possessed by India throughout all the years 
except 2005, 2009 and 2010. These years are influenced by Indian Patent 
(Amendment) Act 2005 and global financial crisis 2008-09. India has comparative 
advantage in chapter 38 (Miscellaneous Chemical Products) only for few years like 
2001, 2005, 2006, 2007, 2008 and 2013. Switzerland has highest degree of 
comparative advantage among all the competitive nations throughout the study 
period. India has comparative advantage in chapter 40 (Rubber and articles thereof) 
for few years like 2002, 2003 and 2005. United Kingdom has the highest comparative 
advantage among all the competitive nations throughout the study period.  
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India does not have comparative advantage in chapters 70, 84, 87, 90 and 94. It is 
beneficial for India to import these products from those countries which have high 
comparative advantage in the world.  
The RCA at 4-digit level has calculated to go at disaggregated level and fulfill the 
inquisitiveness to know the results of trade in health products. The top five products 
among each category of health products have been selected for calculating RCA at 4-
digitlevel. 
India has comparative advantage in 2902 (Cyclic Hydrocarbons) during the study 
period except for 2001 and 2002. Ireland has the highest comparative advantage in 
2933 (Heterocyclic Compounds). India has highest comparative advantage in 2942 
(Organic Compounds) among all competitive nations throughout the study period. 
India should export 2942 (Organic Compounds) to rest of the world. Apart from 
India, only Germany has comparative advantage for 2942 (Organic Compounds) in 
the world market. India also has a significantly high degree of comparative advantage 
in 2941. It is beneficial for India to export 2941 (Antibiotics) in the world market. 
India has comparative advantage in 2915 (Saturated A cyclic mono-carboxylic acids) 
over the years.  
India has comparative advantage in 3004 (Medicaments mixtures) except in the years 
2004 and 2009. India’s degree of comparative advantage in 3002 (Human & animal 
blood) quite fluctuates over the time period. India has significantly high comparative 
advantage in 3003 {Medicaments mixtures (not included in 3002, 3005, 3006)} 
throughout the study period, but it has declined over the years. It is recommended that 
India should export 3003 to the world. India does not have comparative advantage in 
3005 (Dressing packaged for medical use), so it is advisable that India should import 
3005.  
India’s degree of comparative advantage fluctuates over the years. It is suggested that 
India should export 3501 (Casein, Caseinates and other casinates derivatives and 
glues) to the world. France has highest degree of comparative advantage in 3503 
(Gelatin and Gelatin derivatives) among all competitive member countries. India’s 
degree of comparative advantage fluctuates over the time period but it maintain the 
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position of keeping advantage. It is suggested that, India should export 3503 (Gelatin 
and Gelatin derivatives) to the world market.  
India has comparative advantage in 3808 (insecticides, fungicides, herbicides 
packaged for retail sale) over the study period. India has comparative advantage in 
3823 (Binders for foundry molds or cores), so it is fruitful for India to export it in the 
world market.  India has comparative advantage in 3815 (Reaction initiators & 
accelerators catalytic prep.), so it is better that India should export it to the world. For 
India, it is in favor to export 3802 (Activated carbon, activated natural mineral 
products,) to the world. India has significantly high comparative advantage in 4013 
(Inner tunes of rubber) over the years. It has suggested that India should export 4013 
(Inner tunes of rubber) to the world market. 
As India has comparative advantage in 7020 (Articles of glass), thus it beneficial for 
India to export it in the world market. India has leading position with quite high 
degree of comparative advantage in 9018 (Electro medical apparatus). Its comparative 
advantage declined over the year but maintains its leading position in 9018. It is in 
favor of India to export electro medical apparatus in the world market. Germany has 
highest degree of comparative advantage followed by France. India does not have 
comparative advantage in 9405 (Lamps and lighting, fittings, nameplates, signs). 
Germany has high comparative advantage with having leading positions in many 
health products during the study period.  
The chapter-30 (pharmaceutical products) has been selected to calculate RCA at 6-
digit level to know whether, is there any change in the comparative advantageat 
disaggregated level or not. The rationale behind for the selection of this Chapter (30) 
is that, because it constitutes a major share among all the health products exported by 
India. India has comparative advantage in 300490 (Medicaments nes, in dosage) from 
2010 onwards. It is gainful for India to export 300490 (Medicaments nes, in dosage) 
to the world. India has significantly high comparative advantage in 300420 
(Antibiotics nes, in dosage) over the years. Switzerland has highest degree of 
comparative advantage among all the nations. It is favorable for India to export 
300420 (Antibiotics nes, in dosage) in the world market. India has highest degree of 
comparative advantage in 300410 (Penicillin, or other streptomycin, in dosage) 
among all competitive nations. It is beneficial for India to lead in the world with 
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export of 300410 (Penicillin, or other streptomycin, in dosage). India has comparative 
advantage in 300220 (Vaccines, human use), so, it is suggested for India to export it 
in the world market. India also has significantly high degree of comparative 
advantage in 300390 (Medicaments nes, formulated in bulk). It is favorable for India 
to export 300390 (Medicaments nes, formulated in bulk) to the world.  
Relevance of health products shows a descending order of different health products at 
two digit level in India’s trade in health products. The chapter 87 holds the first rank 
followed by the chapter 84, 30, 29, etc. When, we calculate relevance of health 
products at  disaggregated level means at four digit level and six digit level or sub 
categories of these products the relevance of these health products is different. At 
disaggregated level, chapter 30 holds ranks number one followed by the chapter 29, 
38, 90, etc. the reason behind is that the two digit level data also covers sub-categories 
of those products which are used for other purposes as well (apart from health 
products).      
The Intra-industry trade refers to the exchange of similar products belonging to the 
same industry. The term is usually applied to international trade where the same types 
of goods or services are both imported and exported. Balassa (1963) proposed the first 
measures of intra-industry trade that measured the degree of trade overlap-
simultaneous import and export of good within an industry. The Balassa index has not 
found much favour, because an index, which measured trade that gave pure trade 
overlap a value of zero, was not intuitively appealing. In the present study Grubel-
Lloyd (1975) index has been used for measuring the degree of India’s intra-industry 
trade in health products. 
India has intra-industry in chapter 29 (Organic chemicals) over the time period. For 
chapter 30 (Pharmaceutical products) India has intra-industry trade but the degree of it 
remains low over the years. In case of chapter 35 (Albuminoids, Modified starches, 
glues, enzymes), India has intra-industry trade with quite high degree. India has to 
move toward complete intra-industry trade over the time period. In chapter 70 (Glass 
and glassware), India has intra-industry trade over the years. The value of GL index 
remains as high as above 0.80 during the study period. For chapter 94 (Furniture, 
lighting, signs, prefabricated buildings), India has intra-industry trade over the years. 
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The value of GL index remains quite high throughout the years. It maintains more 
than 0.90 over the time period except few years.   
Early empirical investigation of IIT had been confined to “static” indicators such as 
the standard GL-index, which do not have adjustment process.However, a paper by 
Hamilton & Kniest (1991) pioneered the use of indicators based on marginal trade 
flows. It has revealed a new and potentially challenging dimension to the empirical 
analysis of IIT by suggesting a measure of marginal intra-industry trade (MIIT).   
Three methods have been proposed to date for the ‘dynamic’ analysis of IIT; viz. the 
Hamilton-Kniest index, the Greenaway et al. (1993) index, and the Brulhart (1994) 
index. Among the different versions of MIIT index, the most widely used index has 
been the one developed by Brulhart (1994).In this study the Brulhart index for 
measurement of MIIT has been used. 
For chapter 29 (organic chemicals), MIIT index has improvement towards the intra-
industry trade. As the value of MIIT index for organic chemicals has increased from 
89 per cent in 2001 to 98 per cent in 2014 with some fluctuations.For chapter 40 
(rubber and articles thereof), India holds intra-industry trade with significantly high 
MIIT index value. The value of MIIT index fluctuates over the time period. In case of 
chapter 70 (Glass and Glassware), India has intra-industry trade.For chapter 87 
(Vehicles other than railway and tramway), India has intra-industry trade throughout 
the years. The value of MIIT index is significantly high over the years. As far as 
chapter 90 (Optical, photo, technical, medical apparatus) is concerned, MIIT index 
advocates presence of intra-industry trade over the time period. The value of MIIT 
index remains at moderate level or low. In chapter 94 (Furniture, lighting, signs, 
prefabricated buildings), new trade flows due to presence of intra-industry trade over 
the years. The value of MIIT index keep on changing, but remains quite high except 
few years.  
India’s thriving economy is driving urbanization and creating an expanding middle 
class, with more disposable income to spend on healthcare. More women are entering 
the workforce as well, further boosting the purchasing power of Indian households. 
Many of these women are highly educated: the ratio of women to men who have a 
college degree or higher level of education is 40:60. Thanks to rising income, today 
more than 50 million Indians can afford to buy Western medicines, a market only 20 
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per cent smaller than that of the UK. If the economy continues to grow faster than the 
economies of the developed world, and the literacy rate keeps rising, much of western 
and southern India will be middle class. Another factor driving the growth of India’s 
healthcare sector is a rise in both infectious and chronic degenerative diseases. While 
ailments such as poliomyelitis, leprosy, and neonatal tetanus almost eliminated, some 
communicable diseases once thought to be under control, such as dengue fever, viral 
hepatitis, tuberculosis, malaria, and pneumonia, have returned in force or have 
developed a stubborn resistance to drugs. 
This troubling trend can be attributed in part to substandard housing, inadequate 
water, sewage and waste management systems, a crumbling public health 
infrastructure, and increased air travel. In addition to battling infectious diseases, 
India is grappling with the emergence of diseases such as AIDS as well as food- and 
water-borne illnesses. And as Indians live more affluent lives and adopt unhealthy 
western diets that are high in fat and sugar, the country is experiencing arise in 
lifestyle diseases such as hypertension, cancer, and diabetes, which is reaching 
epidemic proportions. Over the next 5-10 years, lifestyle diseases are expected to 
grow at a faster rate than infectious diseases in India, and to result in an increase in 
cost per treatment. Wellness programs targeted at the workplace, where many 
sedentary jobs are contributing to an erosion of employees’ health, could help to 
reduce the rising incidence of lifestyle diseases. 
Globalization, defined as the growth in the international exchange of services, 
products and capital, has not left the healthcare arena untouched. According to the 
World Health Organization, the globalization of health can be seen in the “increasing 
mobility of health professionals across border, the increase in foreign companies 
which provide health services and health insurance schemes, the use of new 
technologies, such as the internet, to provide health services across borders, and the 
increasing mobility of patients travelling abroad to access medical care.” 
It is important to be aware that medical travellers come in all strips and colours. Some 
may have travelled for dental treatment while others may be staying at a hotel after 
undergoing a double knee replacement. The former will require no more attention 
than a regular guest while the latter will need much more hands on attention. To 
provide medical guests with the best possible experience, hotel staff should 
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communicate closely with hospitals and clinics to ensure they understand the patient’s 
particular needs and expectations. 
The international trade in health services has grown through all four modes of service 
supply as defined by GATS. While the migration of healthcare professionals has been 
going on for the last several decades, the economic globalisation has spurred cross-
border delivery of health services by electronic means and greater movement of 
medical tourists (patients). The liberalisation in FDI policy by several countries has 
resulted in an increasing number of joint ventures and collaborative arrangements in 
health sector. 
Since trade in health services has not been conventional, there is a serious dearth of 
credible data on it. Thus, unlike travel and transport services, the two most commonly 
known services sector, there is no reporting and collection of systematic data on trade 
in health services. The poor availability of data is also because trade in health services 
is modest at present. Another important reason behind the lack of authentic data on 
trade in health services is that a large part of trade takes place through movement of 
healthcare professionals. Remittances received by home country are the only indicator 
through which this trade flow can be measured. But neither at the global level nor at 
any country level there is any sector-wise data on remittances. 
India is offering very low cost treatments not only to Indians but also to the 
foreigners. Patient from rest of the world are coming to India to look for alternative 
and cost-effective destinations to get their treatments done. The Indian medical 
tourism industry is presently at a blossoming stage, and has enormous potential to 
become a best medical tourism destination in the world. India‘s medical tourism 
sector is expected to experience an annual growth rate of 30 per cent, making it a Rs. 
9,500-crore industry by 2015. India is a place which offers services of well-trained 
health practitioners, fluent English speaking medical staff, a good stuff of herbal, 
natural, allopathic, and alternative system of medicines. Private/internationally 
accredited and super speciality hospitals of India are serving global health tourist with 
their specialized services and helping in earning the million dollars.  
The Government of India may play a significant role in enhancing the benefits of 
medical tourism. Tourist should be granted quicker visa or visa on arrival so that they 
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can make hassle free travel and can contact the Immigration Department at any point 
of entry for quick clearance. Government should also provide free medical visa for 
other countries nationals as provided to Maldivian nationals for 90 days. There is also 
a need to develop supporting infrastructure such as transport, accommodation, and 
communication and information channels to facilitate medical tourism. The promoters 
should hold various campaigns in different nations and continents, offer better 
discount packages and should also ensure that they cover all kinds of health insurance 
provided in different nations. A nationwide promotion operation about ‘Brand India’ 
and its national standards could also be advertised both domestically and 
internationally.   
There is an opportunity in medical tourism because Indian healthcare institutions in a 
position to offer quality medical services at one-tenth the cost compared to that in 
many countries in the west. With regard to quality of the service, we stand shoulder-
to-shoulder with the best hospitals in the US. For medical tourists coming from 
abroad there is value proposition in terms of costs and quality. Moreover, India as 
unique as it offers holistic medicinal services with yoga, meditation, ayurveda, 
allopathy and other medical facilities; we offer a unique basket of services to an 
individual that will be difficult to match in other countries. For Indian healthcare 
institutions, the quality of service is over biggest Usp, followed by the cost advantage. 
The biggest challenge is to position India as a favourable healthcare destination by 
setting high health standards for ourselves, and work in association with the 
government and the medical council to see to it that all hospitals keep up to those 
standards. Now, the Indian healthcare federation is working along with different 
industry chambers to promote medical tourism in the country.The $ 40 billion 
opportunity is there for all. However, Indian healthcare institutions and Indian will 
lose out if we do no cat over the next 2 years. Competition is building up fast from 
countries like Thailand, Singapore and Australia. 
The road map ahead is simple, there is need to act smart here, and first, need to create 
more information outlets in various markets. Second, Indian healthcare industry 
should work more closely with the industry chambers and various government 
departments to spread the awareness and remove hurdles. Finally, need to work 
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towards getting accreditation for various hospitals to build up perception of quality 
among foreign tourists.  
It is proven that healthcare seekers depend highly on the corporate hospital, since they 
provide a wider variety of services and are considerably more efficient. Thus, with the 
corporate hospitals becoming more prominent in the Indian market, it becomes even 
more imperative that India continues to ride this wave and makes more collaboration 
to bring the people of India a truly global healthcare delivery system at affordable 
prices. 
There are many positive implications of foreign investment in hospitals. One of the 
major impacts foreign investment would have is the creation of the necessary 
infrastructure. Investments are also needed beyond the metros to expand access to 
healthcare. In addition to helping increase physical capacity in the health care sector, 
such as increasing the number of hospital beds, diagnostic facilities, and increasing 
the supply of specialty and super specialty centres, foreign investment can also help in 
raising the standards and quality of healthcare, in upgrading technology, and in 
creating employment opportunities, with potential benefits to the health sector and the 
economy at large. 
India has identified health care service as one of the key sectors where Indian 
professionals have competitive advantages in international market vis-à-vis other 
developing countries.Priority should be given to standardise visa and work permit 
regulations for professionals. Entry visas should be easily granted for medical 
professionals, with a short prescribed duration for procedural formalities. Within these 
procedural formalities, there is a need to ensure transparency and certainty 
particularly a transparent application processes, simplified renewal and transfer 
procedures, and recourse mechanisms to ascertain the status of an application and 
reasons for rejections. Further, quantitative restrictions on number of visas to be 
granted under temporary movement of professionals should not be there, just as there 
are no quantitative limitations on trade in goods. 
At domestic level, Medical and nursing councils who are the nodal agencies 
responsible for regulation and maintenance of a uniform standard of training for 
doctors and Nurses/Midwives/Auxiliary Nurse-Midwives respectively, need to be 
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more proactive. Another domestic issue is government active involvement in 
generating surplus healthcare manpower for export purpose. Regulatory barrier seems 
to apply to an even greater extent to immigration of foreign health professionals into 
India. The fact that India does not recognize health professionals’ qualifications from 
all of the other developing countries is regarded as one of the main barriers to the 
entry of foreign doctors into the country.  
The developing countries like India have made more market access commitments in 
medical and dental services. The GATS do not stipulate any constraints on terms and 
conditions, for example, on treatments of foreign patients. The parties are free to 
make any policy decisions. The Indian market segment is dominated by hospital 
business. Other activities include pharmaceuticals, medical equipment, insurance and 
diagnosis. India has emerged as a hub for clinical research and attracts patients from 
the US, the Middle East and South Asia. The low cost medical services have boosted 
medical tourism. However, all modes are not totally free. In modes 1 and 2 there are 
no national treatment and market access restrictions. In mode 3 foreign equity ceiling 
of 74 per cent remains. In mode 4 restrictions are on foreign personnel on entry visa 
basis. India has established superiority in IT‐enabled and back‐end services. 
India has built up reputation in offering specialist medical and surgical interventions 
at competitive prices under mode 2. The foreign investment under mode 3 is modest 
due to a variety of factors. Though India has an advantage in mode 4 but heavy 
restrictions prevent migration of health personnel. It also causes internal brain drain 
which results in denial of quality services to the poor domestic patients. Some efforts 
are made to rectify this problem but it is not successful. The earning of foreign 
exchange has taken priority. There should be tapping the demand for outsourcing 
financial & accounting services in healthcare sector.Licensing, ethical and legal issues 
needs to be addressed to promote integration of electronic and information technology 
tools to facilitate global healthcare. 
The main negative implications of trade in health services include brain drain of 
quality service providers to overseas markets, creation of a two-tier structure within a 
country, internal brain drain from +the public health system to the private health care 
sector, crowding out of nationals, over investment in specialized and capital-intensive 
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segments at the expense of investments in core health care services, and adverse 
effects on equity in the public health sector. 
India, asides from an increase in revenues, the importance of telemedicine trade in 
improving the national health system and the country image were highlighted as key 
advantages. We can use telemedicine exports as a way to innovate and to catalyze and 
redesign our health system. Africa is the group which depicts that largest percentage 
of total FTAs visit to India for medical treatment i.e. 8 per cent followed by South 
Asia 7.4 per cent. There is significant increase of FTAs for medical treatment in 2012 
i.e. 2.6 from 2.2 per cent in 2011. South Asia shows highest percentage increment 
from 2011 to 2012. More international accreditation is required for Indian hospitals. 
India holds 15th rank in MTI, which is above Thailand (20), China (22), and Russia 
(25), which proves India may be an attractive destination of medical tourism in the 
World. The cost of surgery in India is one-tenth as compare to USA and other 
developed nation.  
FDI cap in health insurance should be raised in India on a priority basis as it will also 
help the export of super-specialty hospital services. The movement of doctors from 
India to developed countries, mainly the US and the UK, is not a new phenomenon. 
They have been movement to developed countries for better training and higher 
medical degree since 1960s. While a majority of doctors prefer to stay there, some of 
them have come back. Since most of the doctors in India come from middle and 
higher income families, they find their own way to migrate. Contrary to this, nurses in 
India belong to lower or lower-middle class background.States Kerala and Tamil 
Nadu have established their own manpower export corporation to help the low-skilled 
professionals to move abroad.India’s comparative advantage w.r.t. the world in health 
services i.e., travel, health related (4.2.1) has shown in favour of India in the years 
2013 and 2014. The degree of comparative advantage has increased over the years. 
It has been found that the international trade in health products have grown in a very 
dynamic way, especially trade in dosified and bulk medicines. Our results further 
indicate that international trade in health products is strongly dominated by a small 
number of developed countries like Belgium, Switzerland, Germany, etc.USA and 
China play dominant role as partner to India trade in health products.India’s export of 
pharmaceutical products (chapter-30) has persistently rising except a mild fall in 
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2014, with having increasing trend in BoT.RCA in 9018 (Electro medical apparatus) 
and 2942 (Organic Compounds)for India is highest among its all competitive 
countries.India has highest comparative advantage in 300410 (Pencililines, or other 
streptomycin, in dosage) throughout the years among all its competitive nations.There 
is high Intra-industry trade for India in chapters 29 (Organic chemicals), 35 
(Albuminoids, enzymes, etc.), 38 (Miscellaneous chemical products), 40 (Rubber and 
articles thereof), 70 (Glass and Glassware), and 84 (Machinery, nuclear reactors, 
boilers etc.).There is increasing MIIT for chapters 29 (Organic chemicals), 30 
(pharmaceutical products), 40 (Rubber and articles thereof), 84 (Machinery, nuclear 
reactors, boilers etc), 38 (Miscellaneous chemical products); while declining for 
chapters 94 (Furniture, lighting, signs etc.), 90 (Optical, photo, medical apparatus), 87 
(Vehicles other than railway and tramway) and 70 (Glass and Glassware) over the 
time period. 
The cost of surgery in India is one-tenth as compare to USA and other developed 
nation.India’s comparative advantage w.r.t. the world in health services i.e., travel, 
health related (4.2.1) has shown in favour of India. India, asides from an increase in 
revenues, the importance of telemedicine trade in improving the national health 
system and the country image were highlighted as key advantages. We can use 
telemedicine exports as a way to innovate and to catalyze and redesign our health 
system. More international accreditation is required for Indian hospitals.FDI cap in 
health insurance should be raised in India on a priority basis as it will also help the 
export of super-specialty hospital services. There should be tapping the demand for 
outsourcing financial & accounting services in healthcare sector. 
Future Agenda 
There is a rise in pharmaceutical outsourcing and investments by multinational 
companies. Therefore, there is a need to study the effect of FDI on health products 
and services. In further studies, the role of tariffs on the health products need to be 
examined. There is a need to have an empirical study on trade in health services based 
on primary data collected from various hospitals. 
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